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Summary 
Summary 
 
i 
 
teroids represent a pharmacologically active class of molecules associated with 
variety of physiological functions. Steroids and their derivatives with heterocyclic 
rings have been of great pharmaceutical interest and developed as drugs for the 
treatment of a large number of diseases. The promise of using steroids for development 
of lead molecules lies in their regulation of a variety of biological processes and being 
a fundamental class of signaling molecules. It is proved that a number of biologically 
important properties of modified steroids are dependent upon structural features of the 
steroid ring system or side chain so this chemical modification of the steroid skeleton 
provides a way to alter the functional groups and numerous structure-activity 
relationships have been established by such synthetic alterations. Naturally occurring 
steroid nuclei have been modified in several ways with the aim of finding more active 
compounds, free from undesirable or harmful side effects, and recognizing as the 
structural and stereochemical features required for the display of specific, selective 
physiological activity. Our laboratory from the past is concerned mainly with the 
synthesis of unknown steroidal compounds in the cholestane series. These includes 
azasteroids, oxasteroids, thiadiazoles, oxadiazolines, pyrrolidine, pyrazolines, 
azetidinones, pyrans, thiazolidinones etc. In continuation of the aforesaid studies, the 
present work embodied the design and synthesis of steroid derivatives along with their 
biological behavior. The identification of newly synthesized hetero-steroids has been 
ascertained by IR, 1H NMR, 13C NMR, DFT, Mass spectroscopy and elemental 
analysis. The whole work of thesis has been divided into five chapters namely: 
Chapter 1: Steroidal thiophenes 
Chapter 2: Steroidal spirothiazolidinones 
Chapter 3: Steroidal thiazoles, oxazoles and imidazoles 
Chapter 4: Steroidal pyrimidines 
Chapter 5: Biological evaluation of newly synthesized compounds 
 
The results are summarized as follows: 
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CHAPTER-1 
Steroidal thiophenes 
Thiophene moiety containing molecules have been reported to exhibit a broad spectrum 
of biological activities. These types of compounds are an important class of heterocyclic 
structures that can be applied in drugs and pharmaceutical fields. Because of the 
importance of these scaffolds in synthestic organic chemistry and their usefulness as 
pharmacological active molecules, much attention has been focused on their synthesis.  
Chemistry of 2-aminothiophenes is one of the most extensive and dynamic field of 
present day research. Since 1961 when first report on the Gewald reaction was 
published it became a universal method for synthesis of substituted 2-aminothiophenes 
and has gained prominence in recent times. This prompted us to carry out the synthesis 
of steroidal thiophene derivatives (IV-IX) namely 3β-acetoxy-5α-cholest-6-eno-[6,7-
d]-2ʹ-amino-3ʹ-cyanothiophene (IV), 3β-chloro-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-
cyanothiophene (V), 5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene (VI), 3β-
acetoxy-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene (VII), 3β-chloro-
5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene (VIII), and 5α-cholest-6-
eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene (IX). 
 
 
 
Green synthesis of ZnO nanoparticles using bacillus subtilis and their catalytic 
performance in the one-pot synthesis of steroidal thiophenes.  
Shamsuzzaman, Abad Ali, M. Asif, A. Mashrai, H. Khanam. Eur. Chem. Bull., 2014, 
3(9), 939-945. 
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CHAPTER-2 
Steroidal spirothiazolidinones 
Thiazolidinone is considered as a biologically important active scaffold that possesses 
almost all types of biological activities. Successful introduction of ralitoline as a potent 
anti-convulsant, etozoline as an antihypertensive, pioglitazone as a hypoglycemic agent 
and thiazolidomycin activity against streptomyces species proved potential of 
thiazolidinone moiety. This diversity in the biological response profile has attracted the 
attention of many researchers to explore this skeleton to its multiple potential against 
several activities. Keeping this in consideration, the synthesis of steroidal 
spirothiazolidinone derivatives namely 3β-chlorocholest-5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-
thiazolidin-4ʹ-one (XIV) and cholest-5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-thiazolidin-4ʹ-one 
(XV) from easily accessible steroidal imines, 3β-chloro-7-iminophenyl cholest-5-ene 
(XII) and 7-Iminophenyl cholest-5-ene (XIII), respectively. The imines were obtained 
from corresponding ketones (X, XI). 
 
 
 
 
 
 
 
Synthesis, characterization, biological evaluation and molecular docking of steroidal 
spirothiazolidinones.  
Shamsuzzaman, K. A. A. A. Baqi, Abad Ali, M. Asif, A. Mashrai, H. Khanam, A. 
Sherwani, Z. Yaseen, M. Owais. J. Mol. Struct., 2015, 1085, 104-114. 
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CHAPTER-3 
Steroidal thiazoles, oxazoles and imidazoles 
There are copious biologically active molecules which contain various heteroatoms 
such as nitrogen, oxygen and sulphur, always drawn the attention of chemist over the 
years mainly because of their biological importance, such as antibacterial, anti-
tubercular, antifungal, anticancer and anti-inflammatory, etc. These compounds turn out 
to be nontoxic, less vulnerable to multi-drug resistance (MDR) and highly bioavailable. 
Different ring modification of steroidal molecules involving the A-, B- and D-ring/ 
incorporation of heteroatom (N/O/S) has been reported to enhance the biological 
activities of these molecules. As a result, a number of different heterocyclic systems 
have been introduced into the core structure of steroids with pyrazolines, pyridines, 
isoxazoles, thiazoles, imidazoles, oxazoles, pyrimidines, etc. as the notable ones. Thus, 
in connection with our ongoing activity intended at developing an expedient synthetic 
approach, we pursued to develop a milder reaction conditions to widen the opportunity 
of this important conversion. We wish to report herein, an efficient, convenient and 
novel procedure for the conversion of 5α-cholestan-6-(iminohydrazono)-2-
methylbenzaldehyde (XIX-XXI) into 5α-cholestan-6-(iminohydrazonomethylphenyl-
2-yl)-benzo-[d]-thiazole (XXII-XXIV), 5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (XXV-XXVII) and 5α-
cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (XXVIII-
XXX). With the best of our knowledge there are no literature data available regarding 
the synthesis of steroidal compounds (XXII-XXX). 
 
 
 
 
 
 
Synthesis and characterization of steroidal heterocyclic compounds, DNA 
condensation and molecular docking studies and their in vitro anticancer and 
acetylcholinesterase inhibition activities.  
Abad Ali, M. Asif, H. Khanam, A. Mashrai, M. A. Sherwani, M. Owais, 
Shamsuzzaman. RSC Adv., 2015, 5, 75964-75984. 
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CHAPTER-4 
Steroidal pyrimidines 
Nitrogen containing heterocycles constitute an important class of compounds. Among 
them, pyrimidine derivatives play a vital role in drug synthesis and are associated with 
many biological activities. The presence of more than one hetero atom and the higher 
π acidity of the pyrimidine rings as compared to that of pyridine bases play an important 
role in chemistry and also serve as a better model in biological systems. An extensive 
literature survey revealed that the numerous fused pyrimidine ring heterocyclic 
moieties possess chemotherapeutic activities such as anticancer, antibacterial, anti-
inflammatory, antioxidant, anxiolytic and antiviral, etc. In the present communication, 
we have described the synthesis, spectral and structural characterizations of a new 
steroidal pyrimidine derivatives (XXXI-XXXIII). In spite of few preliminary reports 
about the synthesis of such kind of products no literature precedents were found 
describing the synthesis of B-ring substituted steroidal pyrimidines through the strategy 
we have employed. 
 
 
 
 
DFT/B3LYP calculations, in vitro cytotoxicity and antioxidant activities of steroidal 
pyrimidines and their interaction with HSA using molecular docking and spectroscopic 
techniques.  
Abad Ali, Shamsuzzaman et al. 
(Communicated) 
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CHAPTER-5 
 
Biological evaluation of newly synthesized compounds 
Nature constitutes an inclusive reservoir of potential drugs that has been overlooked 
during the last decades, despite the fact that about half of the marketed agents in today’s 
arsenal of drugs are either natural products or derivatives thereof. Cancer is the leading 
global health burden that at some time will directly or indirectly affect the lives of most 
people. Local cancer treatments, such as surgical and radiation therapies are not always 
viable due to the position of the tumour in the body. Furthermore, these methods are 
often unsuccessful in completely removing tumours. Chemotherapy is a systemic 
cancer treatment and chemotherapeutic drugs interfere with the cell cycle and thus cell 
division, angiogenesis or induce tumour cell apoptosis by several signaling pathways. 
However, due to the high cancer mortality rate, development of drug resistance and 
undesirable side effects there is an urgent need to design and synthesize new anti-cancer 
drugs. To gain insight on how modifications on ring-B in steroids nucleus can affect 
the biological activity, different steroidal derivatives with a variety of functionalities 
attached to steroidal skeleton have been synthesized and evaluated in silico and in vitro 
for their biological activity. In the in silico studies, we studied the physicochemical 
parameters “Rule of Five” of the synthesized compounds and we calculated the 
bioactivity score for six criteria, GPCR ligand activity, ion channel modulation, kinase 
inhibition activity, protease inhibitor, enzyme inhibitor and nuclear receptor ligand 
activity. The cytotoxic potential of the synthesized compounds were studied against 
panel of selective human cancer cells by MTT assay. The panel of cancerous cells 
comprised HepG2 (human hepatocellular carcinoma), A549 (human lung carcinoma), 
Jurkat (human leukemia carcinoma), HeLa (human cervical carcinoma), MCF 7 
(human breast adenocarcinoma), Hep3 B (human hepatocellular carcinoma), MDA-
MB231 (human breast adenocarcinoma), HL-60 (human leukemia carcinoma) and the 
compounds were tested against one normal cell line PBMCs (peripheral blood 
mononuclear cells). Doxorubicin (Dox) and 5-fluorouracil (5-Fu) were used as 
cytotoxic drugs of reference. The synthesized compounds were also investigated for 
antioxidant activities by various methods (DPPH, ABTS, FRAP, OH. Scavenging, NO. 
scavenging and H2O2 scavenging) and their interaction with DNA/HSA via 
spectroscopic techniques. 
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teroids constitute an extensive and imperative class of biologically active 
polycyclic compounds that is widely used for therapeutic purposes and have high 
ability to penetrate cells and bind to nuclear and membrane receptors. Despite decades 
of research, the total synthesis of steroid nuclei by amended strategies endures to 
receive considerable attention. Numerous methods have been exploited for the total 
synthesis of steroids which are widely distributed in nature and possess practical 
medical importance. Interest in steroid chemistry arises from significant rating that 
these compounds have been accorded in medicine. Commercial research on steroid is 
focused on finding more potent, long acting synthetic drug analogs, possessing essential 
pharmacological properties. The use of steroidal hormones, such as corticoids, 
progesterones, and various anabolic (muscle building) agents, is well known in modern 
clinical therapy. However, the beneficial properties of these drugs are often, if not 
usually, escorted by unwanted side effects. Naturally occurring steroid nuclei have been 
modified in several ways with the aim of finding more active compounds, free from 
undesirable or harmful side effects, and recognizing as the structural and stereo-
chemical features required for the display of specific, selective physiological activity. 
Ring expansion or the replacement of one or more carbon atoms of the sterane skeleton 
by a heteroatom affects the chemical properties of the steroid and thus may play a 
critical role in changing biological activities and in the building of new active 
pharmaceuticals.  Thereafter, scientist diverted their attention towards the steroids and 
the work on isolation as well as on synthesis started with great enthusiasm. Our 
laboratory is mainly concerned with the synthesis of steroidal derivatives and their 
identification by spectral and analytical studies, has reported the preparation of a 
number of hetero-steroidal compounds. The goal of the present work is to survey the 
synthesis of some modified steroids as well as relevant chemistry involving 
transformations of A/B/D ring for the preparation of compounds of biological 
significance. First chapter is dealing with the synthesis of steroidal thiophenes, second 
chapter is concerned with the synthesis of steroidal spirothiazolidinones, and third 
chapter is accredited to the synthesis of steroidal thiazoles, oxazoles and imidazoles, 
while as the fourth chapter is associated with the synthesis of steroidal pyrimidines. The 
fifth chapter is concerned with the biological activities (anticancer, antioxidant, 
acetylcholinesterase, DNA condensation and non-enzymatic degradation etc.,) and 
DNA/HSA binding studies of these newly synthesized hetero-steroidal compounds. 
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hiophene belongs to a class of heterocyclic compounds containing a five-
membered ring made up of one sulfur as heteroatom with the formula C4H4S, 
chemical name is thiacyclopentadiene and it is aromatic as indicated by its 
extensive substitution reactions. Thiophene structure can be found in certain natural 
products and is also incorporated in several pharmacologically active compounds.1 
 
Thiophenes are important target for organic synthetic and medicinal chemists because 
of their unique applications in pharmaceuticals, organic semi-conductors, conducting 
polymers, organic light-emitting diodes (OLEDs) and lasers.2-5 One of the most 
convenient and well-established procedures for the synthesis of 2-aminothiophene 
derivatives is Gewald’s method,6 which involves the multicomponent condensation of 
ketones or aldehydes, activated nitrile and sulfur in the presence of a catalyst. 
 
          Zhang et al.7 carried out a one-pot synthesis of 4-substituted 3-amino-2-
cyanothiophenes (2) from 2-alkyl or aryl substituted acetonitrile (1) by sequential 
treatment with LDA, O-ethyl thioformate and 2-chloroacetonitrile at -40 °C. 
 
          Balamurugan et al.8 reported the reaction of 5-aryldihydro-3(2H)-thiophenones 
(3) with ethyl cyanoacetate/malononitrile and sulfur powder in the presence of 
morpholine under microwave irradiation and conventional thermal conditions afforded 
moderate yield of 2-amino-5-arylthieno[2,3-b]thiophenes (4). 
 
T 
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          Huang et al.9 synthesized 2-aminothiophene derivatives (6a-r) by the addition of 
carbonyl compounds (5a-r), dicyanomethane, sulfur and imidazole in DMF was stirred 
at 60 oC under nitrogen atmosphere. 
 
          Saravanan et al.10 carried out the reaction by refluxing a mixture of ketone (7), 
substituted cyano acetamide/acetanilide (8), ammonium acetate and glacial acetic acid 
in cyclohexane, the intermediate thus obtained was treated with sulfur and diethylamine 
that yield 2-amino-3-(N-substituted carboxamido)-4,5-tetramethylene thiophenes (9). 
 
          Han et al.11 carried out the synthesis of polysubstituted 2-aminothiophenes (11a-
n) from polysubstituted cyclopropane (10a-n), sulfur and morpholine in DMF was 
stirred at 60 oC. 
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          Mohareb et al.12 carried out the reaction of pregnenolone (12) with 3-oxo-3-
phenylpropanenitrile and ammonium acetate at 120 oC which afforded moderate yield 
of pregnenolone nitrile (13). Further, when the reaction was carried out with sulfur in 
1,4-dioxane containing NEt3, pregnenolone benzoylthiophene (14) was obtained. 
 
          Mohareb et al.13 synthesized pregnenolone thiophene (17). Pregnenolone (15) 
with malononitrile/ethyl cyanoacetate in addition of ammonium acetate gave 
pregnenolone ylidene (16). Further reaction of compound 16 with sulfur in 1,4-dioxane 
containing catalytic amount of NEt3 gave pregnenolone thiophene (17). 
 
          Jalani et al.14 reported a multicomponent reaction leading to quinazolinon-2-yl-
tetrasubstituted thiophenes (21), by reacting different enamino esters (18), 
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isothiocyanates (19) and 2-halomethyl quinazolinones (20) in one-pot to furnish 
compound 21 in good to excellent yields. 
 
          Mohareb et al.15 reported the synthesis of steroidal thiophene (23) from a mixture 
of androstenedione (22), sulphur and malononitrile/ethyl cyanoacetate in 1,4-dioxane 
containing NEt3. 
 
          Vatansever et al.16 reported the reaction of alkynones (24a-m) with 2,5-
dihydroxy-1,4-dithiane (25) in the presence of NEt3 followed by treatment with silica 
gel or HCl yielded 2,3-disubstituted thiophene derivatives (26a-m). 
 
 
  
 
 
Discussion 
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hiophenes are well known building blocks in synthetic organic chemistry. 
Literature survey revealed that numerous thiophene derivatives exhibit a wide 
range of biological and pharmacological properties such as antimicrobial and 
antitumor,17 antihypertensive,18 Gonadotropin releasing hormone antagonist,19,20 
cholesterol inhibition activity,21 antiallergic,22 analgesic and anti-inflammatory 
activities.23 These types of compounds are an important class of heterocyclic structures, 
that can be applied in drugs and pharmaceutical fields. Because of the importance of 
these scaffolds in synthetic organic chemistry and their usefulness as pharmacological 
active molecules, much attention has been focused on their synthesis. Continuing our 
efforts directed towards the synthesis of new steroidal heterocyclic compounds,24 we 
hereby report a prompt and novel synthesis of new steroidal thiophene derivatives (30-
35)* based on the reaction of steroidal ketones (27-29) with malononitrile/ethyl 
cyanoacetate and sulfur using biosynthesized ZnO nanoparticles as a catalyst. With the 
best of our knowledge there are no reports, however, describing the synthesis of 
steroidal thiophenes via nano ZnO as a catalyst. Elucidation of the proposed structures 
30-35 was based on their correct elemental analysis and spectral studies (IR, 1H NMR, 
13C NMR and MS). 
 
 
 
*Green synthesis of ZnO nanoparticles using bacillus subtilis and their catalytic 
performance in the one-pot synthesis of steroidal thiophenes. Shamsuzzaman, 
Abad Ali, M. Asif, A. Mashrai, H. Khanam. Eur. Chem. Bull., 2014, 3 (9), 939-945. 
T 
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Reaction of 3β-acetoxy-5α-cholestan-6-one (27) with malononitrile and sulfur: 3β-
Acetoxy-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene (30): 
3β-Acetoxy-5α-cholestan-6-one (27) on reaction with malononitrile and sulfur in the 
presence of ZnO nanoparticles in EtOH under reflux condition for 12.5 h and after usual 
work up, provided a single product 30, m.p. 167-169 °C. 
Characterization of compound 30 as 3β-acetoxy-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-
3ʹ-cyanothiophene: 
The elemental analysis of compound 30 corresponded to the molecular formula 
C32H48N2O2S. The IR data provided evidence for the formation of the expected 
compound. The IR absorption showed intense peaks at 3344 cm-1 for NH2 group and 
for CN and C-S groups the stretching vibration at 2210 and 714 cm-1, respectively. 
Further evidence for the formation of compound 30 was well supported by its 1H NMR 
and 13C NMR spectra. The 1H NMR spectrum of the compound 30 featured a signal at 
δ 6.21 integrating for two protons (exchangeable with D2O), which is characteristic 
signal for NH2 protons. A one proton broad multiplet centered at δ 4.7 was assigned to 
C3α-H (axial) and a sharp singlet for three acetoxy group protons appeared at δ 2.05. 
Angular and side-chain methyl protons were observed at δ 1.14 (C10-CH3), 1.2 (C13-
CH3), 1.04 and 1.02 for other methyl protons. 
13C NMR spectrum of the compound also 
supported the proposed structure and displayed characteristic signals at δ 172.5, 151.1, 
120.4 and 145.2 for OCOCH3, C=C-NH2, CN and C=C-S, respectively. Remaining 
carbon atoms were seen in accordance to the cholestane series. The structure of 
compound 30 was further supported by its mass spectrum in which the distinct 
molecular ion peak at m/z 524 was found. 
          On account of the above descriptive discussion, the compound 30 can be suitably 
characterized as 3β-acetoxy-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene. 
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Reaction of 3β-chloro-5α-cholestan-6-one (28) with malononitrile and sulfur: 3β-
Chloro-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene (31): 
3β-Chloro-5α-cholestan-6-one (28) on reaction with malononitrile and sulfur in the 
presence of ZnO nanoparticles in EtOH under reflux condition for 14 h and after usual 
work up, provided a single product 31, m.p. 154-156 °C. 
Characterization of compound 31 as 3β-chloro-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-
3ʹ-cyanothiophene: 
The elemental analysis of compound 31 corresponded to the molecular formula 
C30H45ClN2S. The IR data provided evidence for the formation of the expected 
compound. The IR absorption showed intense peaks at 3346 cm-1 for NH2 group and 
for CN and C-S groups the stretching vibration at 2215 and 716 cm-1, respectively. 
Further evidence for the formation of compound 31 was well supported by its 1H NMR 
and 13C NMR spectra. The 1H NMR spectrum of the compound 31 featured a signal at 
δ 6.24 integrating for two protons (exchangeable with D2O), which is characteristic 
signal for NH2 protons. A one proton broad multiplet centered at δ 3.8 was assigned to 
C3α-H (axial). Angular and side-chain methyl protons were observed at δ 1.14 (C10-
CH3), 1.2 (C13-CH3), 1.04 and 1.02 for other methyl protons. 
13C NMR spectrum of the 
compound also supported the proposed structure and displayed characteristic signals at 
δ 152.7, 120.4 and 148.3 for C=C-NH2, CN and C=C-S, respectively. Remaining 
carbon atoms were seen in accordance to the cholestane series. The structure of 
compound 31 was further supported by its mass spectrum in which the distinct 
molecular ion peak was observed at m/z 500/502. 
          On account of the above discussion, the compound 31 can be suitably 
characterized as 3β-chloro-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene. 
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Reaction of 5α-cholestan-6-one (29) with malononitrile and sulfur: 5α-Cholest-6-
eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene (32): 
5α-Cholestan-6-one (29) on reaction with malononitrile and sulfur in the presence of 
ZnO nanoparticles in EtOH under reflux condition for 15.5 h and after usual work up, 
provided a single product 32, m.p. 149-151 °C. 
Characterization of compound 32 as 5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-
cyanothiophene: 
The elemental analysis of compound 32 corresponded to the molecular formula 
C30H46N2S. The IR data provided evidence for the formation of the expected compound. 
The IR absorption showed intense peaks at 3343 cm-1 for NH2 group and for CN and 
C-S groups the stretching vibration at 2217 and 718 cm-1, respectively. Further evidence 
for the formation of compound 32 was well supported by its 1H NMR and 13C NMR 
spectra. The 1H NMR spectrum of the compound 32 featured a signal at δ 6.26 
integrating for two protons (exchangeable with D2O), which is characteristic signal for 
NH2 protons. Angular and side-chain methyl protons were observed at δ 1.14 (C10-
CH3), 1.2 (C13-CH3), 1.04 and 1.02 for other methyl protons. 
13C NMR spectrum of the 
compound also supported the proposed structure and displayed characteristic signals at 
δ 150.3, 119.7 and 147.5 for C=C-NH2, CN and C=C-S, respectively. Remaining 
carbon atoms were seen in accordance to the cholestane series. The structure of 
compound 32 was further supported by its mass spectrum in which the distinct 
molecular ion peak at m/z 460 was observed. 
          Thus, on account of above discussion, the compound 32 can be suitably 
characterized as 5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene. 
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Reaction of 3β-acetoxy-5α-cholestan-6-one (27) with ethyl cyanoacetate and sulfur: 
3β-Acetoxy-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene (33): 
3β-Acetoxy-5α-cholestan-6-one (27) on reaction with ethyl cyanoacetate and sulfur in 
the presence of ZnO nanoparticles in EtOH under reflux condition for 13 h and after 
usual work up, provided a single product 33, m.p. 175-177 °C. 
Characterization of compound 33 as 3β-acetoxy-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-
3ʹ-carboethoxythiophene: 
The elemental analysis of compound 33 corresponded to the molecular formula 
C34H53NO4S. The IR data provided evidence for the formation of the expected 
compound. The IR absorption showed intense peaks at 3340 cm-1 for NH2 group and 
for COOC2H5 and C-S groups the stretching vibration at 1669 and 718 cm
-1, 
respectively. Further evidence for the formation of compound 33 was well supported 
by its 1H NMR and 13C NMR spectra. The 1H NMR spectrum of the compound 33 
featured a signal at δ 6.22 integrating for two protonss (exchangeable with D2O), which 
is characteristic signal for NH2 protons. A one proton broad multiplet centered at δ 4.7 
was assigned to C3α-H (axial) and a sharp singlet for three acetoxy group protons 
appeared at δ 2.05. Angular and side-chain methyl protons were observed at δ 1.14 (C10-
CH3), 1.2 (C13-CH3), 1.04 and 1.02 for other methyl protons. 
13C NMR spectrum of the 
compound also supported the proposed structure and displayed characteristic signals at 
δ 175.5, 168.3, 151.5 and 142.1 for OCOCH3, C=C-NH2, COOC2H5 and C=C-S, 
respectively. Remaining carbon atoms were seen in accordance to the cholestane series. 
The mass spectrum also supported the compound 33 with distinct molecular ion peak 
at m/z 571. 
          The above discussion suitably characterized the compound 33 as 3β-acetoxy-5α-
cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene. 
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Reaction of 3β-chloro-5α-cholestan-6-one (28) with ethyl cyanoacetate and sulfur: 
3β-Chloro-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene (34): 
3β-Chloro-5α-cholestan-6-one (28) on reaction with ethyl cyanoacetate and sulfur in 
the presence of ZnO nanoparticles in EtOH under reflux condition for 18 h and after 
usual work up, provided a single product 34, m.p. 176-178 °C. 
Characterization of compound 34 as 3β-chloro-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-
3ʹ-carboethoxythiophene: 
The elemental analysis of compound 34 corresponded to the molecular formula 
C32H50ClNO2S. The IR data provided evidence for the formation of the expected 
compound. The IR absorption showed intense peaks at 3339 cm-1 for NH2 group and 
for COOC2H5 and C-S groups the stretching vibration at 1665 and 720 cm
-1, 
respectively. Further evidence for the formation of compound 34 was well supported 
by its 1H NMR and 13C NMR spectra. The 1H NMR spectrum of the compound 34 
featured a signal at δ 6.27 integrating for two protons (exchangeable with D2O), which 
is characteristic signal for NH2 protons. A one proton broad multiplet centered at δ 3.8 
was assigned to C3α-H (axial). Angular and side-chain methyl protons were observed 
at δ 1.14 (C10-CH3), 1.2 (C13-CH3), 1.04 and 1.02 for other methyl protons. 13C NMR 
spectrum of the compound also supported the proposed structure and displayed 
characteristic signals at δ 169.5, 152.2 and 143.6 for C=C-NH2, COOC2H5 and C=C-S, 
respectively. Remaining carbon atoms were seen in accordance to the cholestane series. 
The distinct molecular ion peak at m/z 547/549 in mass spectrum also supported the 
formation of compound 34. 
          Thus, the compound 34 on account of above discussion can be suitably 
characterized as 3β-chloro-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-
carboethoxythiophene. 
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Reaction of 5α-cholestan-6-one (29) with ethyl cyanoacetate: 5α-Cholest-6-eno-[6,7-
d]-2ʹ-amino-3ʹ-carboethoxythiophene (35): 
5α-Cholestan-6-one (29) on reaction with ethyl cyanoacetate and sulfur in the presence 
of ZnO nanoparticles in EtOH under reflux condition for 16 h and after usual work up, 
provided a single product 35, m.p. 175-177 °C. 
 
Characterization of compound 35 as 5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-
carboethoxythiophene: 
The elemental analysis of compound 35 corresponded to the molecular formula 
C32H51NO2S. The IR absorption showed intense peaks at 3335 cm
-1 for NH2 group and 
for COOC2H5 and C-S groups the stretching vibration at 1668 and 716 cm
-1, 
respectively. The 1H NMR spectrum of the compound 35 featured a signal at δ 6.25 
integrating for two protons (exchangeable with D2O), which is characteristic signal for 
NH2 protons. Angular and side-chain methyl protons were observed at δ 1.14 (C10-
CH3), 1.2 (C13-CH3), 1.04 and 1.02 for other methyl protons. 
13C NMR spectrum 
displayed characteristic signals at δ 171.5, 152.3 and 145.7 for C=C-NH2, COOC2H5 
and C=C-S, respectively, also supported the proposed structure of the compound 35. 
Remaining carbon atoms were seen in accordance to the cholestane series. Further, the 
structure of compound 35 was supported by its mass spectrum in which the distinct 
molecular ion peak was observed at m/z 513. 
          Therefore, on account of the above discussion, the compound 35 can be suitably 
characterized as 5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene. 
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Characterization of catalyst 
UV-vis spectrophotometry study 
The UV-vis absorption spectrum findings demonstrate a novel technique for the 
preparation of ZnO nanoparticles (Figure 1), by dispersing ZnO nanoparticles in 
distilled water and using distilled water as the reference. An absorption peak focused at 
375 nm (3.31 eV) was found. The electronic band gap (Eg) of ZnO nanoparticles was 
determined by employing the following relationship: 
Eg = h c/λ 
Where,  
               h is Planck’s constant  
               c is speed of light  
               λ is the cut off wavelength value of ZnO nanoparticles. 
 
Figure 1. UV-vis spectrum of ZnO nanoparticles. 
 
Fourier transform infrared spectroscopy 
The synthesized zinc oxide nanoparticles showed peaks at 3414.57 cm-1 for NH2 
stretching in adenine, cytosine, quinine and H-bonded OH groups while 2934.14 cm-1 
for C-H stretching in aliphatics of cell walls (fatty acids, carbohydrates). 1625.64 cm-1 
for NH2 bending, C=O, C=N stretching (amide I band). The peak at 1385.69 cm
-1 for 
amide III band and 1052.22 cm-1 for C-O-C asymmetric stretching in aliphatic esters 
(Figure 2).25 Zn-O-Zn stretching modes at 609.33 cm-1 were well supported by 
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available literature.26 These peaks are the combined characteristics of ZnO 
nanoparticles and bacterial strain. 
 
Figure 2. FTIR spectrum of ZnO nanoparticles. 
 
 
 
XRD analysis 
X-ray diffraction was taken in order to further confirm ZnO phase of the nanoparticles. 
The XRD patterns of the obtained ZnO nanoparticles are shown in Figure 3. Powder 
XRD of the product was carried out with Cu Kα radiation (λ = 1.54056 Å), employing 
a scanning rate of 0.02° s-1 and 2θ ranges from 20o to 80o for ZnO. The observed peaks 
correspond to the Bragg angle for the (100), (002), (101), (102), (110) and (200) planes 
of the crystalline ZnO, which are consistent with standard JCPDS No. 89-7102 and no 
indication of a secondary phase. All the peaks of XRD are very well matched with the 
hexagonal phase (wurtzite structure). The strong and narrow diffraction peaks indicate 
that the product has good crystalline structure. The crystallite size of the nanoparticles 
was calculated using Debye Scherrer formula: 
𝐷 = 𝐾 
𝜆
𝛽𝑐𝑜𝑠𝜃
 
 
Where, 
            K is constant 
            λ is the wavelength of employed X-rays (1.54056 Ǻ) 
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            β is corrected full width at half maximum 
            θ is Bragg’s angle. 
The 2θ value from the equation comes out to be at 35.81 and therefore the calculated 
crystallite size of the powder particles is about 24 nm. 
 
Figure 3. XRD analysis of ZnO nanoparticles. 
 
 
 
 
SEM and TEM analysis 
The conformation of the nanostructural morphology of ZnO nanoparticles comes from 
the analysis of SEM and TEM micrographs. SEM micrograph (Figure 4) showed the 
average size of nanoparticles between 20-30 nm. 
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Figure 4. SEM image of the ZnO nanoparticles. 
 
 
 
The size and morphology of ZnO nanoparticles analyzed by TEM is represented in 
Figure 5. This image reveals that most of the ZnO nanoparticles are quasi-spherical 
and their diameter is about ~25 nm. This result is in agreement with the value calculated 
from the X-ray diffraction. 
 
Figure 5. TEM image of the ZnO nanoparticles. 
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Photoluminescence analysis 
The Photoluminescence spectrum of ZnO nanoparticles consists of two emission peaks 
(Figure 6). A weak deep-level emission at 2.25 eV in the visible range is caused by a 
structural defect. The other peak in the UV range at 3.1 eV which can be explained by 
the direct combination of excitons through an exciton-exciton collision process and the 
lower energy peak in the asymmetric UV emission is associated with band-to-acceptor 
transitions due to the large binding energy of ZnO nanoparticles. 
 
Figure 6. The Photoluminescence spectrum of ZnO nanoparticles. 
 
Thermal stability 
The thermo gravimetric analysis (TGA) has been performed on the biosynthesized ZnO 
nanoparticles. TGA curve in Figure 7, indicates that the weight loss starts at 200 oC 
because of the evaporation of water, the major weight loss occurs between 320-430 oC, 
which is around 40 % of the original weight due to the removal and decomposition of 
organic groups present during the biosynthesis. No decomposition or reaction occurs at 
temperatures above 500 °C. 
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Figure 7. TGA curve of ZnO nanoparticles. 
 
 
The catalytic performance of ZnO nanoparticles in the synthesis of steroidal 
thiophenes 
The catalytic system is influenced by various parameters, such as amount of the catalyst 
employed, effect of catalyst and solvent system. 3β-Acetoxy-5α-cholestan-6-one, 
malononitrile and sulfur powder in EtOH were selected as model substrates for carrying 
out the optimization studies for the synthesis of steroidal thiophenes. Initially, the 
model reaction was performed in the absence of ZnO nanoparticles and the reaction did 
not proceeded even with very long reaction time. When the model reaction was 
examined with ZnO nanoparticles the reaction was accelerated. 
 
Catalytic loading 
It was observed that yield was increased with enhancing catalyst concentration. The 
yield was increased from 38 to 70 % by enhancing the catalyst amount from 0.5 to 2.5 
mol % (Table 1). Further increase in the catalyst concentration from 2.5 to 3.5 mol %, 
did not showed any profound effect on the reaction rate as well as the yield. This may 
be attributed to the coagulation of ZnO nanoparticles which decreases the effective 
surface area of the catalyst. 
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Table 1. Effect of catalyst loading on the model reaction. 
Entry Catalysts (mol %) Time (h)                         Yield (%)a 
1 0.5 19 38 
2 1 18 44 
3 1.5 14 53 
4 2.5 12 70 
5 3 12 70 
6 3.5 12 70 
aYield are related to isolated pure products. 
Effect of solvent 
We then tried to screen the reaction in various organic solvents in order to optimize the 
reaction conditions using ZnO nanoparticles as catalyst (Table 2). 
 
Table 2. Solvent screening for the model reaction. 
Entry Solvent Yield (%)a 
1 EtOH 70 
2 Methanol 62 
3 DMF 60 
4 1,4-Dioxane 45 
5 Benzene 30 
aYield are related to isolated pure products. 
The solvent screening experiments revealed that the reaction yield is dependent on the 
polarity and the coordinating ability of the solvents. The use of relatively less polar 
aprotic solvents like DMF and 1,4-dioxane yielded the product in moderate yield while 
non-polar aprotic solvents like benzene afforded poor yield, after extended reaction 
time. However, polar protic solvents, MeOH and EtOH afforded better yield than other 
solvents (less polar/non-polar aprotic solvents) and the best result was obtained in 
ethanol with dip in reaction time in which ZnO nanocatalyst worked most efficiently 
by phasing out of the desired product. Thus, the catalytic activity of ZnO nanocatalysts 
in various solvents was found to be in the order of EtOH > MeOH > DMF > 1,4-
Dioxane > Benzene.  
 
Recyclability of catalyst 
After completion of the model reaction in specified time, the catalyst was recovered by 
filtration, washed with dichloromethane and methanol and dried at 150 ºC for 4 h and 
used for the subsequent cycle (Figure 8).28 The results revealed that the catalyst 
exhibited good catalytic activity up to six cycles. 
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Figure 8. Recyclability of ZnO nanoparticles. 
 
 
 
Studying the superiority of ZnO nanoparticles over some other catalyst 
Various catalysts were employed to evaluate the capability and efficiency of the catalyst 
(Table 3). The model reaction was examined with imidazole, morpholine, diethyl 
amine and ZnO (bulk) using 2.5 mol % of each catalyst separately, the reaction took 
longer time period for completion with lower yield of the product. With ZnO 
nanoparticles the reaction was accelerated and yield of the desired product was 
maximum. 
 
Table 3. The superiority of ZnO nanoparticles over other reagents. 
Entry Catalyst Time (h) Yield (%)a 
1 Without catalyst 45 - 
2 Imidazole 22 58 
3 Morpholine 20 45 
4 Diethyl amine 26 52 
5 ZnO (bulk) 18 53 
6 ZnO NP’s 12 70 
aYield are related to isolated pure products. 
 
Proposed reaction pathway for the synthesis of steroidal thiophenes 
There are two possibilities for the illustration of mechanistic route for the synthesis of 
steroidal thiophenes using nano-ZnO as catalyst is presented in Scheme 1. The 
mechanism involves a three-step process and nano-ZnO has dual characters of Lewis 
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acidic (Zn2+) in one hand and Lewis basic sites (O2-) on the other.28 In the first step, 
Lewis acid sites of ZnO (Zn2+) coordinates to the oxygen of the carbonyl group, hence 
reactivity of carbonyl group increases. Moreover, the Lewis basic sites of nano-ZnO 
(O2-) deprotonated the malononitrile/cyano ethylacetate and then a nucleophilic attack 
to the activated carbonyl group proceeds the reaction forward. As it is presented in 
Scheme 1, the substituted 2-aminothiophene ring is formed during the multi-step 
reaction sequences of (a) condensation, (b) addition of sulfur and (c) ring-closure. At 
first, the methylene group of malononitrile/cyano ethylacetate is being deprotonated 
and then sulfur addition takes place. The ring closure step is the most crucial step which 
is performed as an intra-molecular nucleophilic attack of the sulfur anion to triple bond 
of the cyano group.29 It should be noted that the target 2-aminothiophene in principle 
exists in equilibrium with the tautomeric form of cyclic imine formed during the 
cyclization. However, it is proved, that the parent aminothiophene occurs exclusively 
in the amino form and it is sure that S8 has to be activated to react with Knoevenagel-
Cope product. ZnO nanoparticles may help this crucial step. 
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Scheme 1. Plausible reaction mechanism for the synthesis of steroidal thiophene 
derivatives (30-35). 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental 
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eneral remarks 
Melting points were recorded on Riechert Thermover instrument and are 
uncorrected. IR spectra (KBr disks) were recorded on Perkin Elmer FT-IR 
Spectrometer spectrum two and its values are given in cm-1. 1H and 13C NMR spectra 
were run in CDCl3 on a Bruker Avance II 400 NMR Spectrometer at 400 MHz and 100 
MHz, respectively. Chemical shifts (δ) are reported in ppm relative to the TMS (1H 
NMR spectra) and to the solvent signal (13C NMR spectra). Mass Spectra were recorded 
on a Waters, Micromass Q-TOF micro YB361, UK. Elemental analysis of all the newly 
synthesized compounds were recorded on Perkin Elmer 2400 CHN Elemental Analyzer 
within ± 0.4 % of the theoretical values. Thin layer chromatography (TLC) plates were 
coated with silica gel G and exposed to iodine vapors to check the homogeneity as well 
as the progress of reaction. Sodium sulfate (anhydrous) was used as a drying agent. The 
optical absorbance spectra were taken by using UV-vis double beam Perkin-Elmer 
LAMBDA 35 spectrophotometer at room temperature in the wavelength range of 250-
800 nm. X-ray diffraction (XRD) patterns of the samples were obtained at room 
temperature, with a step of 0.02°, using Bruker D8 ADVANCE X-ray diffractometer 
with Cu Kα radiation (λ = 1.54178 Å) in the range of 0° < 2θ < 100° at 40 kV. SEM 
images were obtained using a field emission scanning electron microscope (JSM-
7600F, JEOL, Tokyo Japan) at an accelerating voltage of 15 kV and TEM images were 
obtained with ultra-high resolution FETEM (JEOL, JEM-2100F) at an accelerating 
voltage of 200 kV. Photoluminescence (PL) spectra were measured using a Cary 
Eclipse EL06063917 fluorescence spectrophotometer with a xenon arc lamp as the light 
source. The thermal studies were carried out using TGA instrument (SHIMADZU) at a 
heating rate of 20 oC min-1. 
 
3β-Acetoxycholest-5-ene: 
A mixture of cholesterol (100.0 g), pyridine (150 mL, freshly distilled over KOH) and 
freshly distilled acetic anhydride (100 mL) was heated on a water bath for 2 h. The 
reaction mixture was poured into ice cold water and solid mass thus obtained was 
filtered under suction, washed thoroughly with water until free from pyridine and then 
air dried. Recrystallization of the crude product from acetone gave 3β-acetoxycholest-
5-ene (95.0 g), m.p. 114 oC (reported, m.p. 115-116 °C).30 
 
 
G 
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3β-Acetoxy-6-nitrocholest-5-ene: 
To a cooled mixture of 3β-acetoxycholest-5-ene (10.0 g) and conc. nitric acid (250 mL), 
sodium nitrite (10.0 g) was gradually added with constant stirring over a period of about 
45 minutes. After complete addition of sodium nitrite stirring was continued for 
additional 2 h. Cold water (300 mL) was added to reaction mixture, yellow solid 
material separated out. The whole mass was extracted with diethyl ether. The ethereal 
layer was washed with water, NaHCO3 solution (5%) (until washings become pink), 
water and dried over anhydrous sodium sulfate. Removal of the solvents provided the 
nitro compound (6.5 g) as an oil which was crystallized from methanol, m.p. 104 °C. 
(reported m.p. 102-104 °C).31 
 
3β-Acetoxy-5α-cholestan-6-one (27): 
3β-Acetoxy-6-nitrocholest-5-ene (6.0 g) was dissolved in glacial acetic acid (120 mL) 
by warming the mixture and zinc dust (12.0 g) was added in small portions with 
shaking. The suspension was heated under reflux for 4 h and water (12 mL) was added 
at regular intervals during the course of reaction. The hot solution was filtered, cooled 
to room temperature and diluted with large excess of ice-cold water and extracted with 
diethyl ether. The ethereal solution was washed with water, NaHCO3 solution (5%) and 
again with water and dried over anhydrous sodium sulfate. Evaporation of solvents 
provided the acetoxy ketone (4.2 g) as an oil which was crystallized from methanol, 
m.p. 128-129 °C (reported m.p. 127-128 °C).32 
 
3β-Chlorocholest-5-ene: 
Freshly distilled SOCl2 (20 mL) was added gradually to cholesterol (25.0 g) at room 
temperature. A vigorous reaction ensured with evolution of gaseous products. When 
the reaction slackened, the mixture was gently heated at temperature 50-60 °C on water 
bath for 1 h and then poured into water with constant stirring. The yellow solid thus 
obtained was filtered under suction and washed several times with ice-cold water and 
air dried. Recrystallization from acetone gave 3β-chlorocholest-5-ene (20.0 g), m.p. 95-
96 °C (reported, m.p. 96-97 °C).33 
 
3β-Chloro-6-nitrocholest-5-ene: 
To a well stirred mixture of 3β-chlorocholest-5-ene (14.0 g), glacial acetic acid (100 
mL) and fuming nitric acid (28 mL; d, 1.52) at temperature below 20 oC, was added 
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sodium nitrite (3.0 g) gradually over a period of 1 h. After the complete addition of 
sodium nitrite, the mixture was further stirred for an additional period of 2 h. Now ice-
cold water was added to it and the yellowish solid thus separated was filtered, washed 
with cold water and air dried. The desired product was recrystallized from methanol to 
give 3β-chloro-6-nitrocholest-5-ene (8.9 g), m.p. 151-152 oC (reported m.p. 153 °C).34 
 
3β-Chloro-5α-cholestan-6-one (28): 
A mixture of 3β-chloro-6-nitrocholest-5-ene (8.0 g) and glacial acetic acid (160 mL) 
was heated just to get a clear solution. The zinc dust (16.0 g) was added gradually in 
small portions with constant shaking. The suspension was heated under reflux for 4 h 
and water (16 mL) was added at regular intervals during the course of reaction. The hot 
solution was filtered and the filtrate was diluted with large excess of ice-cold water. 
The organic matter was extracted with diethyl ether and ethereal layer was washed 
successively with water, NaHCO3 solution (5 %) and again with water and dried over 
anhydrous sodium sulfate. Evaporation of the solvents furnished the ketone (5.8 g) as 
an oil which was crystallized from methanol, m.p. 128-129 °C (reported m.p. 127-128 
°C).35 
 
Cholest-5-ene: 
3β-Chlorocholest-5-ene (10.0 g) was dissolved in warm amyl alcohol (230 mL) and 
sodium metal (20.0 g) was added to the solution with continuous stirring over the period 
of 8 h. The reaction mixture was warmed occasionally. When all the sodium metal was 
dissolved, methanol was added and the reaction mixture was poured into water, 
acidified with HCl and then allowed to stand overnight. A white crystalline solid thus 
obtained was filtered under suction and washed thoroughly with water and air dried. 
The crude material was recrystallized from acetone to provide cholest-5-ene as cubes 
(8.3 g), m.p. 88-89 oC (reported m.p. 89-91 °C).36 
 
6-Nitrocholest-5-ene: 
A suspension of finely powdered cholest-5-ene (6.0 g), in glacial acetic acid (50 mL) 
was vigorously stirred at room temperature for 5 minutes and treated with fuming HNO3 
(15 mL; d, 1.52) followed by the addition of sodium nitrite (3.0 g) in portion, and the 
stirring was continued for further 2 h. The temperature of the reaction mixture was 
maintained below 20 °C by external cooling. The reaction mixture was poured into cold 
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water and the yellow product thus obtained was extracted with diethyl ether. The 
ethereal layer was washed successively with water, NaHCO3 solution (10 %) (until the 
washing were pink) and again with water and dried over anhydrous sodium sulfate. 
Removal of solvents provided the desired compound as an oil which was crystallized 
from methanol as leaflets (4.5 g), m.p. 119-120 oC (reported m.p. 120-121 oC).37 
 
5α-Cholestan-6-one (29): 
6-Nitrocholest-5-ene (4.0 g) was dissolved in warm glacial acetic acid (80 mL) and zinc 
dust (8.0 g) was gradually added with shaking. The mixture was heated under reflux for 
4 h and water (8 mL) was added during the course of reaction. Zinc dust (unreacted) 
was removed by filtration. To the filtrate, water was added till turbidity developed and 
it was allowed to stand overnight at room temperature. The solid material thus separated 
was filtered under suction and washed thoroughly with water in order to remove zinc 
acetate. The organic solid (2.4 g) was air dried and then recrystallized from methanol, 
m.p. 96-98 oC (reported m.p. 98-100 °C).38 
 
General procedure for synthesis of steroidal thiophene derivatives (30-35): 
A mixture of 5α-cholestan-6-one (27-29) (1 mmol), malononitrile/ethyl cyanoacetate 
(1 mmol), S8 (1 mmol) and ZnO nanoparticles as a catalyst (0.003 g), in EtOH (15 mL) 
was refluxed for 12-18 h. The progress of the reaction was followed by TLC. After 
completion of the reaction, the mixture was filtered to remove the catalyst and the 
filtrate was taken in diethyl ether, washed with water and dried over anhydrous sodium 
sulfate. Removal of solvent gave the crude product which was purified by column 
chromatography (petroleum ether/ether) and recrystallization from methanol to obtain 
the pure products (30-35). 
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3β-Acetoxy-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene (30): 
Brown powder, Yield (70 %), m.p. 167-169 °C; 
IR (KBr, v cm
-1): 3344 (NH2), 2210 (CN), 1713 
(OCOCH3), 1623, 1621 (C=C), 1068 (C-O), 714 
(C-S); 1H NMR (400 MHz, CDCl3, ppm): δ 6.21 
(2H, brs, NH2, exchangeable with D2O), 4.7 (1H, 
m, C3α-H, W½ = 14 Hz), 2.3 (dd, 1H, J = 7.55, 
4.52 Hz, C5-H), 2.05 (3H, s, OCOCH3), 1.2 (3H, 
s, C13-CH3), 1.14 (3H, s, C10-CH3), 1.04 and 1.02 (other methyl protons); 
13C NMR 
(100 MHz, CDCl3, ppm): δ 172.5, 151.1, 145.2, 137.7, 120.4, 85.1, 75.5, 58.6, 50.1, 
46.9, 45.2, 43.4, 40.6, 37.3, 35.3, 34.2, 33.9, 32.1, 31.0, 29.5, 27.5, 26.9, 25.2, 24.1, 
23.9, 22.7, 21.2, 20.9, 19.5, 17.6, 15.3, 13.1; Anal. Calcd for C32H48N2O2S; C, 73.24, 
H, 9.22, N, 5.34 found; C, 73.29, H, 9.24, N, 5.37; MS (EI): m/z 524 [M+.]. 
 
3β-Chloro-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene (31): 
Green brown powder, Yield (72 %), m.p. 154-156 
°C; IR (KBr, v cm
-1): 3346 (NH2), 2215 (CN), 1620, 
1624 (C=C), 742 (C-Cl), 716 (C-S); 1H NMR (400 
MHz, CDCl3, ppm): δ 6.24 (2H, brs, NH2, 
exchangeable with D2O), 3.8 (1H, m, C3α-H, W½ = 
17 Hz), 2.2 (dd, 1H, J = 7.53, 4.56 Hz, C5-H), 1.2 
(3H, s, C13-CH3), 1.14 (3H, s, C10-CH3), 1.04 and 
1.02 (other methyl protons); 13C NMR (100 MHz, CDCl3, ppm): δ 152.7, 148.3, 137.1, 
120.4, 87.4, 66.3, 59.9, 55.7, 51.7, 48.5, 45.9, 41.6, 40.2, 39.4, 38.9, 37.4, 36.2, 34.9, 
32.7, 31.5, 30.7, 28.6, 27.4, 26.3, 25.4, 24.9, 23.7, 20.6, 16.8, 14.8; Anal. Calcd for 
C30H45ClN2S; C, 71.89, H, 9.05, N, 5.59 found; 71.87, H, 9.09, N, 5.57; MS (EI): m/z 
500/502 [M+.]. 
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5α-Cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene (32): 
Brown powder, Yield (71 %), m.p. 149-151 °C; IR (KBr, 
v cm
-1): 3343 (NH2), 2217 (CN), 1630, 1617 (C=C), 718 
(C-S); 1H NMR (400 MHz, CDCl3, ppm): δ 6.26 (2H, 
brs, NH2, exchangeable with D2O), 2.7 (dd, 1H, J = 7.51, 
4.53 Hz, C5-H), 1.2 (3H, s, C13-CH3), 1.14 (3H, s, C10-
CH3), 1.04 and 1.02 (other methyl protons); 
13C NMR 
(100 MHz, CDCl3, ppm): δ 150.3, 147.5, 139.1, 119.7, 
85.1, 61.4, 59.7, 55.1, 49.4, 46.1, 43.5, 42.7, 41.5, 40.2, 38.7, 37.4, 35.2, 32.6, 31.5, 
30.4, 29.3, 27.1, 26.3, 25.6, 24.1, 23.7, 20.5, 17.2, 14.3, 12.9; Anal. Calcd for 
C30H46N2S; C, 77.20, H, 9.93, N, 6.00 found; C, 77.24, H, 9.97, N, 6.02; MS (EI): m/z 
460 [M+.]. 
 
3β-Acetoxy-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ- carboethoxythiophene (33): 
Brown powder, Yield (74 %), m.p. 175-177 °C; 
IR (KBr, v cm
-1): 3340 (NH2), 1710 (OCOCH3), 
1669 (COOC2H5), 1620, 1618 (C=C), 1246, 
1136 (C-O), 718 (C-S); 1H NMR (400 MHz, 
CDCl3, ppm): δ 6.22 (2H, brs, NH2, 
exchangeable with D2O), 4.34 (2H, q, J = 7.02, 
CH2), 4.7 (1H, m, C3α-H, W½ = 14 Hz), 2.6 (dd, 
1H, J = 7.52, 4.51 Hz, C5-H), 2.05 (3H, s, OCOCH3), 1.2 (3H, s, C13-CH3), 1.14 (3H, 
s, C10-CH3), 1.04 and 1.02 (other methyl protons); 
13C NMR (100 MHz, CDCl3, ppm): 
δ 175.5, 168.3, 151.5, 142.1, 139.5, 118.7, 77.8, 65.3, 59.7, 56.9, 52.1, 45.7, 43.2, 42.1, 
40.5, 39.5, 37.4, 36.2, 35.6, 33.1, 30.6, 29.9, 28.1, 26.6, 24.1, 23.9, 22.8, 21.0, 20.9, 
19.9, 16.1, 15.6, 13.9, 12.4; Anal. Calcd for C34H53NO4S; C, 71.41, H, 9.34, N, 2.45 
found; C, 71.45, H, 9.38, N, 2.49; MS (EI): m/z 571 [M+.]. 
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3β-Chloro-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene (34): 
Green brown powder, Yield (72 %), m.p. 176-178 
°C; IR (KBr, v cm
-1): 3339 (NH2), 1665 (COOC2H5), 
1623, 1615 (C=C), 1140 (C-O), 740 (C-Cl), 720 (C-
S); 1H NMR (400 MHz, CDCl3, ppm): δ 6.27 (2H, 
brs, NH2, exchangeable with D2O), 4.35 (2H, q, J = 
7.01, CH2), 3.8 (1H, m, C3α-H, W½ = 16 Hz), 2.7 
(dd, 1H, J = 7.55, 4.53 Hz,C5-H), 1.2 (3H, s, C13-
CH3), 1.14 (3H, s, C10-CH3), 1.04 and 1.02 (other methyl protons); 
13C NMR (100 MHz, 
CDCl3, ppm): δ 169.5, 152.2, 143.6, 140.1, 114.6, 67.1, 64.2, 59.9, 56.1, 53.7, 49.4, 
45.4, 41.5, 40.2, 39.1, 38.3, 37.2, 36.5, 34.7, 32.9, 30.5, 29.3, 28.9, 26.3, 25.2, 24.5, 
23.9, 21.7, 20.6, 17.2, 15.7, 13.1; Anal. Calcd for C32H50ClNO2S; C, 70.10, H, 9.19, N, 
2.55 found; C, 70.13, H, 9.16, N, 2.52; MS (EI): m/z 547/549 [M+.]. 
 
5α-Cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene (35): 
Brown powder, Yield (71 %), m.p. 175-177 °C; IR 
(KBr, v cm
-1): 3335 (NH2), 1668 (COOC2H5), 1623, 
1621 (C=C), 1138 (C-O), 716 (C-S); 1H NMR (400 
MHz, CDCl3, ppm): δ 6.25 (2H, brs, NH2, 
exchangeable with D2O), 4.32 (2H, q, J = 7.02, CH2), 
2.7 (dd, 1H, J = 7.53, 4.54 Hz, C5-H), 1.2 (3H, s, C13-
CH3), 1.14 (3H, s, C10-CH3), 1.04 and 1.02 (other 
methyl protons); 13C NMR (100 MHz, CDCl3, ppm): δ 171.4, 152.3, 145.7, 138.2, 
118.1, 65.7, 59.6, 57.7, 53.1, 46.2, 44.5, 43.2, 42.9, 41.7, 40.5, 39.7, 37.3, 35.1, 32.1, 
31.7, 29.1, 28.3, 27.2, 25.9, 24.1, 23.4, 22.9, 21.5, 20.9, 17.3, 15.6, 13.9; Anal. Calcd 
for C32H51NO2S; C, 74.80, H, 10.00, N, 2.73 found; C, 74.83, H, 10.02, N, 2.70; MS 
(EI): m/z 513 [M+.]. 
 
Synthesis of ZnO nanoparticles 
ZnO nanoparticles were biosynthesized under green conditions by using B. subtilis as 
a green, reusable, nontoxic and inexpensive heterogeneous catalyst. 
Bacillus subtilis cells were allowed to grow as a suspension culture in sterile distilled 
water containing nutrient broth media for 24 h. 25 mL of culture was taken and diluted 
four times by adding 75 mL of sterile distilled water containing nutrients. This diluted 
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culture solution was again allowed to grow for 24 h. 50 mM zinc acetate dihydrate 
aqueous solution was injected into the bacterial suspension at a rate of 10 mL min-1 
through a buret. After the mixture was stirred for 30 min, 200 mL of a 50 mM NaBH4 
aqueous solution as the reducing agent, was slowly poured into the mixture at a flow 
rate of 10 mL min-1 through the buret. Then the final mixture was robustly stirred for 
24 h at room temperature. After the mixture was fully reacted, the mixture was 
centrifuged and subsequently the precipitate was collected.39 
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hiazolidinones (1-3) are thiazolidine derivatives and have an atom of sulfur at 
position 1, an atom of nitrogen at position 3 and a carbonyl group at position 2, 
4, or 5. However, its derivatives belong to the most frequently studied moieties and its 
presence in penicillin was the first recognition of its occurrence in nature.1,2 Similarly 
1,3-thiazolidin-4-ones (2) are heterocyclic nucleus that have an atom of sulfur and 
nitrogen at position 1 and 3, respectively and a carbonyl group at position 4 have been 
subjected to extensive study in the recent years.  
 
The 4-thiazolidinone scaffold is very versatile and has featured in a number of clinically 
used drugs. They have found uses as antitubercular, antimicrobial, anti-inflammatory 
and as antiviral agents, especially as anti-HIV agents. That’s why preparation of 
thiazolidinone itself shows remarkable interest and has been highly attractive area of 
synthetic organic chemistry. 
          Mali et al.3 carried out the reaction of quinazolinyl azomethines (4) with 
mercaptoacetic acid in the presence of silica chloride as a catalyst to accelerate the intra-
molecular cyclocondensation under solvent-free condition, yielded 4-thiazolidinones 
(5). 
 
          Kunzler et al.4 reported the reaction of 2-(piperidin-2-yl)ethyl amine (6) with 
arenealdehyde (7) in addition of mercaptoacetic acid in toluene was heated at 110 oC, 
yielded thiazolidinones derivatives (8). 
 
T 
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          Foroughifar et al.5 synthesized thiazolidin-4-one derivatives (11a-k) by the 
addition of aromatic aldehydes (9a-f), aromatic amine (10a-d) and thioglycolic acid in 
the presence of catalyst under solvent free condition at 70 oC for 2 h. 
 
           Anekal and Biradar6 reported the reaction of ethyl 2-hydrazinyl-5,6-dihydro-5-
oxo-4H-1,3,4-thiadiazine-6-carboxylate (12) with 2,5-disubstituted-1H-indol-3-
carboxaldehydes (13a-g) and fused sodium acetate in EtOH that yielded ethyl 2-{(2E)-
2-[(-[(5,2-disubstituted-1H-indol-3-yl)methyleno]hydrazine}-5-oxo-5,6-dihydro-4H-
1,3,4-thiadiazine-6-carboxylate (14a-g) which upon reaction with mercaptoacetic acid 
and catalytic amount of zinc chloride (anhydrous) in DMF to provide corresponding 
ethyl 2-[2-(2,5-disubstituted-1H-indol-3-yl)-4-oxothiazolid-3-ylamino]-5,6-dihydro-5-
oxo-4H-1,3,4-thiadiazine-6-carboxylate (15a-g). 
 
          Suthar et al.7 reported the reaction of amine (16) and aldehyde (17) in THF under 
ice cold condition and further thioglycolic acid was added followed by addition of DCC 
at 0 oC to provide corresponding 4-(4-oxo-2-arylthiazolidin-3-yl)benzenesulfonamides 
(18). 
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          Desai et al.8 reported the reaction of 2-chloroquinoline-3-carbaldehyde (19) with 
3-amino-2-phenyl-4(3H)-quinazolinone (20) in ethanol and a few drops of glacial 
acetic acid was added that yielded 3-((2-chloroquinolin-3-yl)methyleneamino)-2-
phenylquinazolin-4(3H)-one (21) which later reacted with mercaptoacetic acid in 1,4-
dioxane in presence of anhydrous ZnCl2 to provide the resultant 2-(2-chloroquinolin-3-
yl)-3-(4-oxo-2-phenylquinazolin-3(4H)-yl)thiazolidin-4-one (22). 
 
          Zhang et al.9 synthesized 2,3-disubstituted-1,3-thiazolidin-4-one (25) by the 
reaction of 4-nitrobenzaldehyde (23), 4-methylphenylamine (24) and mercaptoacetic 
acid under different solvents and temperature conditions. 
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          Mushtaque et al.10 reported the reaction of phenylisothiocyanate (26) with 
isobutyl amine (27) in toluene that yielded 1-isobutylphenylthiourea (28) which upon 
reaction with anhydrous sodium acetate and chloroacetic acid in ethanol to provide 
corresponding 3-isobutyl-2-(phenylimino)thiazolidin-4-one (29). 
 
          Bolognese et al.11 synthesized 1,3-thiazolidin-4-one derivatives (31) by the 
microwave-assisted reaction between benzylidene-anilines (30) and mercaptoacetic 
acid in benzene at 30 oC. 
 
 
          Shingade and Bari12 reported the reaction of 1-(2-aminoethyl)-piperazine (32) 
and the substituted/unsubstituted aromatic aldehydes (33) in acetonitrile that yielded N-
(arylmethylidene)-2-piperazin-1-ylethanamine (34) which later reacted with 
mercaptoacetic acid in ethanol in presence of anhydrous ZnCl2 to provide  resultant 2-
aryl-3-(2-piperazin-1-ylethyl)-1,3-thiazolidin-4-one (35). 
 
  
 
 
Discussion 
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umerous reports have appeared in the literature describing a broad spectrum of 
pharmacological properties of thiazolidinones due to their synthetic and 
biological versatility such as anti-inflammatory,13 antiproliferative,14 
anticyclooxygenases (COX-1 and COX-2),15 anti-histaminic16 and antibacterial 
activities.17  The diversity of their biological functions has stimulated efforts in the 
expedient development of their synthesis.18 Various protocols have been developed to 
prepare more structurally diverse thiazolidinones and related compounds for 
quantitative structure-activity relationship (QSAR) studies. Due to the importance of 
thiazolidinones, various research groups incorporated this heterocyclic moiety to the 
steroidal skeleton.19 As a part of our intensive research program focused on the design 
and synthesis of structurally modified steroidal derivatives,20 herein we describe the 
synthesis of steroidal spirothiazolidinones (40, 41)* derived from steroidal ketones (36, 
37), aniline and mercaptoacetic acid in a two-step process via a sequence of imine 
formation (38, 39), nucleophilic attack of sulfur on the imine carbon and intramolecular 
cyclization. The structure of newly synthesized compounds has been assigned on the 
basis of analytical and spectral (IR, 1H NMR, 13C NMR and MS) studies. 
 
 
 
 
 
*Synthesis, characterization, biological evaluation and molecular docking of 
steroidal spirothiazolidinones. Shamsuzzaman, K. A. A. A. Baqi, Abad Ali, M. Asif, 
A. Mashrai, H. Khanam, A. Sherwani, Z. Yaseen, M. Owais. J. Mol. Struct., 2015, 
1085, 104-114. 
N 
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Reaction of 3β-chloro-7-iminophenyl cholest-5-ene (38) with mercaptoacetic acid: 
3β-Chlorocholest-5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-thiazolidin-4ʹ-one (40): 
3β-Chloro-7-iminophenyl cholest-5-ene (38) in dry benzene was refluxed with excess 
of mercaptoacetic acid for 8 h. After completion of the reaction, the excess solvent was 
removed under reduced pressure and the reaction mixture was then taken in diethyl 
ether, washed with water, dried and recrystallized from methanol, which provided a 
single product 40, m.p. 180-182 oC. 
 
Characterization of compound 40 as 3β-chlorocholest-5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-
thiazolidin-4ʹ-one: 
The elemental analysis of compound 40 corresponded to the molecular formula 
C35H50ClNOS. Its IR data provided evidence for the formation of the expected 
compound. The diagnostic signals at 1380, 740 and 685 cm-1 appeared in the IR 
spectrum were assigned to C-N, C-Cl and C-S-C stretching vibrations, respectively, and 
the absorption band at 3078, 1562, 1394 cm-1 confirmed the presence of aromatic ring. 
Further evidence for the formation of compound 40 was well supported by its 1H NMR 
and 13C NMR spectra. The 1H NMR spectrum of the compound 40 exhibited a signal 
at δ 7.5-7.9, assigned to aromatic ring. A one proton broad multiplet centered at δ 3.91 
was assigned to C3α-H (axial) while as the singlet integrating for one proton and two 
protons at δ 5.42 and δ 3.83 showed the presence of C6-H and Cʹ2-H, respectively. 
Angular and side-chain methyl protons were observed at δ 1.10 (C10-CH3), 0.71 (C13-
CH3), 0.93 and 0.81 for other methyl protons. 
13C NMR spectrum of the compound also 
supported the proposed structure and displayed characteristic signals at δ 172.1 for C=O 
and 70.1 for N-C-S. Remaining carbon atoms were seen in accordance to the cholestane 
series. The structure of compound 40 was further supported by its mass spectrum in 
which the distinct molecular ion peak at m/z 567/569 was found. 
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          On account of the above descriptive discussion, the compound 40 can be suitably 
characterized as 3β-chlorocholest-5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-thiazolidin-4ʹ-one. 
 
Reaction of 7-iminophenyl cholest-5-ene (39) with mercaptoacetic acid: Cholest-5-
en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-thiazolidin-4ʹ-one (41): 
7-Iminophenyl cholest-5-ene (39) in dry benzene was refluxed with excess of 
mercaptoacetic acid for 10 h. After completion of the reaction, the excess solvent was 
removed under reduced pressure and the reaction mixture was then taken in diethyl 
ether, washed with water, dried and recrystallized from methanol, which provided a 
single product 41, m.p. 170-172 oC. 
 
Characterization of compound 41 as cholest-5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-
thiazolidin-4ʹ-one: 
The elemental analysis of compound 41 corresponded to the molecular formula 
C35H51NOS. Its IR data provided evidence for the formation of the expected compound. 
The diagnostic signals at 1378 and 682 cm-1 appeared in the IR spectrum were assigned 
to C-N and C-S-C stretching vibrations, respectively, and the absorption band at 3074, 
1567, 1392 cm-1 confirmed the presence of aromatic ring. Further evidence for the 
formation of compound 41 was well supported by its 1H NMR and 13C NMR spectra. 
The 1H NMR spectrum of the compound 41 exhibited a signal at δ 7.5-7.9, assigned to 
aromatic ring. A one proton singlet at δ 5.31 was assigned to C6-H and two protons 
singlet at δ 3.85 showed the presence of Cʹ2-H. Angular and side-chain methyl protons 
were observed at δ 1.10 (C10-CH3), 0.71 (C13-CH3), 0.93 and 0.81 for other methyl 
protons. 13C NMR spectrum of the compound also supported the proposed structure and 
displayed characteristic signals at δ 173.2 for C=O and 70.2 for N-C-S. Remaining 
carbon atoms were seen in accordance to the cholestane series. The structure of 
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compound 41 was further supported by its mass spectrum in which the distinct 
molecular ion peak was observed at m/z 533. 
          On the basis of above discussion, the compound 41 can be suitably characterized 
as cholest-5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-thiazolidin-4ʹ-one. 
 
Mechanism of the reaction 
A conceivable reaction mechanism for the synthesis of steroidal spirothiazolidinones 
(40, 41) is represented in Scheme 1. The reaction steps included the condensation of 
steroidal ketones (36, 37) with aniline to produce steroidal iminophenyls (38, 39) and 
their subsequent conversion to steroidal spirothiazolidinones (40, 41). We attempted 
the synthesis of the target compounds in a two-step process. First we obtained steroidal 
iminophenyls (38, 39) by the condensation of steroidal ketones (36, 37) with aniline. 
Then compounds (38, 39) were allowed to react with excess of mercaptoacetic acid in 
dry benzene to furnish the desired products (40, 41). Our assumption is based on the 
fact that the sulfur atom (soft nucleophile) of mercaptoacetic acid will preferentially 
attack the carbon atom (soft electrophile) of imine group and the nitrogen atom (hard 
nucleophile) of imine group will attack the carbonyl centre (hard electrophile) to 
eliminate water molecule causing the closure of the thiazolidinone ring and hence, 
leading to the formation of products (40, 41). 
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Scheme 1. Plausible reaction mechanism for the formation of steroidal 
spirothiazolidinones (40, 41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental 
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eneral remarks 
All glass apparatus were oven-dried prior to use. Chemicals were purchased 
from Merck and Sigma-Aldrich as ‘synthesis grade’ and solvents were purified prior to 
use. Melting points were determined on a Biogen digital auto melting point apparatus. 
IR spectra (KBr disks) were recorded on Perkin Elmer FT-IR Spectrometer spectrum 
two and its values are given in cm-1. 1H and 13C NMR spectra were run in CDCl3 on a 
Bruker Avance II 400 NMR Spectrometer (operating at 400 MHz for 1H and at 100 
MHz for 13C NMR) with TMS as internal standard and chemical shift (δ) values are 
given in parts per million (ppm). Splitting patterns are described as singlet (s), doublet 
(d), multiplet (m) and coupling constants (J) are given in Hertz. Elemental analysis for 
C, H and N were within ±0.4 % of the theoretical values. Mass spectra were recorded 
on a Waters, Micromass Q-TOF micro YB361, UK. Thin layer chromatography (TLC) 
plates were coated with silica gel G and exposed to iodine vapors to check the 
homogeneity as well as the progress of reaction. Sodium sulfate (anhydrous) was used 
as a drying agent.  
The synthesis of 3β-Chlorocholest-5-ene and Cholest-5-ene are shown in Chapter 1, 
page 24 and 25, respectively. 
 
3β-Chlorocholest-5-en-7-one (36): 
A solution of butyl chromate [t-butyl alcohol (60 mL), CrO3 (20.0 g), acetic acid (84 
mL) and acetic anhydride (10 mL)]21 was added at 0 °C to a solution of 3β-
chlorocholest-5-ene (8.0 g) in CCl4 (150 mL), acetic acid (30 mL) and acetic anhydride 
(10 mL). The contents were refluxed for 3 h and then diluted with water. The organic 
layer was washed with NaHCO3 solution (5 %) and water and then dried over anhydrous 
sodium sulfate. Evaporation of the solvent under reduced pressure furnished 3β-
chlorocholest-5-en-7-one (36) which was recrystallized from methanol (3.4 g), m.p. 
144 °C (reported, m.p. 144-145 °C).22 
 
Cholest-5-en-7-one (37): 
A solution of butyl chromate [t-butyl alcohol (60 mL), CrO3 (20.0 g), acetic acid (84 
mL) and acetic anhydride (10 mL)]21 was added at 0 oC to a solution of cholest-5-ene 
(8.0 g) in CCl4 (150 mL), acetic acid (30 mL) and acetic anhydride (10 mL). The 
contents were refluxed for 3 h and then diluted with water. The organic layer was 
G 
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washed with NaHCO3 solution (5 %) and water and then dried over anhydrous sodium 
sulfate. Evaporation of the solvent under reduced pressure furnished cholest-5-en-7-one 
(37) which was recrystallized from methanol (3.1 g), m.p. 128 °C (reported, m.p. 125-
129 °C).23 
 
General procedure for synthesis of steroidal iminophenyls (38, 39): 
Steroidal ketones (36, 37) (1 mmol) was fused with aniline (1 mmol) for 30 min, then 
25 mL of absolute ethanol was added to the reaction mixture. The reaction mixture was 
refluxed for 6-8 h and then cooled to room temperature. The separated solid was 
filtered, washed with water and recrystallized from benzene to give steroidal 
iminophenyls (38, 39). 
 
3β-Chloro-7-iminophenyl cholest-5-ene (38): 
White powder, Yield (72 %); m.p. 217-219 oC; IR 
(KBr, v cm-1): 3075, 1562, 1390 (C-H, aromatic), 
1625 (C=N), 1602 (C=C), 745 (C-Cl); 1H NMR (400 
MHz, CDCl3, ppm): δ 7.53-7.9 (m, 5H, aromatic), 
5.41 (s, 1H, C6-H), 3.92 (m, 1H, C3α-H, W1/2  = 14 
Hz, axial), 1.10 (C10-CH3), 0.71 (C13-CH3), 0.93 & 
0.81 (other methyl protons); 13C NMR (100 MHz, 
CDCl3, ppm): δ 164.2, 141.3, 138.4, 130.2, 128.3, 
127.2, 122.4, 122.1, 119.2, 70.2, 54.2, 46.3, 42.2, 39.2, 38.4, 37.2, 36.6, 35.2, 33.2, 
32.4, 31.1, 28.1, 27.2, 26.4, 24.1, 23.2, 22.6, 21.1, 20.2, 19.3, 18.5, 16.4, 11.3; Anal. 
Calcd for C33H48ClN; C, 80.20; H, 9.79; N, 2.83 found; C, 80.40; H, 9.59; N, 2.80; MS 
(EI): m/z 493/ 495 [M+.]. 
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7-Iminophenyl cholest-5-ene (39): 
White powder, Yield (70 %); m.p. 214-216 oC; IR (KBr, 
v cm-1): 3076, 1565, 1394 (C-H, aromatic), 1625 (C=N), 
1606 (C=C); 1H NMR (400 MHz, CDCl3, ppm): δ 7.5-
7.9 (m, 5H, aromatic), 5.43 (s, 1H, C6-H), 1.10 (C10-
CH3), 0.71 (C13-CH3), 0.93 & 0.81 (other methyl 
protons); 13C NMR (100 MHz, CDCl3, ppm): δ 161.2, 
141.3, 132.4, 131.2, 128.3, 127.2, 122.4, 122.1, 119.2, 
54.2, 46.3, 42.2, 39.2, 38.4, 37.2, 36.6, 35.2, 33.2, 32.4, 
31.1, 28.1, 27.2, 26.4, 24.1, 23.2, 22.6, 22.4, 21.1, 20.2, 19.3, 18.5, 16.4, 11.3; Anal. 
Calcd for C33H49N; C, 86.21; H, 10.74; N, 3.05 found; C, 86.41; H, 10.54; N, 3.02; MS 
(EI): m/z 459 [M+.]. 
 
General procedure for synthesis of steroidal spirothiazolidinones (40, 41): 
To a solution of 7-iminophenyl cholest-5-ene (1.0 mmol) (38, 39) in dry benzene (20 
mL), an excess of mercaptoacetic acid (2.5 mmol) was added. The reaction mixture was 
refluxed for 8-10 h. The progress as well as completion of reaction was monitored by 
TLC. After completion of the reaction, the excess solvent was removed to three fourths 
of the original volume under reduced pressure. The reaction mixture was then taken in 
diethyl ether, washed with water and dried over anhydrous sodium sulfate and 
evaporated to dryness under reduced pressure. The crude product obtained was purified 
over silica gel column (light petroleum ether-ethyl acetate; 4:1). Recrystallization from 
methanol afforded the respective products (40, 41). 
 
3β-Chlorocholest-5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-thiazolidin-4ʹ-one (40): 
Pale yellow solid, Yield (76 %); m.p. 180-182 oC; IR 
(KBr, v cm-1): 3078, 1562, 1394 (C-H, aromatic), 
1718 (C=O), 1602 (C=C), 1380 (C-N), 740 (C-Cl), 
685 (C-S-C); 1H NMR (400 MHz, CDCl3, ppm): δ 
7.5-7.9 (m, 5H, aromatic), 5.42 (s, 1H, C6-H), 3.91 
(m, 1H, C3α-H, W1/2 = 17 Hz, axial), 3.83 (s, 2H, Cʹ2-
H), 1.10 (C10-CH3), 0.71 (C13-CH3), 0.93 & 0.81 
(other methyl protons); 13C NMR (100 MHz, CDCl3, 
ppm): δ 172.1, 160.2, 141.1, 140.3, 129.2, 128.1, 127.2, 126.1, 121.2, 70.1, 56.3, 54.2, 
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50.1, 46.2, 42.1, 39.3, 38.2, 37.2, 36.2, 35.3, 33.1, 32.2, 31.2, 28.3, 27.2, 26.3, 25.2, 
24.3, 23.3, 22.2, 21.3, 20.1, 18.2, 16.3, 11.8; Anal. Calcd for C35H50ClNOS; C, 73.97; 
H, 8.87; N, 2.46; found: C, 73.82; H, 8.98; N, 2.43; MS (EI): m/z 567/569 [M+.]. 
  
Cholest-5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-thiazolidin-4ʹ-one (41): 
Yellow solid, Yield (80 %); m.p. 170-172 oC; IR (KBr, v 
cm-1): 3074, 1567, 1392 (C-H, aromatic), 1716 (C=O), 
1604 (C=C), 1378 (C-N), 682 (C-S-C); 1H NMR (400 
MHz, CDCl3, ppm): δ 7.5-7.9 (m, 5H, aromatic), 5.31 (s, 
1H, C6-H), 3.85 (s, 2H, Cʹ2-H), 1.10 (C10-CH3), 0.71 
(C13-CH3), 0.93 & 0.81 (other methyl protons); 
13C NMR 
(100 MHz, CDCl3, ppm): δ 173.2, 160.2, 141.2, 140.2, 
129.3, 128.1, 127.3, 126.2, 121.4, 70.2, 56.2, 54.3, 50.1, 
46.2, 42.3, 39.1, 38.1, 37.2, 36.2, 35.2, 33.2, 32.4, 31.2, 28.4, 27.2, 26.2, 25.3, 24.2, 
23.1, 22.2, 20.3, 19.3, 18.2, 16.4, 11.7; Anal. Calcd for C35H51NOS; C, 78.74; H, 9.63; 
N, 2.62; found: C, 78.62; H, 9.75; N, 2.53; MS (EI): m/z 533 [M+.]. 
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eterocyclic compounds containing N, O and S, for example imidazole, oxazole 
and thiazole are bioactive moieties that are ubiquitously present in nature and 
have been adopted in numerous pharmaceutical products.1 The oxazole ring is endowed 
with various activities such as hypoglycemic,2 analgesic,3 anti-inflammatory and 
antibacterial4. Moreover, oxazoles showed antiproliferative activity against many 
cancer cells, especially human prostate cancer and human epidermoid carcinoma.5-7 
The thiazolyl group is also of great importance as it appears frequently in the structures 
of various natural products and biologically active compounds like thiamine (vitamin-
B) and also in some antibiotic drugs like penicillin, micrococcin8 and many metabolic 
products of fungi and primitive marine animals etc. In recent years, the high therapeutic 
properties of the imidazole related drugs have been attracting the attention of medicinal 
chemists to synthesize a large number of novel chemotherapeutic agents and have 
gained tremendous significant pharmacological properties such as anticancer,9 
antimicrobial10-13 and antioxidant.14 It is known that clinically useful drugs such as 
miconazole, econazole and oxiconazole having imidazole moiety exhibit strong 
antifungal activity. That’s why synthesis of thiazole, oxazole and imidazole itself shows 
significant interest and has been highly attractive area of synthetic organic chemistry. 
 
          Rahim et al.15 reported the synthesis of thiazole derivatives (5a-u) by two step 
reaction process. In the first step, different substituted benzaldehyde/acetophenone (1a-
u) was mixed with thiosemicarbazide (2) in methanol in the presence of few drops of 
glacial acetic acid. In second step, the product obtained in the first step (3a-u) was 
mixed and refluxed with chloro or methoxy phenacyl bromide (4a-u) for 3-5 h that 
yielded thiazole derivatives (5a-u). 
H 
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          Wade et al.16 carried out the photochemical synthesis of 2-substituted 
benzothiazole/2-substituted benzoimidazole (8) from a mixture of aldehyde (6), 2-
aminothiophenol/o-phenylenediamine (7) and catalyst in ethanol was taken in double-
walled quartz photoreactor equipped with water chiller to maintain the temperature of 
the reaction vessel. 
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          Shen et al.17 reported the CuI-catalyzed one-pot synthesis of N-substituted-2-
aminobenzothiazoles 12a-m and 13a-g from 2-iodoanilines (9a-m)/2-bromoaniline 
(10a-g), respectively, and isothiocyanates (11a-m, 11a-g) in the presence of base in 
DMSO at 95 °C and 115 °C, respectively, under a nitrogen atmosphere. 
 
 
 
          Tyagarajan et al.18 reported the synthesis of biphenyl heterocyclic compounds 
(16-25, 29). These analogs were constructed from the biphenyl bromoketone 16, a 
common key intermediate. The intermediate 16 was prepared via a palladium catalyzed 
Suzuki cross-coupling reaction of the aryl bromide 14 with the commercially available 
3-acetophenone boronic acid 15 followed by acid-catalyzed bromination.19 Cyclization 
of the bromo ketone 16 with urea afforded the 2-amino oxazoles 17. Biphenyl oxazole 
19 was prepared from the 2-methyl oxazole analog 18, which was, in turn derived from 
the corresponding acetate. Cyclization of the bromo ketone 16 with formamide gave 
the biphenyl imidazole 20. The 2-carboxamide imidazole 21 was derived from 
condensation with methyl glyoxalate. The thiazoles were prepared according to the 
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method described by Wright and coworkers.20 The biphenyl thiazoles 22 were derived 
from the cyclization of bromo ketone 16 with ethanethioamide. Similarly, thiourea 
cyclization afforded the 2-thiazolamine 23 which was then functionalized to the 
sulfonamide 24. Cyclization of 16 with ethyl thioxamate afforded the ester which was 
converted to the 2-thiazolecarboxamides 25. A different synthetic route was utilized to 
synthesize 4-thiazolecarboxamides 29. Commercially available 3-bromo acetic acid 26 
was converted to the thioamide 27 which was cyclized to 4-thiazole ethyl ester 28. The 
carboxamide 29 was prepared from the corresponding ester 28. 
 
 
 
          Yoo et al.21 carried out the synthesis of oxazole (33) by two step reaction. In the 
first step, salicylaldehyde (30) and 2-aminophenol (31) were dissolved in ethanol, 
stirred for 1 h at room temperature to afford probe 32 as orange precipitates. In second 
step, the solution of 32 and Bu4NCN in acetone and ethanol was stirred at room 
temperature for 8 h, gave the desired product (33) as a white solid in 67% yield. 
 
 
Chapter 3                                                                             Steroidal thiazoles, oxazoles and imidazoles 
 
52 
 
          Imai et al.22 reported the synthesis of 2-ethyl-5-phenyloxazole (35) from a 
mixture of acetophenone (34), molecular iodine, Oxone® and TfOH in propionitrile. 
The mixture was stirred for 5 h at 100 oC under an Ar atmosphere. 
 
 
 
          Meng et al.23 synthesized 2,4,5-trisubstituted oxazoles (38a-p) from a mixture of 
2-cyanopyridine (37) and aldehydes (36a-p) in acetic acid, the mixture was heated at 
170 oC for 10 h in a Teflon-lined stainless steel autoclave, that yielded respective 
product (38a-p). 
 
 
 
         Chen et al.24 synthesized 3α-hydroxy-21-(1ʹ-imidazolyl)-3β-methoxymethyl-5α-
pregnan-20-one (40). A solution of imidazole in THF was added with lithium hydride 
and heated at reflux for 30 min. The solution was cooled and compound 39 in THF was 
slowly added to the reaction mixture that yielded 3α-hydroxy-21-(1ʹ-imidazolyl)-3β-
methoxymethyl-5α-pregnan-20-one (40). 
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          Nikalje et al.25 carried out the synthesis of 3-[(4,5-diphenyl-2-substituted 
aryl/heteryl)-1H-imidazol-1-yl]-1H-1,2,4-triazole-5-carboxylic acid derivatives (44a-
o) from addition of benzil (41), 3-amino-1,2,4-triazole-5-carboxylic acid (42), aromatic 
aldehydes (43a-o) and ammonium acetate were refluxed in ethanol using cerric 
ammonium nitrate (CAN) as a catalyst. 
 
          Zhang et al.26 reported the synthesis of imidazole derivatives (47a-b) from a 
mixture of subsitituted aldehyde (45a-b), ammonium acetate and diketone (46) in 
glacial acetic acid was stirred and heated at reflux for 12 h, that yielded corresponding 
product (47a-b). 
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hiazole, oxazole and imidazole are valuable scaffold in the field of medicinal 
chemistry and has accounted to display a variety of biological activities, such as 
antibacterial11,27-29, anti-tubercular30,31, antifungal32, anticancer33,34 and anti-
inflammatory35, etc. Moreover, imidazole and oxazole compounds have drawn 
considerable attention for their desirable properties in the fields of coordination 
chemistry, photoluminescence/pH sensing studies and biochemistry of 
metalloenzymes.36-42 Moieties such as adenine, guanine and histidine, contain the 
imidazole ring and are involved in intramolecular and/or intermolecular chemistries of 
biological macromolecules.43-46 In the past few decades, thiazoles have been widely 
used to develop a variety of therapeutic agents against numerous CNS targets. Thiazole 
containing drug molecules are currently being used in the treatment of various CNS 
disorders and a number of thiazole derivatives are also presently in clinical trials.47 In 
view of these reports and in continuation of our previous work48 in steroidal chemistry, 
we have synthesized some new compounds (51-59)* containing thiazole, oxazole and 
imidazole ring. The structure of newly synthesized compounds has been assigned on 
the basis of analytical and spectral (IR, 1H NMR, 13C NMR, MS) studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Synthesis and characterization of steroidal heterocyclic compounds, DNA 
condensation and molecular docking studies and their in vitro anticancer and 
acetylcholinesterase inhibition activities. Abad Ali, M. Asif, H. Khanam, A. 
Mashrai, M. A. Sherwani, M. Owais, Shamsuzzaman. RSC Adv., 2015, 5, 75964-
75984. 
T 
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Reaction of 3β-acetoxy-6-hydrazono-5α-cholestane (48d) with phthalaldehyde: 3β-
Acetoxy-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (48e): 
To a solution of 3β-acetoxy-6-hydrazono-5α-cholestane (48d) in absolute ethanol, 
phthalaldehyde was added. Then the reaction mixture was stirred at 70 oC. After 
completion of reaction, solvent was evaporated under reduced pressure. The residue 
was purified by recrystallization, which provided a single product 48e, m.p. 166-168 
oC. 
Characterization of compound 48e as 3β-acetoxy-5α-cholestan-6-(iminohydrazono)-
2-methylbenzaldehyde: 
The elemental analysis of compound 48e corresponded to the molecular formula 
C37H54N2O3. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1630 and 1696 cm-1 
for stretching of C=N and -CHO groups, respectively, and at 1057, 1059 cm-1 for C-O 
groups. Another absorption bands at 3080, 1567, 1394 cm-1 confirmed the presence of 
aromatic ring. Further evidence for the formation of compound 48e was well supported 
by its 1H NMR and 13C NMR spectra (Figure 1.1, 1.2). The 1H NMR spectrum of the 
compound 48e exhibited a signal at δ 7.9-8.3, assigned to aromatic ring. A one proton 
broad multiplet centered at δ 4.77 was assigned to C3α-H (axial) and a sharp singlet for 
three acetoxy group protons appeared at δ 2.01 while as the multiplet integrating for 
one proton at δ 10.4 showed the presence of aldehydic group. Angular and side-chain 
methyl protons were observed at δ 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 and 0.84 for 
other methyl protons. 13C NMR spectrum of the compound also supported the proposed 
structure and displayed characteristic signals at δ 172.3 for OCOCH3 and 194.6 for –
CHO, respectively, and 162.7, 144.3 for C=N. Remaining carbon atoms were seen in 
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accordance to the cholestane series. The mass spectrum also supported the structure of 
compound 48e with distinct molecular ion peak at m/z 574. 
          The above evocative discussion, suitably characterized the compound 48e as 3β-
acetoxy-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde. 
 
Figure 1.1. 1H NMR spectrum of 3β-acetoxy-5α-cholestan-6-(iminohydrazono)-2-
methylbenzaldehyde (48e). 
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Figure 1.2. 13C NMR spectrum of 3β-acetoxy-5α-cholestan-6-(iminohydrazono)-2-
methylbenzaldehyde (48e). 
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Reaction of 3β-chloro-6-hydrazono-5α-cholestane (49d) with phthalaldehyde: 3β-
Chloro-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (49e): 
To a solution of 3β-chloro-6-hydrazono-5α-cholestane (49d) in absolute ethanol, 
phthalaldehyde was added. Then the reaction mixture was stirred at 70 oC. After 
completion of reaction, solvent was evaporated under reduced pressure. The residue 
was purified by recrystallization, which provided a single product 49e, m.p. 160-162 
oC. 
Characterization of compound 49e as 3β-chloro-5α-cholestan-6-(iminohydrazono)-
2-methylbenzaldehyde: 
The elemental analysis of compound 49e corresponded to the molecular formula 
C35H51ClN2O. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1627 and 1700 cm-1 
for stretching of C=N and -CHO groups, respectively, and at 740 cm-1 for C-Cl groups. 
Another absorption bands at 3081, 1560, 1388 cm-1 confirmed the presence of aromatic 
ring. Further evidence for the formation of compound 49e was well supported by its 1H 
NMR and 13C NMR spectra (Figure 2.1, 2.2). The 1H NMR spectrum of the compound 
49e exhibited a signal at δ 7.9-8.3, assigned to aromatic ring. A one proton broad 
multiplet centered at δ 3.71 was assigned to C3α-H (axial) while as the multiplet 
integrating for one proton at δ 10.5 showed the presence of aldehydic group. Angular 
and side-chain methyl protons were observed at δ 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 
and 0.84 for other methyl protons. 13C NMR spectrum of the compound also supported 
the proposed structure and displayed characteristic signals at δ 196.7 for -CHO and 58.7 
for C-Cl, repectively, and 159.8, 142.3 for C=N. Remaining carbon atoms were seen in 
accordance to the cholestane series. The distinct molecular ion peak at m/z 550/552 in 
mass spectrum also supported the formation of compound 49e. 
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          Thus, the compound 49e on account of above discussion can be suitably 
characterized as 3β-chloro-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde. 
 
Figure 2.1. 1H NMR spectrum of 3β-chloro-5α-cholestan-6-(iminohydrazono)-2-
methylbenzaldehyde (49e). 
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Figure 2.2. 13C NMR spectrum of 3β-chloro-5α-cholestan-6-(iminohydrazono)-2-
methylbenzaldehyde (49e). 
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Reaction of 6-hydrazono-5α-cholestane (50d) with phthalaldehyde: 5α-Cholestan-6-
(iminohydrazono)-2-methylbenzaldehyde (50e): 
To a solution of 6-hydrazono-5α-cholestane (50d) in absolute ethanol, phthalaldehyde 
was added. Then the reaction mixture was stirred at 70 oC. After completion of reaction, 
solvent was evaporated under reduced pressure. The residue was purified by 
recrystallization, which provided a single product 50e, m.p. 155-157 oC. 
 
Characterization of compound 50e as 5α-cholestan-6-(iminohydrazono)-2-
methylbenzaldehyde: 
The elemental analysis of compound 50e corresponded to the molecular formula 
C35H52N2O. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1631 cm-1 for 
stretching of C=N group and at 1702 cm-1 for -CHO group. Another absorption bands 
at 3085, 1564, 1391 cm-1 confirmed the presence of aromatic ring. Further evidence for 
the formation of compound 50e was well supported by its 1H NMR and 13C NMR 
spectra (Figure 3.1, 3.2). The 1H NMR spectrum of the compound 50e exhibited a 
signal at δ 7.9-8.3, assigned to aromatic ring, while as the multiplet integrating for one 
proton at δ 10.4 showed the presence of aldehydic group. Angular and side-chain 
methyl protons were observed at δ 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 and 0.84 for 
other methyl protons. 13C NMR spectrum of the compound also supported the proposed 
structure and displayed characteristic signals at δ 195.2 for -CHO and 160.5, 141.7 for 
C=N. Remaining carbon atoms were seen in accordance to the cholestane series. The 
structure of compound 50e was further supported by its mass spectrum in which the 
distinct molecular ion peak was observed at m/z 516. 
          On account of above discussion, the compound 50e can be suitably characterized 
as 5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde. 
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Figure 3.1. 1H NMR spectrum of 5α-cholestan-6-(iminohydrazono)-2-
methylbenzaldehyde (50e). 
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Figure 3.2. 13C NMR spectrum of 5α-cholestan-6-(iminohydrazono)-2-
methylbenzaldehyde (50e). 
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Reaction of 3β-acetoxy-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(48e) with o-aminothiophenol: 3β-Acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (51): 
A mixture of 3β-acetoxy-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(48e) and o-aminothiophenol in DMSO was refluxed for 2 h. After completion of 
reaction, the reaction mixture was poured into water. The precipitate thus obtained was 
filtered, washed with water and air dried. For further purification, the compound was 
recrystallized from methanol to give desirable product 51, m.p. 156-158 oC. 
Characterization of compound 51 as 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole: 
The elemental analysis of compound 51 corresponded to the molecular formula 
C43H57N3O2S. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1635 and 687 cm-1 
for stretching of C=N and C-S-C groups, respectively, and at 1050, 1054 cm-1 for C-O 
groups. Another absorption bands at 3085, 1569, 1396 cm-1 confirmed the presence of 
aromatic ring. Further evidence for the formation of compound 51 was well supported 
by its 1H NMR and 13C NMR spectra (Figure 4.1, 4.2). The 1H NMR spectrum of the 
compound 51 exhibited a signal at δ 7.7-8.0, assigned to aromatic ring. A one proton 
broad multiplet centered at δ 4.75 was assigned to C3α-H (axial) and a sharp singlet for 
three acetoxy group protons appeared at δ 2.03. Angular and side-chain methyl protons 
were observed at δ 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 and 0.84 for other methyl 
protons. 13C NMR spectrum of the compound also supported the proposed structure and 
displayed characteristic signals at δ 171.4 for OCOCH3 and 161.2, 159.2, 142.6 for 
C=N. Remaining carbon atoms were seen in accordance to the cholestane series. The 
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structure of compound 51 was further supported by its mass spectrum in which the 
distinct molecular ion peak was observed at m/z 679 (Figure 4.3). 
          Thus, the compound 51 on account of above discussion can be suitably 
characterized as 3β-acetoxy-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-
benzo-[d]-thiazole. 
 
Figure 4.1. 1H NMR spectrum of 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (51). 
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Figure 4.2. 13C NMR spectrum of 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (51). 
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Figure 4.3. HRMS spectrum of 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (51). 
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Reaction of 3β-acetoxy-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(48e) with o-aminophenol: 3β-Acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (54): 
A mixture of 3β-acetoxy-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(48e) and o-aminophenol in DMSO was refluxed for 3 h. After completion of reaction, 
the reaction mixture was poured into water. The precipitate thus obtained was filtered, 
washed with water and air dried. For further purification, the compound was 
recrystallized from methanol to give desirable product 54, m.p. 175-177 oC. 
Characterization of compound 54 as 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole: 
The elemental analysis of compound 54 corresponded to the molecular formula 
C43H57N3O3. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1631 cm-1 for 
stretching of C=N group and at 1053, 1059 cm-1 for C-O group. Another absorption 
bands at 3083, 1564, 1390 cm-1 confirmed the presence of aromatic ring. Further 
evidence for the formation of compound 54 was well supported by its 1H NMR and 13C 
NMR spectra (Figure 5.1, 5.2). The 1H NMR spectrum of the compound 54 exhibited 
a signal at δ 8.0-8.3, assigned to aromatic ring. A one proton broad multiplet centered 
at δ 4.79 was assigned to C3α-H (axial) and a sharp singlet for three acetoxy group 
protons appeared at δ 2.02. Angular and side-chain methyl protons were observed at δ 
1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 and 0.84 for other methyl protons. 
13C NMR 
spectrum of the compound also supported the proposed structure and displayed 
characteristic signals at δ 173.4 for OCOCH3 and 163.4, 153.5, 141.2 for C=N. 
Remaining carbon atoms were seen in accordance to the cholestane series. Moreover, 
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the structure of compound 54 was also supported by its mass spectrum in which the 
distinct molecular ion peak at m/z 663 was found (Figure 5.3). 
          Thus, the compound 54 can be suitably characterized as 3β-acetoxy-5α-
cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole. 
 
Figure 5.1. 1H NMR spectrum of 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (54). 
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Figure 5.2. 13C NMR spectrum of 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (54). 
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Figure 5.3. HRMS spectrum of 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (54). 
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Reaction of 3β-acetoxy-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(48e) with o-phenylenediamine: 3β-Acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (57): 
A mixture of 3β-acetoxy-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(48e) and o-phenylenediamine in DMSO was refluxed for 5 h. After completion of 
reaction, the reaction mixture was poured into water. The precipitate thus obtained was 
filtered, washed with water and air dried. For further purification, the compound was 
recrystallized from methanol to give desirable product 57, m.p. 167-169 oC. 
Characterization of compound 57 as 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole: 
The elemental analysis of compound 57 corresponded to the molecular formula 
C43H58N4O2. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1636 and 1310 cm-1 
for stretching of C=N and C-N groups, respectively, and at 1061, 1065 cm-1 for C-O 
group. Another absorption bands at 3087, 1563, 1391 cm-1 confirmed the presence of 
aromatic ring and at 3331 cm-1 for NH group. Further evidence for the formation of 
compound 57 was well supported by its 1H NMR and 13C NMR spectra (Figure 6.1, 
6.2). The 1H NMR spectrum of the compound 57 featured a signal at δ 5.3 integrating 
for one hydrogen (exchangeable with D2O), which is characteristic signal for NH proton 
and the signal at δ 7.9-8.2, assigned to aromatic ring. A one proton broad multiplet 
centered at δ 4.71 was assigned to C3α-H (axial) and a sharp singlet for three acetoxy 
group protons appeared at δ 2.01. Angular and side-chain methyl protons were observed 
at δ 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 and 0.84 for other methyl protons. 13C NMR 
spectrum of the compound also supported the proposed structure and displayed 
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characteristic signals at δ 169.9 for OCOCH3 and 159.9, 147.3, 143.8 for C=N. 
Remaining carbon atoms were seen in accordance to the cholestane series. The mass 
spectrum also supported the structure of compound 57 with distinct molecular ion peak 
at m/z 662 (Figure 6.3). 
          Thus, the above descriptive discussion, suitably characterized the compound 57 
as 3β-acetoxy-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-
imidazole. 
 
Figure 6.1. 1H NMR spectrum of 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (57). 
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Figure 6.2.  13C NMR spectrum of 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (57). 
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Figure 6.3. HRMS spectrum of 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (57). 
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Reaction of 3β-chloro-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(49e) with o-aminothiophenol: 3β-Chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (52): 
A mixture of 3β-chloro-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(49e) and o-aminothiophenol in DMSO was refluxed for 3.5 h. After completion of 
reaction, the reaction mixture was poured into water. The precipitate thus obtained was 
filtered, washed with water and air dried. For further purification, the compound was 
recrystallized from methanol to give desirable product 52, m.p. 162-164 oC. 
Characterization of compound 52 as 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole: 
The elemental analysis of compound 52 corresponded to the molecular formula 
C41H54ClN3S. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1632 and 685 cm-1 
for stretching of C=N and C-S-C groups, respectively, and at 743 cm-1 for C-Cl groups. 
Another absorption bands at 3086, 1562, 1393 cm-1 confirmed the presence of aromatic 
ring. Further evidence for the formation of compound 52 was well supported by its 1H 
NMR and 13C NMR spectra (Figure 7.1, 7.2). The 1H NMR spectrum of the compound 
52 exhibited a signal at δ 7.9-8.2, assigned to aromatic ring. A one proton broad 
multiplet centered at δ 3.91 was assigned to C3α-H (axial). Angular and side-chain 
methyl protons were observed at δ 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 and 0.84 for 
other methyl protons. 13C NMR spectrum of the compound also supported the proposed 
structure and displayed characteristic signals at δ 59.6 for C-Cl and 160.3, 157.7, 140.8 
for C=N. Remaining carbon atoms were seen in accordance to the cholestane series. 
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The structure of compound 52 was further supported by its mass spectrum in which the 
distinct molecular ion peak was observed at m/z 655/657 (Figure 7.3). 
          On account of the above discussion, the compound 52 can be suitably 
characterized as 3β-chloro-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-
[d]-thiazole. 
 
Figure 7.1. 1H NMR spectrum of 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (52). 
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Figure 7.2. 13C NMR spectrum of 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (52). 
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Figure 7.3. HRMS spectrum of 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (52). 
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Reaction of 3β-chloro-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(49e) with o-aminophenol: 3β-Chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (55): 
A mixture of 3β-chloro-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(49e) and o-aminophenol in DMSO was refluxed for 6 h. After completion of reaction, 
the reaction mixture was poured into water. The precipitate thus obtained was filtered, 
washed with water and air dried. For further purification, the compound was 
recrystallized from methanol to give desirable product 55, m.p. 181-183 oC. 
Characterization of compound 55 as 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole: 
The elemental analysis of compound 55 corresponded to the molecular formula 
C41H54ClN3O. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1637 and 1056 cm-1 
for stretching of C=N and C-O groups, respectively, and at 741 cm-1 for C-Cl groups. 
Another absorption bands at 3081, 1561, 1395 cm-1 confirmed the presence of aromatic 
ring. Further evidence for the formation of compound 55 was well supported by its 1H 
NMR and 13C NMR spectra (Figure 8.1, 8.2). The 1H NMR spectrum of the compound 
55 exhibited a signal at δ 7.9-8.3, assigned to aromatic ring. A one proton broad 
multiplet centered at δ 3.81 was assigned to C3α-H (axial). Angular and side-chain 
methyl protons were observed at δ 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 and 0.84 for 
other methyl protons. 13C NMR spectrum of the compound also supported the proposed 
structure and displayed characteristic signals at δ 59.6 for C-Cl and 156.1, 151.3, 143.5 
for C=N. Remaining carbon atoms were seen in accordance to the cholestane series. 
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Moreover, the structure of compound 55 was further supported by its mass spectrum in 
which the distinct molecular ion peak was observed at m/z 639/641 (Figure 8.3). 
          Thus, on account of above discussion, the compound 55 can be suitably 
characterized as 3β-chloro-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-
[d]-oxazole. 
 
Figure 8.1. 1H NMR spectrum of 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (55). 
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Figure 8.2. 13C NMR spectrum of 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (55). 
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Figure 8.3. HRMS spectrum of 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (55). 
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Reaction of 3β-chloro-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(49e) with o-phenylenediamine: 3β-Chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (58): 
A mixture of 3β-chloro-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde 
(49e) and o-phenylenediamine in DMSO was refluxed for 4.5 h. After completion of 
reaction, the reaction mixture was poured into water. The precipitate thus obtained was 
filtered, washed with water and air dried. For further purification, the compound was 
recrystallized from methanol to give desirable product 58, m.p. 152-154 oC. 
Characterization of compound 58 as 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole: 
The elemental analysis of compound 58 corresponded to the molecular formula 
C41H55ClN4. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1633 and 1317 cm-1 
for stretching of C=N and C-N groups, respectively, and at 744 cm-1 for C-Cl group. 
Another absorption bands at 3084, 1566, 1387 cm-1 confirmed the presence of aromatic 
ring and at 3335 cm-1 for NH group. Further evidence for the formation of compound 
58 was well supported by its 1H NMR and 13C NMR spectra (Figure 9.1, 9.2). The 1H 
NMR spectrum of the compound 58 featured a signal at δ 4.7 integrating for one 
hydrogen (exchangeable with D2O), which is characteristic signal for NH proton and 
the signal at δ 7.9-8.2, assigned to aromatic ring. A one proton broad multiplet centered 
at δ 3.72 was assigned to C3α-H (axial). Angular and side-chain methyl protons were 
observed at δ 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 and 0.84 for other methyl protons. 
13C NMR spectrum of the compound also supported the proposed structure and 
displayed characteristic signals at δ 59.5 for C-Cl and 160.2, 149.2, 141.5 for C=N. 
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Remaining carbon atoms were seen in accordance to the cholestane series. Furthermore, 
the distinct molecular ion peak in the mass spectrum at m/z 638/640 also supported the 
formation of compound 58 (Figure 9.3). 
          Thus, the compound 58 on account of above discussion can be suitably 
characterized as 3β-chloro-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-
[d]-imidazole. 
 
Figure 9.1. 1H NMR spectrum of 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (58). 
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Figure 9.2. 13C NMR spectrum of 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (58). 
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Figure 9.3. HRMS spectrum of 3β-chloro-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (58). 
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Reaction of 5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (50e) with o-
aminothiophenol: 5α-Cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-
thiazole (53): 
A mixture of 5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (50e) and o- 
aminothiophenol in DMSO was refluxed for 6 h. After completion of reaction, the 
reaction mixture was poured into water. The precipitate thus obtained was filtered, 
washed with water and air dried. For further purification, the compound was 
recrystallized from methanol to give desirable product 53, m.p. 154-156 oC. 
 
Characterization of compound 53 as 5α-cholestan-6-(iminohydrazonomethylphenyl-
2-yl)-benzo-[d]-thiazole: 
The elemental analysis of compound 53 corresponded to the molecular formula 
C41H55N3S. The IR data provided evidence for the formation of the expected compound. 
It showed the characteristic strong absorption bands at 1629 cm-1 for stretching of C=N 
group and at 682 cm-1 for C-S-C group. Another absorption bands at 3082, 1565, 1389 
cm-1 confirmed the presence of aromatic ring. Further evidence for the formation of 
compound 53 was well supported by its 1H NMR and 13C NMR spectra (Figure 10.1, 
10.2). The 1H NMR spectrum of the compound 53 exhibited a signal at δ 7.9-8.2, 
assigned to aromatic ring. Angular and side-chain methyl protons were observed at δ 
1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 and 0.84 for other methyl protons. 
13C NMR 
spectrum of the compound also supported the proposed structure and displayed 
characteristic signals at δ 158.7, 156.4 and 139.7 for C=N. Remaining carbon atoms 
were seen in accordance to the cholestane series. In addition, the mass spectrum also 
Chapter 3                                                                             Steroidal thiazoles, oxazoles and imidazoles 
 
91 
 
supported the structure of compound 53 with distinct molecular ion peak was found at 
m/z 621 (Figure 10.3). 
          However, the above descriptive discussion, suitably characterized the compound 
53 as 5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole. 
 
Figure 10.1. 1H NMR spectrum of 5α-cholestan-6-(iminohydrazonomethylphenyl-2-
yl)-benzo-[d]-thiazole (53). 
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Figure 10.2. 13C NMR spectrum of 5α-cholestan-6-(iminohydrazonomethylphenyl-2-
yl)-benzo-[d]-thiazole (53). 
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Figure 10.3. HRMS spectrum of 5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-
benzo-[d]-thiazole (53). 
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Reaction of 5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (50e) with o-
aminophenol: 5α-Cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-
oxazole (56): 
A mixture of 5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (50e) and o- 
aminophenol in DMSO was refluxed for 5 h. After completion of reaction, the reaction 
mixture was poured into water. The precipitate thus obtained was filtered, washed with 
water and air dried. For further purification, the compound was recrystallized from 
methanol to give desirable product 56, m.p. 176-178 oC. 
 
Characterization of compound 56 as 5α-cholestan-6-(iminohydrazonomethylphenyl-
2-yl)-benzo-[d]-oxazole: 
The elemental analysis of compound 56 corresponded to the molecular formula 
C41H55N3O. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1634 cm-1 for 
stretching of C=N group and at 1058 cm-1 for C-O group. Another absorption bands at 
3088, 1560, 1397 cm-1 confirmed the presence of aromatic ring. Further evidence for 
the formation of compound 56 was well supported by its 1H NMR and 13C NMR spectra 
(Figure 11.1, 11.2). The 1H NMR spectrum of the compound 56 exhibited a signal at δ 
7.9-8.3, assigned to aromatic ring. Angular and side-chain methyl protons were 
observed at δ 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 and 0.84 for other methyl protons. 
13C NMR spectrum of the compound also supported the proposed structure and 
displayed characteristic signals at δ 157.3, 150.2 and 137.6 for C=N. Remaining carbon 
atoms were seen in accordance to the cholestane series. The structure of compound 56 
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was further supported by its mass spectrum in which the distinct molecular ion peak at 
m/z 605 was found (Figure 11.3). 
          On account of the above discussion, the compound 56 can be suitably 
characterized as 5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-
oxazole. 
 
Figure 11.1. 1H NMR spectrum of 5α-cholestan-6-(iminohydrazonomethylphenyl-2-
yl)-benzo-[d]-oxazole (56). 
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Figure 11.2. 13C NMR spectrum of 5α-cholestan-6-(iminohydrazonomethylphenyl-2-
yl)-benzo-[d]-oxazole (56). 
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Figure 11.3. HRMS spectrum of 5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-
benzo-[d]-oxazole (56). 
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Reaction of 5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (50e) with o-
phenylenediamine: 5α-Cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-
imidazole (59): 
A mixture of 5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (50e) and o-
phenylenediamine in DMSO was refluxed for 2.5 h. After completion of reaction, the 
reaction mixture was poured into water. The precipitate thus obtained was filtered, 
washed with water and air dried. For further purification, the compound was 
recrystallized from methanol to give desirable product 59, m.p. 164-166 oC. 
 
Characterization of compound 59 as 5α-cholestan-6-(iminohydrazonomethylphenyl-
2-yl)-benzo-[d]-imidazole: 
The elemental analysis of compound 59 corresponded to the molecular formula 
C41H56N4. The IR data provided evidence for the formation of the expected compound. 
It showed the characteristic strong absorption bands at 1628 cm-1 for stretching of C=N 
group and at 1329 cm-1 for C-N group. Another absorption bands at 3089, 1568, 1388 
cm-1 confirmed the presence of aromatic ring and at 3342 cm-1 for NH group. Further 
evidence for the formation of compound 59 was well supported by its 1H NMR and 13C 
NMR spectra (Figure 12.1, 12.2). The 1H NMR spectrum of the compound 59 featured 
a signal at δ 4.4 integrating for one hydrogen (exchangeable with D2O), which is 
characteristic signal for NH proton and the signal at δ 7.9-8.3, assigned to aromatic ring. 
Angular and side-chain methyl protons were observed at δ 1.15 (C10-CH3), 0.73 (C13-
CH3), 0.91 and 0.84 for other methyl protons. 
13C NMR spectrum of the compound also 
supported the proposed structure and displayed characteristic signals at δ 162.5, 145.6 
and 140.3 for C=N. Remaining carbon atoms were seen in accordance to the cholestane 
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series. Additionally, the structure of compound 59 was also supported by its mass 
spectrum in which the distinct molecular ion peak was observed at m/z 604 (Figure 
12.3). 
          However, on account of above discussion, the compound 59 can be suitably 
characterized as 5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-
imidazole. 
 
Figure 12.1. 1H NMR spectrum of 5α-cholestan-6-(iminohydrazonomethylphenyl-2-
yl)-benzo-[d]-imidazole (59). 
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Figure 12.2. 13C NMR spectrum of 5α-cholestan-6-(iminohydrazonomethylphenyl-2-
yl)-benzo-[d]-imidazole (59). 
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Figure 12.3. HRMS spectrum of 5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-
benzo-[d]-imidazole (59). 
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Mechanism of the reaction 
A conceivable reaction mechanism for the synthesis of steroidal compounds (51-59) is 
represented in Scheme 1. The reaction steps included the condensation of steroidal 
ketones (48c-50c) with hydrazine hydrate to produce steroidal hydrazones (48d-50d) 
and their reaction with phthalaldehyde to produce 5α-cholestan-6-(iminohydrazono)-2-
methylbenzaldehyde (48e-50e). Further, compounds 48e-50e were allowed to react 
with o-aminothiophenol/o-aminophenol/o-phenylenediamine in DMSO to furnish the 
desired products 51-59. Finally the proposed fragmentation mechanisms (Scheme 2, 3) 
of molecular ion peak [M+.] at m/z: 679, 655/657, 621, 663, 639/641, 605, 662, 638/640 
and 604 in the MS spectra as shown in Figure 4.3-12.3, also proved the formation of 
the compounds 51-59. 
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Scheme 1. A provisional reaction mechanism for the synthesis of steroidal compounds 
(51-59). 
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Scheme 2. Proposed fragmentation mechanisms of molecular ion [M+.] of compounds 
(51-59). 
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Scheme 3. Proposed fragmentation mechanisms of molecular ion [M+.] of compounds 
(51-59). 
 
 
 
 
 
 
 
 
Experimental 
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eneral remarks 
All glass apparatus were oven-dried prior to use. Chemicals and solvents used in this 
study were of ACS grade and used directly without additional steps of puriﬁcation. Melting 
points were determined on a Biogen digital auto melting point apparatus. The IR spectra 
were recorded on KBr pellets with Perkin Elmer FT-IR Spectrometer spectrum Two and 
values are given in cm-1. 1H and 13C NMR spectra were run in CDCl3 on a Bruker Avance 
II 400 NMR Spectrometer (operating at 400 MHz for 1H and at 100 MHz for 13C NMR) 
with TMS as internal standard and values are given in parts per million (ppm) (δ). Mass 
spectra were recorded on a Waters, Micromass Q-TOF micro YB361, UK. Elemental 
analysis were recorded on Perkin Elmer 2400 CHN Elemental Analyzer. Thin layer 
chromatography (TLC) plates were coated with silica gel G and exposed to iodine vapours 
to check the homogeneity as well as the progress of reaction. Sodium sulfate (anhydrous) 
was used as a drying agent.  
The synthesis of 3β-Acetoxy-5α-cholestan-6-one, 3β-Chloro-5α-cholestan-6-one and 5α-
Cholestan-6-one are shown in Chapter 1, page 24-26, respectively. 
 
3β-Acetoxy-6-hydrazono-5α-cholestane (48d) 
The steroidal ketone 48c reacted with hydrazine hydrate in ethanol solution in the presence 
of few drops of acetic acid in cold conditions. After completion of the reaction (monitored 
by TLC), the precipitate thus obtained was filtered, washed with water, air dried and 
recrystallized from methanol to gave 3β-acetoxy-6-hydrazono-5α-cholestane (48d).49 
 
3β-Chloro-6-hydrazono-5α-cholestane (49d) 
The steroidal ketone 49c reacted with hydrazine hydrate in ethanol solution in the presence 
of few drops of acetic acid in cold conditions. After completion of the reaction (monitored 
by TLC), the precipitate thus obtained was filtered, washed with water, air dried and 
recrystallized from methanol to gave 3β-chloro-6-hydrazono-5α-cholestane (49d).49 
 
6-Hydrazono-5α-cholestane (50d) 
The steroidal ketone 50c reacted with hydrazine hydrate in ethanol solution in the presence 
of few drops of acetic acid in cold conditions. After completion of the reaction (monitored 
G 
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by TLC), the precipitate thus obtained was filtered, washed with water, air dried and 
recrystallized from methanol to gave 6-hydrazono-5α-cholestane (50d).49 
 
Representative procedure for the synthesis of 5α-cholestan-6-(iminohydrazono)-2-
methylbenzaldehyde (48e-50e):  
To a solution of steroidal hydrazone (48d-50d) (1.5 mmol) in absolute ethanol (20 mL), 
phthalaldehyde (1.5 mmol) was added. Then the reaction mixture was stirred at 70 oC. 
After completion of reaction (monitored by TLC), solvent was evaporated under reduced 
pressure. The residue was purified by recrystallization to afford the corresponding target 
products (48e-50e). 
 
3β-Acetoxy-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (48e): 
Yield (82 %), m.p. 166-168 oC; IR (KBr, ν cm-1): 
3080, 1567, 1394 (C-H aromatic), 1735 (OCOCH3), 
1630 (C=N), 1057, 1059 (C-O), 1696 (-CHO); 1H 
NMR (400 MHz, CDCl3, ppm): δ 7.9-8.3 (m, 5H, 
aromatic), 10.4 (s, 1H, aldehyde), 4.77 (m, 1H, C3α-
H, W1/2 = 17 Hz, axial), 2.01 (s, 3H, OCOCH3), 1.15 
(C10-CH3), 0.73 (C13-CH3), 0.91 & 0.84 (other 
methyl protons); 13C NMR (100 MHz, CDCl3, ppm): 
δ 194.6, 172.3, 162.7, 144.3, 137.6, 133.3, 131.9, 
129.2, 128.7, 127.4, 71.1, 60.6, 58.3, 53.8, 43.6, 40.5, 39.2, 38.8, 36.3, 35.7, 34.6, 32.3, 
31.9, 30.6, 29.2, 26.7, 25.4, 24.8, 23.5, 22.6, 21.4, 20.1, 19.5, 17.4, 16.3, 15.4, 13.7; Anal. 
Calcd for C37H54N2O3; C, 77.31; H, 9.47; N, 4.87 found; C, 77.33; H, 9.49; N, 4.85; MS 
(EI): m/z 574 [M+.]. 
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3β-Chloro-5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (49e): 
Yield (79 %), m.p. 160-162 oC; IR (KBr, ν cm-1): 3081, 
1560, 1388 (C-H, aromatic), 1627 (C=N), 740 (C-Cl), 
1700 (-CHO); 1H NMR (400 MHz, CDCl3, ppm): δ 7.9-
8.3 (m, 5H, aromatic), 10.5 (s, 1H, aldehyde), 3.71 (m, 
1H, C3α-H, W1/2 = 15 Hz, axial), 1.15 (C10-CH3), 0.73 
(C13-CH3), 0.91 & 0.84 (other methyl protons); 
13C 
NMR (100 MHz, CDCl3, ppm): δ 196.7, 159.8, 142.3, 
139.4, 137.3, 135.8, 132.2, 127.6, 125.3, 58.7, 57.4, 
55.8, 52.2, 47.4, 45.2, 41.5, 40.2, 37.1, 36.3, 35.7, 34.6, 
32.4, 32.9, 31.1, 29.9, 26.7, 25.1, 23.3, 21.7, 20.6, 19.2, 17.8, 16.5, 14.9, 11.5; Anal. Calcd 
for C35H51ClN2O; C, 76.26; H, 9.33; N, 5.08 found; C, 76.24; H, 9.35; N, 5.09; MS (EI): 
m/z 550/552 [M+.]. 
 
5α-Cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (50e): 
Yield (77 %), m.p. 155-157 oC; IR (KBr, ν cm-1): 3085, 
1564, 1391 (C-H, aromatic), 1631 (C=N), 1702 (-CHO); 1H 
NMR (400 MHz, CDCl3, ppm): δ 7.9-8.3 (m, 5H, aromatic), 
10.4 (s, 1H, aldehyde), 1.15 (s, 3H, C10-CH3), 0.73 (s, 3H, 
C13-CH3), 0.91 & 0.84 (other methyl protons); 
13C NMR 
(100 MHz, CDCl3, ppm): δ 195.2, 160.5, 141.7, 135.2, 
134.7, 132.2, 129.8, 127.4, 126.1, 57.9, 53.3 43.0, 42.9, 39.2, 
38.7, 37.9, 36.4, 34.8, 33.2, 32.4, 32.0, 30.7, 29.8, 27.6, 26.1, 
25.8, 22.9, 21.5, 20.4, 19.6, 18.5, 17.7, 15.3, 12.1, 11.2; 
Anal. Calcd for C35H52N2O; C, 81.34; H, 10.14; N, 5.42 found; C, 81.37; H, 10.12; N, 5.41; 
MS (EI): m/z 516 [M+.]. 
 
Representative procedure for the synthesis of steroidal heterocyclic compounds (51-59): 
A mixture of 5α-cholestan-6-(iminohydrazono)-2-methylbenzaldehyde (48e-50e) (1mmol) 
and o-aminothiophenol/o-aminophenol/o-phenylenediamine (1.25 mmol, 1.25 equiv) in 
DMSO (30 mL) was refluxed for 2-6 h.50 The progress as well as completion of reaction 
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was monitored by TLC. After completion of reaction, the reaction mixture was poured into 
water. The precipitate thus obtained was filtered, washed with water and air dried. The 
crude product was purified by column chromatography on silica gel column using light 
petroleum ether/ether (10:1). For further purification, the compounds were recrystallized 
from methanol to give desirable products 51-59. 
 
3β-Acetoxy-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole 
(51): 
Yield (75 %), m.p. 156-158 oC; IR (KBr, ν cm-1): 
3085, 1569, 1396 (C-H aromatic), 1739 (OCOCH3), 
1635 (C=N), 1050, 1054 (C-O), 687 (C-S-C); 1H 
NMR (400 MHz, CDCl3, ppm): δ 7.7-8.0 (m, 5H, 
aromatic), 4.75 (m, 1H, C3α-H, W1/2 = 16 Hz, axial), 
2.03 (s, 3H, OCOCH3), 1.15 (C10-CH3), 0.73 (C13-
CH3), 0.91 & 0.84 (other methyl protons); 
13C NMR 
(100 MHz, CDCl3, ppm): δ 171.4, 161.2, 159.2, 
151.1, 142.6, 135.7, 132.1, 130.2, 127.4, 126.8, 
126.1, 125.9, 123.7, 122.9, 120.3, 119.9, 70.2, 58.3, 
57.1, 53.8, 44.1, 42.5, 40.1, 38.1, 37.5, 35.9, 35.6, 33.2, 32.9, 28.8, 27.9, 26.1, 25.2, 24.9, 
24.0, 22.9, 21.3, 21.9, 20.3, 19.7.0, 18.9, 15.1, 11.9; Anal. Calcd for C43H57N3O2S; C, 
75.95; H, 8.45; N, 6.18 found; C, 75.91; H, 8.49; N, 6.15; MS (EI): m/z 679 [M+.]. 
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3β-Chloro-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (52): 
Yield (72 %), m.p 162-164 oC; IR (KBr, ν cm-1): 3086, 
1562, 1393 (C-H, aromatic), 1632 (C=N), 743 (C-Cl), 
685 (C-S-C); 1H NMR (400 MHz, CDCl3, ppm): δ 7.9-
8.2 (m, 5H, aromatic), 3.91 (m, 1H, C3α-H, W1/2 = 14 
Hz, axial), 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 & 0.84 
(other methyl protons); 13C NMR (100 MHz, CDCl3, 
ppm): δ 160.3, 157.7, 152.6, 140.8, 135.7, 134.0, 130.3, 
129.1, 127.0, 127.9, 126.7, 124.2, 122.9, 120.0, 118.2, 
59.6, 57.6, 55.0, 52.4, 41.4, 40.7, 39.2, 38.5, 37.9, 36.5, 
35.9, 34.6, 34.0, 33.9, 31.2, 29.5, 27.2, 26.8, 23.0, 22.9, 
21.6, 20.1, 20.9, 17.3, 15.1, 13.7; Anal. Calcd for C41H54ClN3S; C, 75.02; H, 8.29; N, 6.40 
found; C, 75.05; H, 8.25; N, 6.44; MS (EI): m/z 655/657 [M+.]. 
 
5α-Cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (53): 
Yield (71 %), m.p. 154-156 oC; IR (KBr, ν cm-1): 3082, 
1565, 1389 (C-H, aromatic), 1629 (C=N), 682 (C-S-C); 1H 
NMR (400 MHz, CDCl3, ppm): δ 7.9-8.2 (m, 5H, aromatic), 
1.15 (s, 3H, C10-CH3), 0.73 (s, 3H, C13-CH3), 0.91 & 0.84 
(other methyl protons); 13C NMR (100 MHz, CDCl3, ppm): 
δ 158.7, 156.4, 151.7, 139.7, 135.9, 132.4, 130.9, 129.1, 
127.4, 126.5, 125.9, 123.9, 122.6, 120.7, 118.9, 54.2, 52.9, 
50.1, 45.3, 41.6, 40.2, 39.0, 37.7, 36.4, 35.3, 34.8, 33.9, 30.3, 
28.1, 27.3, 26.7, 24.1, 22.9, 21.6, 21.1, 20.6, 19.5, 17.2, 16.9, 
15.9, 11.5; Anal. Calcd for C41H55N3S; C, 79.18; H, 8.91; N, 
6.76 found; C, 79.21; H, 8.87; N, 6.77; MS (EI): m/z 621 [M+.]. 
 
 
 
 
Chapter 3                                                                                    Steroidal thiazoles, oxazoles and imidazoles 
 
111 
 
3β-Acetoxy-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole 
(54): 
Yield (78 %), m.p. 175-177 oC; IR (KBr, ν cm-1): 
3083, 1564, 1390 (C-H, aromatic), 1736 (OCOCH3), 
1631 (C=N), 1053, 1059 (C-O); 1H NMR (400 MHz, 
CDCl3, ppm): δ 8.0-8.3 (m, 5H, aromatic), 4.79 (m, 
1H, C3α-H, W1/2 = 17 Hz, axial), 2.02 (s, 3H, 
OCOCH3), 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 & 
0.84 (other methyl protons); 13C NMR (100 MHz, 
CDCl3, ppm): δ 173.4, 163.4, 153.5, 145.2, 141.2, 
139.5, 135.6, 130.1, 129.3, 127.9, 126.4, 123.4, 
121.5, 119.4, 115.5, 108.4, 69.6, 53.2, 52.7, 50.1, 
42.8, 40.2, 38.4, 37.2, 37.9, 36.1, 35.7, 34.2, 32.9, 30.9, 29.0, 28.6, 26.3, 25.1, 23.9, 22.1, 
21.7, 20.9, 19.7, 17.9, 16.6, 15.4, 10.9; Anal. Calcd for C43H57N3O3; C, 77.79; H, 8.65; N, 
6.33; found: C, 77.81; H, 8.62; N, 6.35; MS (EI): m/z 663 [M+.]. 
 
3β-Chloro-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (55): 
Yield (76 %), m.p. 181-183 oC; IR (KBr, ν cm-1): 3081, 
1561, 1395 (C-H, aromatic), 1637 (C=N), 1056 (C-O), 
741 (C-Cl); 1H NMR (400 MHz, CDCl3, ppm): δ 7.9-8.3 
(m, 5H, aromatic), 3.81 (m, 1H, C3α-H, W1/2 = 16 Hz, 
axial), 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 & 0.84 
(other methyl protons); 13C NMR (100 MHz, CDCl3, 
ppm): δ 156.1, 151.3, 148.6, 143.5, 140.2, 135.9, 130.3, 
129.4, 128.1, 126.9, 124.3, 122.5, 121.2, 117.9, 109.9, 
59.6, 55.3, 54.6, 53.9, 41.5, 40.9, 38.7, 37.5, 36.9, 36.7, 
35.4, 34.9, 33.8, 32.7, 31.4, 29.9, 27.1, 26.3, 24.9, 22.9, 
21.7, 20.2, 19.1, 18.8, 15.7, 13.1; Anal. Calcd for C41H54ClN3O; C, 76.90; H, 8.50; N, 6.56; 
found: C, 76.87; H, 8.52; N, 6.59; MS (EI): m/z 639/641 [M+.]. 
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5α-Cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (56): 
Yield (80 %), m.p. 176-178 oC; IR (KBr, ν cm-1): 3088, 
1560, 1397 (C-H, aromatic),1634 (C=N), 1058 (C-O); 1H 
NMR (400 MHz, CDCl3, ppm): δ 7.9-8.3 (m, 5H, aromatic), 
1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 & 0.84 (other methyl 
protons); 13C NMR (100 MHz, CDCl3, ppm): δ 157.3, 150.2, 
149.4, 140.7, 137.6, 136.7, 132.2, 128.5, 127.2, 126.5, 
124.6, 122.1, 121.5, 118.7, 111.5, 58.2, 56.7, 55.4, 48.7, 
41.5, 40.1, 39.2, 38.5, 37.9, 36.5, 34.3, 33.2, 29.0, 27.9, 26.4, 
25.2, 24.9, 23.6, 22.7, 21.4, 20.1, 19.8, 18.3, 17.7, 15.9, 13.2; 
Anal. Calcd for C41H55N3O; C, 81.27; H, 9.15; N, 6.94; 
found: C, 81.31; H, 9.20; N, 6.95; MS (EI): m/z 605 [M+.]. 
 
3β-Acetoxy-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole 
(57): 
Yield (79 %), m.p. 167-169 oC; IR (KBr, ν cm-1): 
3331 (NH), 3087, 1563, 1391 (C-H aromatic), 1738 
(OCOCH3), 1636 (C=N), 1061, 1065 (C-O), 1310 
(C-N); 1H NMR (400 MHz, CDCl3, ppm): δ 5.3 (s, 
1H, NH, exchangeable with D2O), 7.9-8.2 (m, 5H, 
aromatic), 4.71 (m, 1H, C3α-H, W1/2 = 18 Hz, axial), 
2.01 (s, 3H, OCOCH3), 1.15 (C10-CH3), 0.73 (C13-
CH3), 0.91 & 0.84 (other methyl protons); 
13C NMR 
(100 MHz, CDCl3, ppm): δ 169.9, 159.9, 147.3, 
144.6, 143.8, 139.2, 138.4, 132.7, 129.3, 128.1, 
126.5, 124.6, 123.1, 122.8, 113.7, 111.5, 71.5, 54.2, 52.6, 50.3, 42.8, 40.3, 39.2, 38.5, 37.5, 
36.2, 35.9, 34.2, 33.7, 30.5, 29.7, 28.2, 26.4, 25.2, 24.9, 23.6, 22.5, 21.8, 20.4, 19.7, 18.2, 
16.8, 14.2; Anal. Calcd for C43H58N4O2; C, 77.90; H, 8.82; N, 8.45 found; C, 77.86; H, 
8.85; N, 8.48; MS (EI): m/z 662 [M+.]. 
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3β-Chloro-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole 
(58): 
Yield (77 %), m.p. 152-154 oC; IR (KBr, ν cm-1): 3335 
(NH), 3084, 1566, 1387 (C-H, aromatic), 1633 (C=N), 
1317 (C-N), 744 (C-Cl); 1H NMR (400 MHz, CDCl3, 
ppm): δ 4.7 (s, 1H, NH, exchangeable with D2O), 7.9-
8.2 (m, 5H, aromatic), 3.72 (m, 1H, C3α-H, W1/2 = 14 
Hz, axial), 1.15 (C10-CH3), 0.73 (C13-CH3), 0.91 & 0.84 
(other methyl protons); 13C NMR (100 MHz, CDCl3, 
ppm): δ 160.2, 149.2, 141.5, 140.8, 139.4, 138.0, 133.7, 
130.9, 129.7, 128.5, 125.4, 124.8, 120.3, 112.9, 110.5, 
59.5, 57.1, 55.9, 52.7, 45.2, 43.7, 40.2, 39.5, 38.8, 37.4, 
36.1, 35.4, 34.7, 33.8, 32.5, 29.3, 27.5, 26.7, 25.9, 24.1, 23.6, 22.1, 20.6, 17.3, 16.7, 14.2; 
Anal. Calcd for C41H55ClN4; C, 77.02; H, 8.67; N, 8.76 found; C, 77.05; H, 8.70; N, 8.75; 
MS (EI): m/z 638/640 [M+.]. 
 
5α-Cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (59): 
Yield (81 %), m.p. 164-166 oC; IR (KBr, ν cm-1): 3342 (NH), 
3089, 1568, 1388 (C-H, aromatic), 1628 (C=N), 1329 (C-
N); 1H NMR (400 MHz, CDCl3, ppm): δ 4.4 (s, 1H, NH, 
exchangeable with D2O), 7.9-8.3 (m, 5H, aromatic), 1.15 (s, 
3H, C10-CH3), 0.73 (s, 3H, C13- CH3), 0.91 & 0.84 (other 
methyl protons); 13C NMR (100 MHz, CDCl3, ppm): δ 
162.5, 147.6, 145.6, 143.2, 140.3, 137.6, 134.2, 129.6, 
128.1, 125.9, 124.7, 123.2, 122.8, 117.3, 112.6, 59.2, 57.5, 
55.2, 49.5, 44.7, 39.1, 37.9, 36.9, 35.4, 34.7, 32.5, 30.8, 29.7, 
27.9, 26.6, 25.3, 24.7, 23.4, 22.8, 21.2, 20.5, 19.8, 18.2, 17.6 
15.9, 13.6; Anal. Calcd for C41H56N4; C, 81.41; H, 9.33; N, 9.26 found; C, 81.44; H, 9.29; 
N, 9.21; MS (EI): m/z 604 [M+.]. 
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he pyrimidine structures are an important class of nitrogen heterocyclic 
compounds with a wide range of bioactive products and pharmacological 
activities such as analgesic,1 antihypertensive,2 anti-tumor agents,3 antipyretic,4 
antifungal,5 antibacterial,6 anti-inflammatory,7 antioxidant,8 and antimitotic activities.9 
Moreover, the pyrimidine-based scaffolds have been explored in medicinal chemistry 
and as new α-helix mimetics in peptide chemistry. Therefore, developing an efficient 
and practical method to construct biologically active pyrimidine derivatives is a 
significant and challenging work. 
          Belhadj et al.10 reported the synthesis of 4-substituted aminopyrido[2,3-
d]pyrimidines (3) from the mixture of  N,N-dimethyl-Nʹ-(pyridin-2-yl)formamides (1) 
and primary amine (2) under solvent free conditions.  
 
 
          Sirakanyan et al.11 synthesized 9(10)-thioxopyrido[3ʹ,2ʹ:4,5]furo(thieno)[3,2-
d]pyrimidin-7(8)-ones (6a-d). Firstly, the reaction of ethyl 1-aminofuro(thieno)[2,3-
b]pyridine-2-carboxylates (4a-d) with benzoyl isothiocyanate in dry benzene to give  
thioureido derivatives (5a-d) which further react with solution of potassium hydroxide 
in ethanol that yielded 9(10)-thioxopyrido[3ʹ,2ʹ:4,5]furo(thieno)[3,2-d]pyrimidin-7(8)-
ones (6a-d). 
 
T 
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          Barthakur et al.12 reported the synthesis of 2ʹ-aryl-steroidal[3,2-d]pyrimidine (9) 
from the mixture of 2-hydroxymethylene-3-ketosteroid (7), aromatic aldehyde (8) and 
ammonium acetate under microwave irradiation. 
 
 
          Jiang et al.13 synthesized polysubstituted fused pyrimidines (13) from the 
reaction of aromatic aldehydes (10) and tetrahydrothiopyran-4-one/tetrahydropyran-4-
one (11) with aryl amidines (12) in a ratio of 2:1:1.1 under microwave irradiation 
through one-pot four-component strategy. 
 
 
 
 
          Alizadeh et al.14 reported the reaction of N,Nʹ-
bis(arylmethylidene)arylmethanediamine (14) with different diamines in the presence 
of 1,1-bis(methylthio)-2-nitroethylene (15), gave the desired product pyrimido[1,6-
a]pyrimidine and imidazo[1,2-c]pyrimidine (16-18) in high yields. 
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          Shamsuzzaman et al.15 reported the synthesis of steroidal pyrimidines (21) by 
two step reaction. In the first step, steroidal thiosemicarbazones (20) were synthesized 
by the reaction of steroidal ketones (19) with thiosemicarbazide in ethanol in the 
presence of a few drops of HCl. In second step, steroidal thiosemicarbazones (20) react 
with ethyl cyanoacetate in 1,4-dioxane that yielded corresponding product (21). 
 
 
          Kaswan et al.16 synthesized 5,7-diarylpyrazolo[1,5-a]pyrimidine (24) from the 
reaction of chalcone (22) with 1H-pyrazol-3-amine (23) in the presence of K2CO3 in 
toluene at 110 oC. 
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          Giles et al.17 reported the synthesis of pyrimidine derivatives (28a-l). In the first 
step, 2-acetylindane-1,3-dione (25) was treated with different aldehydes (26a-l) to form 
chalcone derivatives (27a-l). The chalcones 27a-l were further treated with urea to form 
pyrimidine derivatives (28a-l). 
 
 
 
          Chen et al.18 reported the reaction of 5-amino-1H-1,2,4-triazole-3-thiol (29) with 
ethyl bromoacetate to afford intermediate 30, which cyclized with acetylacetaldehyde 
dimethyl acetal to give ethyl 2-(5-methyl-1,2,4-triazolo-[1,5-a]pyrimidin-2-
ylthio)acetate (31) and ethyl 2-(5,7-dimethyl-1,2,4-triazolo[1,5-a]-pyrimidin-2-
ylthio)propanoate (32) in a high yield (80% and 96%, respectively). 
 
 
          Davoodnia et al.19 reported the reaction of ethyl 2-amino-4,5-dimethylthiophene-
3-carboxylate (33) with aryl isocyanates (34) under basic conditions that yielded 
corresponding product, 3-aryl-5,6-dimethylthieno[2,3-d]pyrimidine-2,4(1H,3H)-
diones (35). 
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ing modifications of the steroid nucleus affect the chemical properties of the 
steroidal molecules and often result in useful variations in their biological 
activities20 as a result of which, hetero-steroids have conquered a unique position in the 
present scenario of drug discovery. The advantage of employing hydrophobic steroid 
moieties is their ability to interact with cell membranes thereby paving way for the 
biological activity of such hybrid molecules. In view of these advantageous outcomes 
of hetero-steroids, enormous efforts are being made to develop new methodologies to 
annelate steroidal molecule with different heterocycles such as pyridine, pyrazole, 
isoxazole, pyrrole, and pyrimidine using various synthetic strategies.21 On the other 
hand, pyrimidine derivatives are of great biological importance because of their wide 
range of biological activities. In vision of the pharmacological importance of hetero-
steroids and in continuation of our previous work in developing new bioactive modified 
steroids,22 recently we reported the synthesis of novel steroidal pyrimidine derivatives 
(39-41)*. In view of the above-mentioned facts, the products obtained have been 
characterized on the basis of spectral (IR, 1H NMR, 13C NMR, MS, DFT) and elemental 
analysis. 
 
 
 
 
 
*DFT/B3LYP calculations, in vitro cytotoxicity and antioxidant activities of 
steroidal pyrimidines and their interaction with HSA using molecular docking and 
spectroscopic techniques. Abad Ali, Shamsuzzaman et al. 
(Communicated) 
R 
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Reaction of 3β-acetoxy-5α-cholestan-6-one (36) with urea and benzaldehyde: 3β-
Acetoxy-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine (39): 
To a solution of 3β-acetoxy-5α-cholestan-6-one (36) in DMF/CH3CN, urea, ArCHO 
and TMSCl at room temperature was added. Then the reaction mixture was stirred at 
90 oC for 13 h. After completion of the reaction, the mixture was cooled to room 
temperature, water was added to the reaction mixture and the resulting mixture was 
extracted with CH2Cl2, the organic phase was washed with water and brine, and dried 
over anhydrous Na2SO4. After removal of solvent, the residue was purified by 
recrystallization, which provided a single product 39, m.p. 165-166 oC. 
Characterization of compound 39 as 3β-acetoxy-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-
[6,7-b]-pyrimidine: 
The elemental analysis of compound 39 corresponded to the molecular formula 
C37H52N2O3. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1632 cm-1 for 
stretching of C=N group and at 3221 cm-1 for -OH group. Another absorption bands at 
3083, 1568, 1391 cm-1 confirmed the presence of aromatic ring. Further evidence for 
the formation of compound 39 was well supported by its 1H NMR and 13C NMR spectra 
(Figure 1.1, 1.2). The 1H NMR spectrum of the compound 39 exhibited a signal at δ 
7.72-7.99, assigned to aromatic ring. A one proton broad multiplet centered at δ 4.62-
4.70 was assigned to C3α-H (axial) and a sharp singlet for three acetoxy group protons 
appeared at δ 2.02 while as the singlet integrating for one proton at δ 8.46 showed the 
presence of -OH group. Angular and side-chain methyl protons were observed at δ 1.14 
(C10-CH3), 0.74 (C13-CH3), 0.92 and 0.86 for other methyl protons. 
13C NMR spectrum 
of the compound also supported the proposed structure and displayed characteristic 
signals at δ 172.4 for OCOCH3 and  for C-OH, C-N, C=N, C=C and C-O at δ 155.3, 
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149.6, 160.6, 113.6 and 70.1, respectively. Remaining carbon atoms were seen in 
accordance to the cholestane series. The structure of compound 39 was further 
supported by its mass spectrum in which the distinct molecular ion peak was observed 
at m/z 572 (Figure 1.3). 
          Thus, the compound 39 on account of above discussion can be suitably 
characterized as 3β-acetoxy-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine. 
 
Figure 1.1. 1H NMR spectrum of 3β-acetoxy-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-
b]-pyrimidine (39). 
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Figure 1.2. 13C NMR spectrum of 3β-acetoxy-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-
b]-pyrimidine (39). 
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Figure 1.3. HRMS spectrum of 3β-acetoxy-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-
pyrimidine (39). 
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Reaction of 3β-chloro-5α-cholestan-6-one (37) with urea and benzaldehyde: 3β-
Chloro-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine (40): 
To a solution of 3β-chloro-5α-cholestan-6-one (37) in DMF/CH3CN, urea, ArCHO and 
TMSCl at room temperature was added. Then the reaction mixture was stirred at 90 oC 
for 14.5 h. After completion of the reaction, the mixture was cooled to room 
temperature, water was added to the reaction mixture and the resulting mixture was 
extracted with CH2Cl2, the organic phase was washed with water and brine, and dried 
over anhydrous Na2SO4. After removal of solvent, the residue was purified by 
recrystallization, which provided a single product 40, m.p. 169-170 oC. 
 
Characterization of compound 40 as 3β-chloro-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-
[6,7-b]-pyrimidine: 
The elemental analysis of compound 40 corresponded to the molecular formula 
C35H49ClN2O. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1629 cm-1 for 
stretching of C=N group and at 3219 cm-1 for -OH group. Another absorption bands at 
3081, 1567, 1383 cm-1 confirmed the presence of aromatic ring. Further evidence for 
the formation of compound 40 was well supported by its 1H NMR and 13C NMR spectra 
(Figure 2.1, 2.2). The 1H NMR spectrum of the compound 40 exhibited a signal at δ 
7.52-7.95, assigned to aromatic ring. A one proton broad multiplet centered at δ 3.85-
3.94 was assigned to C3α-H (axial) whereas the singlet integrating for one proton at δ 
8.76 showed the presence of -OH group. Angular and side-chain methyl protons were 
observed at δ 1.13 (C10-CH3), 0.72 (C13-CH3), 0.91 and 0.85 for other methyl protons. 
13C NMR spectrum of the compound also supported the proposed structure and 
displayed characteristic signals at δ 65.3 for C-Cl group and for C-OH, C-N, C=N and 
C=C at δ 156.5, 147.4, 161.3 and 115.1, respectively. Remaining carbon atoms were 
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seen in accordance to the cholestane series. The distinct molecular ion peak at m/z 
548/550 in mass spectrum also supported the formation of compound 40 (Figure 2.3). 
         Hence, the above discussion suitably characterized the compound 40 as 3β-
chloro-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine. 
 
Figure 2.1. 1H NMR spectrum of 3β-chloro-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-
pyrimidine (40). 
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Figure 2.2. 13C NMR spectrum of 3β-chloro-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-
b]-pyrimidine (40). 
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Figure 2.3. HRMS spectrum of 3β-chloro-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-
pyrimidine (40). 
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Reaction of 5α-cholestan-6-one (38) with urea and benzaldehyde: 6-Cholsteno-2ʹ-
hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine (41): 
To a solution of 5α-cholestan-6-one (38) in DMF/CH3CN, urea, ArCHO and TMSCl at 
room temperature was added. Then the reaction mixture was stirred at 90 oC for 13.5 h. 
After completion of the reaction, the mixture was cooled to room temperature, water 
was added to the reaction mixture and the resulting mixture was extracted with CH2Cl2, 
the organic phase was washed with water and brine, and dried over anhydrous Na2SO4. 
After removal of solvent, the residue was purified by recrystallization, which provided 
a single product 41, m.p. 158-159 oC. 
 
Characterization of compound 41 as 6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-
pyrimidine: 
The elemental analysis of compound 41 corresponded to the molecular formula 
C35H50N2O. The IR data provided evidence for the formation of the expected 
compound. It showed the characteristic strong absorption bands at 1635 cm-1 for 
stretching of C=N group and at 3225 cm-1 for -OH group. Another absorption bands at 
3079, 1563, 1392 cm-1 confirmed the presence of aromatic ring. Further evidence for 
the formation of compound 41 was well supported by its 1H NMR and 13C NMR spectra 
(Figure 3.1, 3.2). The 1H NMR spectrum of the compound 41 exhibited a signal at δ 
7.54-7.93, assigned to aromatic ring while as the singlet integrating for one proton at δ 
8.56 showed the presence of -OH group. Angular and side-chain methyl protons were 
observed at δ 1.14 (C10-CH3), 0.72 (C13-CH3), 0.92 and 0.85 for other methyl protons. 
13C NMR spectrum of the compound also supported the proposed structure and 
displayed characteristic signals at δ 157.6, 150.7, 162.5 and 114.7 for C-OH, C-N, C=N 
and C=C groups, respectively. Remaining carbon atoms were seen in accordance to the 
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cholestane series. The mass spectrum further supported the compound 41 with distinct 
molecular ion peak was observed at m/z 514 (Figure 3.3). 
         Therefore, on account of above discussion, the compound 41 can be suitably 
characterized as 6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine. 
 
Figure 3.1. 1H NMR spectrum of 6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine 
(41). 
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Figure 3.2. 13C NMR spectrum of 6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-
pyrimidine (41). 
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Figure 3.3. HRMS spectrum of 6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine 
(41). 
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Mechanism of the reaction 
A sequence of reactions involving Biginelli-like condensation took place during 
formation of the compounds (39-41). This may be concluded from the fact that when 
condensation of steroidal ketones (36-38) and benzaldehyde was carried out, compound 
C was isolated as the product, thereby indicating that a condensation reaction is the first 
step in this three-component process. The proposed mechanism for the synthesis of 
compounds (39-41) is depicted in Scheme 1. The silylenol ether A is initially generated 
by TMSCl. A siloxy ketone B is formed by nucleophilic addition reaction of the 
aldehyde with the silyl enol ether A; expectedly, the siloxy substituent plays the role of 
the leaving group, followed by subsequent elimination of trimethylsilyl alcohol to give 
the α, β-unsaturated ketone C and Michael addition reaction with urea promoted by 
TMSCl to yield the new silyl enol ether D. Next, the silyl enol ether D isomerises to 
ketone E quickly. Then, as the key step, the nitrogen of urea within the 5α-cholestan-
6-one moiety of steroidal skeleton forms the six-membered hetero-ring F in an 
intramolecular cyclisation reaction. Subsequently, water is eliminated from compound 
F, giving the dihydropyrimidinone compound G. Finally, aromatisation occurs under 
air that leads to the steroidal pyrimidines (39-41).23 The air oxygen apparently acts as 
an effective oxidant for the aromatisation of the dihydropyrimidinone. In general, 
unsaturated pyrimidinol compounds F are difficult to oxidise. Here, the aromatisation 
of dihydropyrimidinones G with aromatic groups was promoted by “HCl” generated 
from TMSCl.24 However, the aromatization took a long time. Finally the proposed 
fragmentation mechanisms (Scheme 2, 3) of molecular ion peak [M+.] at m/z: 572, 
548/550 and 514 in the MS spectra as shown in Figure 1.3-3.3, also proved the 
formation of the compounds (39-41). In conclusion, we have developed an efficient 
synthetic approach for the synthesis of a novel class of steroidal pyrimidines which 
were synthesized through a one-pot multicomponent Biginelli-like condensation via 
TMSCl under mild conditions.  
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Scheme 1. Plausible reaction mechanism for the synthesis of compounds (39-41). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                                                                                                                  Steroidal pyrimidines 
 
137 
 
Scheme 2. Proposed fragmentation mechanisms of molecular ion [M+.] of compounds 
(39-41). 
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Scheme 3. Proposed fragmentation mechanisms of molecular ion [M+.] of compounds 
(39-41). 
 
 
 
Theoretical investigation of the compounds 39-41 
The experimental IR and NMR data have been supported by the results obtained at DFT 
(B3LYP)/6-31G(d,p) level of theory. All the analytical and spectral data of compounds 
(39-41) were in accordance with the proposed structure. The selected diagnostic bands 
of IR spectra of synthesized products provide useful information for determining 
structures of the compounds. The signals at 3219-3225 and 1629-1635 cm-1 appeared 
in the IR spectra of compounds 39-41 were attributed to O-H and C=N stretching 
vibrations and the absorption bands at 3079-3083, 1563-1568, 1383-1392 cm-1 are 
attributed to the aromatic ring. Although, theoretical harmonic frequencies of O-H, 
C=C (aromatic) and C=N stretching were predicted around 3787, 1658 and 1599 cm-1, 
respectively, while for aromatic C-H and other C-H stretching of compounds (39-41) 
were found in the region of 3181-3220 and 2977-3180 cm-1, respectively. The aromatic 
C-H in-plane bending vibrations with mixing of others are appeared theoretically 
Chapter 4                                                                                                                  Steroidal pyrimidines 
 
139 
 
around 1448 cm-1 in compounds 39-41. The experimental and theoretical IR frequency 
due to C=O stretching vibration is found to be 1734 and 1821 cm-1, respectively for 
compound 39. The IR band due to C-Cl stretching vibration is observed at 743 cm-1 
while the corresponding theoretical value is found to be 663 cm-1. The C-Cl stretching 
vibration is found with mixing of other skeleton vibrations. The deviation in theoretical 
frequency is noticed due to fact that the experimental IR belongs to molecule in solid 
phase where the vibrations observed mainly due to strong anharmonicity while the 
calculations have been carried out in the harmonic approximation for the isolated 
molecule in gaseous phase. 
The NMR spectra (1H and 13C) of the present compounds (39-41) are studied using 
experiment as well as quantum chemical calculations in the solvent phase. The GIAO 
method within DFT framework is an efficient tool for computing NMR spectra. The 
spectra were obtained in the solvent phase (chloroform) using PCM model within 
GIAO approach at B3LYP/6-31G(d,p) level of theory. The simulated NMR spectra is 
presented in Figure 4.1-4.6.  
 
Figure 4.1. 1H NMR spectrum of 3β-acetoxy-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-
b]-pyrimidine (39). 
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Figure 4.2. 13C NMR spectrum of 3β-acetoxy-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-
b]-pyrimidine (39). 
 
 
 
 
 
 
Figure 4.3. 1H NMR spectrum of 3β-chloro-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-
pyrimidine (40). 
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Figure 4.4. 13C NMR spectrum of 3β-chloro-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-
b]-pyrimidine (40). 
 
 
 
 
 
 
Figure 4.5. 1H NMR spectrum of 6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine 
(41). 
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Figure 4.6. 13C NMR spectrum of 6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-
pyrimidine (41). 
 
 
 
The molecular structures with labelling of atoms are used according to Figure 5, for 
the NMR spectra. The NMR spectra have been discussed also with the help of 
calculated atomic charges as shown in Figure 6. 
 
Figure 5. Optimized molecular structure with numbering scheme for the compounds 
39-41. 
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Figure 6. Natural and Mullikan’s atomic charges of the compounds 39-41. 
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The signals for the experimental 1H NMR spectra are observed between 0 to 9 ppm 
while for 13C NMR these are occurred in the region 0-180 ppm. Therefore, the 1H NMR 
spectra of compounds (39-41) displayed singlet at δ 8.46-8.76 due to O-H proton and 
the signal at δ 162.5-160.6, 123.9-132.5 in 13C NMR spectra confirm the presence of 
C=N and aromatic ring, respectively, in the compounds 39-41. Thus, all these are found 
in good agreement with the theoretically obtained data as shown in Figure 4.1-4.6. The 
NMR signals appear at different ppm values even for the same nuclei as the nuclei are 
chemically inequivalent in the molecule due to surrounding electrons. The signals 
appeared at low ppm values show the large electron density over the nuclei due to 
shielding effect while signals at high ppm values show the less electron density over 
the nuclei because of deshielding effect.25,26 In 13C NMR spectra, the signals due to C6, 
C38, C32, C36 for the compound 39, C6, C35, C33 for the compound 40 and C6, C34, C32 
for the compound 41 are occurred on higher ppm value scale around 150-160 ppm 
because of deshielding effect. The high ppm values due to these atoms show the less 
electron density over them as these atoms possess high positive charges (Figure 6). On 
the lower ppm scale around 10 ppm, the signals are appeared due to C22, C20, C27, C33, 
C18 of compound 39, C22, C20, C27, C18 of compound 40 and C22, C20, C27, C2, C18 of 
compound 41 because of shielding effect as these atoms are surrounded by high electron 
density due to high negative charges (Figure 6). In similar way, for 1H NMR spectra, 
the atoms H90, H94, H91, H92, H93 of compound 39, H84, H88, H85, H86, H87 of compound 
40 and compound 41 are observed with high chemical shift values around 8 ppm while 
the signals with low ppm values below 1 ppm are appeared due to atoms H61, H72, H77, 
H55, H76, H69, H75 of compound 39, H58, H69, H74, H52, H73, H66, H72 of compound 40 
and compound 41. The signals due to these atoms appeared on high and low ppm values 
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show respectively the less and high electron density in surroundings. The present NMR 
data shows good correlation with the atomic charge values of the molecules as the atoms 
with positive to negative charges show the NMR signals with high to low ppm values, 
respectively. Therefore, atomic charges of the atoms in molecules with large negative 
and positive values may be responsible for the low and high chemical shifts, 
respectively.          
 
Other theoretical molecular parameters 
In this study, the various other molecular properties of the present compounds have 
been also computed at B3LYP/6-31G(d,p) level of theory. The molecular energy 
(minimum SCF energy), thermodynamic parameters, field independent dipole moment 
and chemical reactivity indices based on HOMO and LUMO energy Eigen values for 
the compounds 39-41 are depicted in Table 1. The minimum SCF energy for the 
compound 40 is found to be lowest and hence it is more stable than compound 39 and 
41. The compound 40 may show strong interactions with other species as its dipole 
moment is found to be high as compared to others. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                                                                                                                  Steroidal pyrimidines 
 
147 
 
Table 1. Calculated SCF energy, zero point vibrational energy, thermodynamic 
quantities (at 298.15 K), dipole moment, energies of frontier molecular orbitals and 
global reactivity descriptors of compounds (39-41). 
Parameters B3LYP/6-31G(d,p) 
 Compound 39     Compound 40    Compound 41 
SCF energy 
(kcal/mol) 
-1114808.761 -1260210.247 -971809.050 
Zero point vibrational energy 
(kcal/mol) 
522.78428 490.51520 496.57146 
Total thermal energy 
(kcal/mol) 
548.535 514.093 519.329 
Molar heat capacity at const. 
volume, Cv 
(cal mol-1 K-1 ) 
162.284 150.506 146.860 
Total entropy, S 
(cal mol-1 K-1 ) 
247.191 229.560 219.532 
    
Field independent dipole 
moment (Debye) 
   
μx -3.1632 -4.8818 -2.2783 
μy 1.8781 0.2507 -0.0406 
μz 1.7551 2.7328 1.9639 
μtotal 4.0759 5.6002 3.0082 
 
Frontier MO Energies (eV)    
LUMO -1.326 -1.351 -1.239 
HOMO -6.269 -6.295 -6.185 
GAP = LUMO - HOMO 4.943 4.944 4.946 
 
Global reactivity 
descriptors (eV) 
   
Hardness 2.472 2.472 2.473 
Chemical Potential -3.797 -3.823 -3.712 
Electron Affinity 1.326 1.351 1.240 
Electrophilicity 2.917 2.956 2.787 
Electronegativity 3.797 3.823 3.712 
Ionization Potential 6.269 6.295 6.185 
Softness 0.202 0.202 0.202 
 
Atomic charges for the compounds 39-41 are computed using Mullikan and Natural 
population analysis at same level of theory. Natural charges are found stronger than 
Mullikan charges. The variation of charges (Natural and Mullikan) are shown in Figure 
6. The natural charges of all carbon atoms for all the three kind of molecules vary from 
0.9e to -0.8e. The hydrogen atom in O-H group is appeared with high positive charge 
(about 0.5e) among the others as this atom is connected with high electronegative atom 
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O in molecule. The natural charges of all other hydrogen atoms are predicted about 
0.3e.   
The frontier molecular orbitals, HOMO (highest occupied molecular orbital) and 
LUMO (lowest unoccupied molecular orbital), play important role in defining the 
reactivity of molecules. The various chemical reactivity indices27 have been computed 
for the present compounds using HOMO and LUMO energy Eigen values (Table 1). 
The gap between HOMO and LUMO energy do help in defining the charge transfer 
properties of the molecules. The low value of HOMO-LUMO gap shows the more 
reactivity and less kinetic stability of the molecule. The low HOMO-LUMO gap 
supports the bioactive molecules.28-31 The spatial plots of HOMO and LUMO are shown 
in Figure 7, which shows the charge delocalization within the molecule upon 
excitation.     
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Figure 7. Spatial arrangement of frontier molecular orbitals (HOMO and LUMO) with 
energy Eigen values and gaps of compounds (39-41). 
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The molecular electrostatic potential (MEP) mapping of all the compounds 39-41 have 
been constructed (Figure 8). These are used to predict the behaviour and reactivity of 
the molecules. MEP is created by mapping of electrostatic potential on the total electron 
density of the molecule. MEP mapping helps in interpretation of the electrophilic and 
nucleophilic reactions for the study of biological recognition process and hydrogen 
bonding interactions.32 The 3 colours; blue, red and green are used to indicate the value 
of the electrostatic potential. The blue and red colour surfaces show the positive and 
negative values of the potential, respectively, while the surfaces with green colour show 
the neutral regions of the molecule.28-30,33 The MEP plots play important role to explain 
inter/intra-molecular interactions, drug-protein interactions and structure-activity 
relationship. 
 
Figure 8. Molecular electrostatic potential (MEP) plots for the compounds 39-41. 
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eneral remarks 
Melting points were recorded on Riechert Thermover instrument and are 
uncorrected. IR spectra (KBr disks) were recorded on Perkin Elmer FT-IR 
Spectrometer spectrum two and its values are given in cm-1. 1H and 13C NMR spectra 
were run in CDCl3 on a Bruker Avance II 400 NMR Spectrometer at 400 MHz and 100 
MHz, respectively. Chemical shifts (δ) are reported in ppm relative to the TMS (1H 
NMR spectra) and to the solvent signal (13C NMR spectra). Mass Spectra were recorded 
on a Waters, Micromass Q-TOF micro YB361, UK. Elemental analysis of all the newly 
synthesized compounds were recorded on Perkin Elmer 2400 CHN Elemental Analyzer 
within ± 0.4 % of the theoretical values. Thin layer chromatography (TLC) plates were 
coated with silica gel G and exposed to iodine vapors to check the homogeneity as well 
as the progress of reaction. Sodium sulfate (anhydrous) was used as a drying agent.  
The synthesis of 3β-Acetoxycholest-5-ene, 3β-Acetoxy-6-nitrocholest-5-ene, 3β-
Chlorocholest-5-ene, 3β-Chloro-6-nitrocholest-5-ene, Cholest-5-ene and 6-
Nitrocholest-5-ene are shown in Chapter 1, page 23-25. 
 
Computational details 
Theoretical calculations have been carried out using hybrid functional B3LYP34,35 along 
with double zeta Pople’s type basis set, 6-31G(d,p), as implemented in Gaussian 09 
package.36 The molecular geometry of the compounds were optimized in the ground 
electronic state without imposing any constraints under tight convergence criterion and 
subsequently the harmonic IR frequencies were computed at same level of theory. The 
calculated IR frequencies were found real that revealed the optimized geometry 
corresponds to an energy minimum. The theoretical NMR spectra (1H and 13C) were 
calculated in the solvent phase using polarizable continuum model (PCM) along with 
gauge independent atomic orbital (GIAO) method within DFT/B3LYP framework. The 
NMR spectra have been presented by relative chemical shifts (ppm) (δ) obtained by 
subtracting the corresponding TMS shielding calculated at GIAO-B3LYP/6-
311++G(2d,p) level of theory as the reference. Moreover, various other molecular 
properties like molecular energy, atomic charges, dipole moment, frontier molecular 
orbitals, chemical reactivity indices and thermodynamic properties of the present 
compounds have been also computed for the ground state optimized geometry. The 
frontier molecular orbitals (HOMO and LUMO) and molecular electrostatic potential 
G 
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mapping (MEP) plots of the present compounds have been generated with the help of 
a visualization program GaussView 5.37 
 
3β-Acetoxy-5α-cholestan-6-one (36): 
3β-Acetoxy-6-nitrocholest-5-ene (6.0 g) was dissolved in glacial acetic acid (120 mL) 
by warming the mixture and zinc dust (12.0 g) was added in small portions with 
shaking. The suspension was heated under reflux for 4 h and water (12 mL) was added 
at regular intervals during the course of reaction. The hot solution was filtered, cooled 
to room temperature and diluted with large excess of ice-cold water and extracted with 
diethyl ether. The ethereal solution was washed with water, NaHCO3 solution (5%) and 
again with water and dried over anhydrous sodium sulfate. Evaporation of solvents 
provided the acetoxy ketone (4.2 g) as an oil which was crystallized from methanol, 
m.p. 128-129 °C (reported m.p. 127-128 °C).38 
 
3β-Chloro-5α-cholestan-6-one (37): 
A mixture of 3β-chloro-6-nitrocholest-5-ene (8.0 g) and glacial acetic acid (160 mL) 
was heated just to get a clear solution. The zinc dust (16.0 g) was added gradually in 
small portions with constant shaking. The suspension was heated under reflux for 4 h 
and water (16 mL) was added at regular intervals during the course of reaction. The hot 
solution was filtered and the filtrate was diluted with large excess of ice-cold water. 
The organic matter was extracted with diethyl ether and ethereal layer was washed 
successively with water, NaHCO3 solution (5 %) and again with water and dried over 
anhydrous sodium sulfate. Evaporation of the solvents furnished the ketone (5.8 g) as 
an oil which was crystallized from methanol, m.p. 128-129 °C (reported m.p. 129 °C).39 
 
5α-Cholestan-6-one (38): 
6-Nitrocholest-5-ene (4.0 g) was dissolved in warm glacial acetic acid (80 mL) and zinc 
dust (8.0 g) was gradually added with shaking. The mixture was heated under reflux for 
4 h and water (8 mL) was added during the course of reaction. Zinc dust (unreacted) 
was removed by filtration. To the filtrate, water was added till turbidity developed and 
it was allowed to stand overnight at room temperature. The solid material thus separated 
was filtered under suction and washed thoroughly with water in order to remove zinc 
acetate. The organic solid (2.4 g) was air dried and then recrystallized from methanol, 
m.p. 96-98 oC (reported m.p. 98-100 °C).40 
Chapter 4                                                                                                                  Steroidal pyrimidines 
 
156 
 
General procedure for the synthesis of steroidal pyrimidine derivatives (39-41): 
A mixture of steroidal ketones (36-38) (1 mmol), urea (120.0 mg, 2 mmol) and ArCHO 
(1.5 mmol) in DMF/CH3CN (6/12 mL) were added TMSCl (0.26 mL, 2 mmol) at room 
temperature. The resultant mixture was heated at 90 oC for 13-14.5 h. The progress as 
well as completion of reaction was monitored by TLC. After completion of the reaction, 
the mixture was cooled to room temperature, water (20 mL) was added to the reaction 
mixture and the resulting mixture was extracted with CH2Cl2 (2×15 mL), the organic 
phase was washed with water and brine, and dried over anhydrous Na2SO4. After 
removal of solvent, the residue was purified by column chromatography and 
recrystallization from methanol to give desired products (39-41).24  
 
3β-Acetoxy-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine (39): 
Yield (81 %), m.p. 165-166 ˚C; IR (KBr, ν cm-1): 
3083, 1568, 1391 (C-H aromatic), 1734 
(OCOCH3), 1632 (C=N), 1054, 1056 (C-O), 
3221 (OH); 1H NMR (400 MHz, CDCl3, ppm): δ 
7.72-7.99 (m, 5H, aromatic), 4.62-4.70 (m, 1H, 
C3α-H, W1/2 = 17 Hz, axial), 8.46 (s, 1H, OH, 
exchangeable with D2O), 2.02 (s, 3H, OCOCH3), 
1.14 (C10-CH3), 0.74 (C13-CH3), 0.92 & 0.86 
(other methyl protons); 13C NMR (100 MHz, CDCl3, ppm): δ 172.4, 160.6, 155.3, 149.6, 
131.0, 130.1, 129.3, 128.2, 127.8, 126.1, 113.6, 70.1, 51.4, 49.2, 46.7, 41.5, 40.0, 39.2, 
38.1, 37.2, 36.5, 36.0, 35.5, 30.9, 29.5, 27.1, 26.6, 24.1, 23.0, 21.5, 21.0, 20.4, 19.1, 
17.1, 15.2, 13.0, 11.7; Anal. Calcd for C37H52N2O3; C, 77.58; H, 9.15; N, 4.89 found; 
C, 77.55; H, 9.19; N, 4.87; MS (EI): m/z 572 [M+.]. 
 
 
 
 
 
 
 
 
 
Chapter 4                                                                                                                  Steroidal pyrimidines 
 
157 
 
3β-Chloro-6-cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine (40): 
Yield (89%), m.p. 169-170˚C; IR (KBr, ν cm-1): 
3081, 1567, 1383 (C-H, aromatic), 1629 (C=N), 743 
(C-Cl), 3219 (OH); 1H NMR (400 MHz, CDCl3, 
ppm): δ 7.52-7.95 (m, 5H, aromatic), 3.85-3.94 (m, 
1H, C3α-H, W1/2 = 15 Hz, axial), 8.76 (s, 1H, OH, 
exchangeable with D2O), 1.13 (C10-CH3), 0.72 (C13-
CH3), 0.91 & 0.85 (other methyl protons); 
13C NMR 
(100 MHz, CDCl3, ppm): δ 161.3, 156.5, 147.4, 
132.5, 130.1, 129.0, 128.1, 126.9, 126.5, 115.1, 65.3, 56.0, 52.9, 50.7, 47.1, 46.2, 41.1, 
40.0, 39.4, 38.5, 36.1, 35.6, 33.3, 32.1, 31.6, 28.7, 26.5, 25.9, 24.1, 23.0, 21.9, 20.5, 
18.8, 14.1, 12.0; Anal. Calcd for C35H49ClN2O; C, 76.54; H, 8.99; N, 5.10 found; C, 
76.52; H, 8.95; N, 5.08; MS (EI): m/z 548/550 [M+.]. 
 
6-Cholsteno-2ʹ-hydroxy-4ʹ-phenyl-[6,7-b]-pyrimidine (41): 
Yield (87%), m.p. 158-159 oC; IR (KBr, ν cm-1): 3079, 
1563, 1392 (C-H, aromatic), 1635 (C=N), 3225 (OH); 1H 
NMR (400 MHz, CDCl3, ppm): δ 7.54-7.93 (m, 5H, 
aromatic), 8.56 (s, 1H, OH, exchangeable with D2O), 
1.14 (s, 3H, C10-CH3), 0.72 (s, 3H, C13-CH3), 0.92 & 0.85 
(other methyl protons); 13C NMR (100 MHz, CDCl3, 
ppm): δ 162.5, 157.6, 150.7, 131.6, 129.7, 129.0, 128.6, 
125.7, 123.9, 114.7, 56.5, 53.6, 46.4, 43.8, 39.6, 38.6, 
38.5, 38.1, 35.7, 35.5, 34.0, 33.9, 32.7, 31.8, 31.5, 31.4, 29.6, 24.3, 24.1, 22.8, 19.6, 
18.0, 16.7, 14.8, 12.8; Anal. Calcd for C35H50N2O; C, 81.66; H, 9.79; N, 5.44 found; C, 
81.67; H, 9.76; N, 5.45; MS (EI): m/z 514 [M+.]. 
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teroids are an important class of multi-cyclic compounds that exhibit diverse 
biological activities in living organisms. These biologically important properties 
of modified steroids depend on structural features of the steroid ring system and side 
chain.1-2 Therefore, modifications on the steroid ring system and side chain, especially 
the introduction of heteroatom and/or replacement of one or more carbon atoms by a 
heteroatom, and addition of heterocyclic rings or new functional groups, have drawn 
wide attention in steroid chemistry, numerous structure activity relationships have been 
established by such synthetic alterations.3-4 However, investigating this type of 
compounds mainly focuses on the improvement of synthetic methodology and the 
creation of novel analogs.5 Over the past few decades development of new heterocyclic 
steroid derivatives has been one of the major goals of the steroid chemistry. As 
expected, the addition of heterocycles to steroids has usually led to changes in their 
physiological properties and caused new, interesting biological activities.6-8 These 
compounds turn out to be non-toxic, less susceptible to multi-drug resistance (MDR) 
and highly bioavailable because of being accomplished of penetrating the cell wall.9  
          Steroids represent constituents of biomembranes and hormones, fulfil protective 
functions, stimulate plant growth, etc. Many representatives of this group are widely 
used in medicine as essentials of anti-inflammatory, anabolic and contraceptive 
drugs10,some of them are extremely toxic against tumor cells and show antimicrobial 
and other effects.11 Steroid based antimicrobial agents continue to show a conspicuous 
role in those organisms which do not rely upon external supply of drugs to fight against 
pathogens12 because the entire morbidity and mortality mostly in developing countries 
is due to these microbial infections13 among which  Escherichia coli is responsible for 
the most common and serious infectious diseases like invasive dysentery and diarrhea.14 
The different microbes such as Staphylococcus aureus, Lactobacillus acidophilus, 
Treponema pallidum, Streptococcus pyogenes, Salmonella typhimurium,  
Staphylococcus epidermidis, Neisseria gonorrheae and Helicobacter pylori have 
important effect on the human’s health. The infection with these microorganisms may 
have a major impact on huge demolition of host tissue and severe diseases.15,16 Some 
steroidal compounds have been used as traditional medicines, such as, antibacterium 
and hormone kind medication. Besides the naturally occurring substances, the majority 
of steroidal drugs are semi-synthetic compounds.17-20 Increasing the selectivity and 
minimizing the side effects are still the priority of the medicinal chemists. Due to their 
diverse biological properties and wide applications, heterocyclic compounds have 
S 
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gained plenty of attention. These moieties exist not only in naturally occurring 
compounds, like alkaloids, vitamins, hormones and antibiotics, but also in 
pharmaceutical synthetic herbicides and dyes.21  
          Nitrogen containing steroidal heterocyclic systems have the ability to regulate a 
variety of biological processes and thus are potential drug candidates for the treatment 
of a large number of diseases including breast cancer, prostate cancer, leukaemia, 
autoimmune diseases and osteoporosis.22,23 SO is the case with the nitrogen containing 
derivatives, pyrimidines, pyrans, pyrazoles, pyrazolones, benzothiazines, oxazoles, 
imidazoles and thiazoles which exhibit a broad spectrum of biological activities such 
as anticancer, antiviral, antibacterial, antifungal, antioxidant, anxiolytic and 
antidepressant. Furthermore, they possess anti-inflammatory and analgesic activities 
which are well documented in the literature.24-32 The Heterocyclic analogs appended to 
the steroid nucleus were positioned on the α face and the β face of the steroid to test 
their ability to coordinate the heme iron of the P450 enzyme complex.33 The position 
of the heterocycle with respect to the steroid skeleton was determined to be important 
for optimum affinity and in general, compounds with the heterocycle attached to a 
trigonal centre at C-17 had the best affinity for C17(20) lyase.34 The invesfigation of 
new modified steroid derivatives condensed with various heterocyclic rings has been 
given great attention.35  
          Steroidal heterocycles containing the isoxazole (1), pyrazole (2), pyrane (3), 
thiazole (4) and pyridine ring (5) were reported to be active against some bacteria and 
fungi36 while some steroids like withanolide (6), withaferin A (7) and cardiotonic 
steroids (8, 9) were found to possess pronounced cytotoxicity.37  
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          Krstic et al.38 synthesized androst-4-en-17-spiro-1,3,2-oxathiaphospholane-2-
sulfides (10, 11) and reported them as promising in vitro cytotoxic and antimicrobial 
agents. 
 
 
          Kakati et al.2 reported the synthesis and antimicrobial bioevaluation of novel 
steroidal chalcone derivatives (12). 
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          Lone et al.39 carried out synthesis of oximes of steroidal chalcone derivatives (13) 
and reported antimicrobial and antioxidant activities. 
 
          Richmond et al.40 synthesized 2β,3α-disulfoxy-5α-cholestan-6-one (14, 15) and 
reported acetylcholinesterase inhibitory activity of synthesized compounds. 
 
 
          Krstic et al.41 reported the synthesis of steroid dimers {16(a-e)-18(a-e)}. In vitro 
cytotoxic activity was tested against four cancer cell lines (HeLa, MDA-MB-453, 
MDA-MB-361 and K562) and antimicrobial activity of all steroidal dimers was 
evaluated against Gram-positive bacteria Micrococcus luteus (ATCC 4698), Gram-
negative bacteria Escherichia coli (ATCC 25922), yeast species Candida albicans 
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(ATCC 10231) and Saccharomyces cerevisiae (ATCC 9763) and against Penicillium 
sp. (isolated from Calendulae flos).42 
 
 
          Gogoi et al.43 synthesized steroidal quinolone derivatives (19, 20) via microwave 
irradiation and reported in vitro antimicrobial activity of synthesized compounds. 
 
 
 
          Abdalla et al.44 carried out synthesis of steroidal pyrazoline derivatives (21-26) 
and analyzed the cytotoxicity of these compounds against two cancer cell lines HeLa 
(cervical) and MCF-7 (breast) and reported the aromatase and quinone reductase-2 
inhibition activities. 
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          Banday et al.45 carried out synthesis of steroidal pyrazoline derivatives (27) and 
evaluated them as potential anticancer agents against HT-29, HCT-15, 502713 cancer 
cell lines. 
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          Ivanyi et al.46 reported the synthesis of D-ring-substituted (5ʹR)- and (5ʹS)-17β-
pyrazolinylandrostene epimers (28a-l) and evaluated them as potential anticancer 
agents. 
 
 
          Bansal et al.47 reported the synthesis of novel 16-imidazolyl substituted steroidal 
derivatives {29-31, 32(a,b)} possessing potent diversified pharmacological properties. 
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       Khan et al.48 synthesized steroidal thiazolo quinoxalines (33) as antibacterial 
agents against E. coli. 
 
 
          Khan et al.49 carried out steroidal-5-en-7-thiazoloquinoxaline derivatives (34) as 
potential antibacterial agents against E. coli. 
 
 
          Shamsuzzaman et al.50 reported the synthesis of steroidal tetrazoles (35) as 
antiproliferative and antioxidant agents. 
 
  
 
 
Discussion 
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teroidal thiophenes1 
In vitro antiproliferative activity 
The novel compouds 3β-acetoxy-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-
cyanothiophene (30), 3β-chloro-5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene 
(31), 5α-cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-cyanothiophene (32), 3β-acetoxy-5α-
cholest-6-eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene (33), 3β-chloro-5α-cholest-6-
eno-[6,7-d]-2ʹ-amino-3ʹ-carboethoxythiophene (34) and 5α-cholest-6-eno-[6,7-d]-2ʹ-
amino-3ʹ-carboethoxythiophene (35) were evaluated for in vitro cytotoxicity against 
human cancer and normal cell lines, using MTT assay. The cancer cells encompassed 
HL-60 (human leukemia cells) and A549 (human lung carcinoma cells) while PBMCs 
(peripheral blood mononuclear cells) were used as normal cells. A period of 48 h of 
drug exposure was chosen to test cytotoxicity. Doxorubicin (Dox) and 5-Fluorouracil 
(5-Fu) were used as cytotoxic drugs of reference. The cytotoxicity (IC50) of the 
synthesized steroidal thiophene derivatives (30-35) against cancer cell lines (HL-
60/A549) as well as normal cells (PBMCs) are detailed in Table 1. 
 
Table 1. Anticancer activity (IC50 ± SD values) of compounds (30-35) in human cancer 
cell lines and normal cell lines.  
IC50 ( µmol L
-1) 
       Comp.                              HL-60                          A549                         PBMCs 
30 28.8 ± 3.3 14.7 ± 0.2 >50 
31 31.4 ± 2.1 43.3 ± 1.6 >50 
32 22.7 ± 2.4 37.8 ± 3.5 >50 
33 25.6 ± 1.4 35.1 ± 1.4 >50 
34 38.3 ± 4.0 34.2 ± 2.6 >50 
35 13.7 ± 1.0 15.1 ± 0.7 >50 
Doxa   6.2 ± 0.2   6.3 ± 0.4 - 
5-Flub   9.1 ± 0.1   8.2 ± 0.5 - 
Standard drugs used for reference. 
a Doxorubicin.  
b 5-Fluorouracil. 
 
 
 
                                                          
1 Synthesis and characterization, in chapter 1. 
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teroidal spirothiazolidinones2 
Pharmacology 
Rule of Five and bioactivity score: 
The use of Lipinski’s rule as a filter to choose the reasonable scaffolds for biological 
activity.51 The rule states that most molecules with good membrane permeability have 
log P ≤ 5, molecular weight ≤ 500, number of hydrogen bond acceptors ≤ 10, number 
of hydrogen bond donors ≤ 5 and polar surface area less than 140 Å2. The synthesized 
compounds 3β-chloro-7-iminophenyl cholest-5-ene (38), 7-Iminophenyl cholest-5-ene 
(39), 3β-chlorocholest-5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-thiazolidin-4ʹ-one (40) and cholest-
5-en-7-spiro-3ʹ-phenyl-1ʹ,3ʹ-thiazolidin-4ʹ-one (41) showed two violations of Lipinski 
rules due to a calculated Clog P value above the limit of 5 and the molecular weight 
above 500 (Table 2).  
 
Table 2. Calculated physicochemical properties of compounds 38-41. 
Comp. Mw ClogP HBD HBA TPSA No 
violations 
38 494.19 12.33 0 1 38.66 1 
39 459.75 12.50 0 3 12.36 1 
40 568.30 8.92 0 2 20.31 2 
41 533.85 9.09 0 2 20.31 2 
 
On the basis of the above results we can say that the synthesized compounds (38-41) 
adhere to Lipinski’s “Rule of Five”52 and the exceptions to the Lipinski’s rule are 
recognized and involve anticancer drugs such as Doxorubicin.53 The physicochemical 
properties of these new scaffolds suggest that the synthesized compounds (38-41) are 
reasonable starting points for a drug discovery effort. The bioactivity scores of the 
synthesized compounds (38-41) were also calculated for six criteria, GPCR ligand 
activity, ion channel modulation, kinase inhibition activity, protease inhibitor, enzyme 
inhibitor and nuclear receptor ligand activity. For organic molecules if the bioactivity 
score is more than 0.00 then the compound is active but if it is between -0.50 to 0.00 
then the compound is moderately active and if the compound has less than -0.50 then it 
is inactive compound.54 As we can see in Table 3, the synthesized compounds (38-41) 
show good bioactivity score. 
                                                          
2 Synthesis and characterization, in chapter 2. 
 
S 
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Table 3. Bioactivity score of compounds 38-41. 
Comp. GPCR 
ligand 
Ion 
channel 
Modulator 
kinase 
Protease 
inhibitor 
Nuclear 
receptor ligand 
Enzyme 
inhibitor 
38 -0.10 -0.26 -0.46 -0.27 0.11 0.20 
39 -0.08 -0.19 -0.58 -0.23 0.23 0.26 
40 -0.17 -0.43 -0.82 -0.24 -0.07 0.03 
41 -0.16 -0.32 -0.76 -0.21 0.04 0.09 
 
DNA-binding 
UV-vis spectroscopy is one of the most useful techniques to study the binding of any 
compound to DNA. As depicted in Figure 1, the addition of increasing amounts of CT-
DNA (0.70-4.24) × 10-5 M to steroidal spirothiazolidinones (40, 41) exhibited variation 
in the intense absorption bands. The absorption spectra reveal strong hyperchromism 
implying the higher DNA binding propensity. The hyperchromic effect is related to the 
electrostatic binding mode or to the partial uncoiling of DNA helix structure, exposing 
more bases of DNA indicative of strong binding of compounds to CT-DNA.55 
Moreover, hyperchromic effect reflects the corresponding changes in the secondary 
structure of DNA in its conformation after the compounds-DNA interaction.56 To 
compare quantitatively the effect of binding strength of compounds, the intrinsic 
binding constant Kb values of the compounds-DNA were determined by monitoring 
changes in the absorbance of π-π* bands with increasing concentration of CT-DNA. 
The intrinsic binding constant, Kb for the synthesized compounds (40, 41) were 
calculated from Equation: 
[DNA]│ εa - εf │= [DNA] │ εa - εf │+1/Kb│ εa - εf │ 
Where [DNA] represents the concentration of DNA and εa, εf and εb the apparent 
extinction coefficient (Aobs/[M]), the extinction coefficient for free compound (M) and 
the extinction coefficient for the free steroidal spirothiazolidinone (M) in the fully 
bound form, respectively. Through a plot of [DNA]/εa-εf versus [DNA], and were found 
to be 3.5 ×103 M-1 and 5.7×103 M-1, respectively. In the absence of CT-DNA, the 
synthesized compounds (40, 41) emit luminescence in Tris-HCl buffer pH 7.2 at 
ambient temperature, with a fluorescence maximum appearing at 458 and 450 nm, 
respectively, when excited at 270 nm (Figure 2) clearly shows that upon the addition 
of increasing concentration of DNA (0.70-4.24) ×10-5 M, there was a gradual 
enhancement in the fluorescence intensity of the compounds with no apparent change 
in the shape and position of the emission bands. This implies that the compounds (40, 
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41) interacted with CT-DNA due to the inaccessibility of the solvent water molecules 
to reach the hydrophobic environment inside the DNA helix,57 and the mobility of the 
compounds is restricted at the binding site ultimately leading to decrease in vibrational 
mode of relaxation. To compare the binding affinity of synthesized compounds (40, 
41), the binding data obtained from the emission spectra were fitted in the Scatchard 
equation to acquire the binding parameters.58 A plot of r/Cf versus r gave the binding 
constant for synthesized compounds as 1.14×103 M-1 and 2.86×103 M-1, respectively. 
The number of steroidal spirothiazolidinones (40, 41) bound per DNA (n) calculated59 
was found to be 1.13 and 1.52, indicating that compound 41 interacted with DNA more 
strongly as compared to other compounds. 
 
Figure 1. Absorption spectra of steroidal spirothiazolidinones (40, 41) in Tris-HCl 
buffer upon the addition of CT-DNA [compound] = 6.67×10-6 M, [DNA] = (0.70-4.24) 
×10-5 M. Arrow shows change in intensity with increasing concentration of DNA. Inset: 
plots of [DNA]/εa-εf versus [DNA] for the titration of DNA with the compound. 
 
 
                          Compound 40                                            Compound 41 
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Figure 2. Emission spectra of steroidal spirothiazolidinones (40, 41) in Tris-HCl buffer 
(pH 7.2) in the presence and absence of CT-DNA at room temperature. Arrow shows 
change in intensity with increasing concentration of DNA. 
 
 
                       Compound 40                                              Compound 41 
 
Molecular docking 
To understand steroidal spirothiazolidinones-DNA interaction, the molecular docking 
technique has been used. It is an attractive tool to get insight of the mechanistic study, 
by placing a molecule into the binding site of the target specific region of the DNA. In 
our experiment, rigid molecular docking studies were performed to calculate the 
binding modes of compounds (40, 41) with a DNA duplex of sequence 
d(CGCAAATTTCGC)2 dodecamer (PDB ID: 1BNA), and provide an energetically 
favorable docked structures (Figure 3). It is evident from the figures that these 
compounds gets attached with DNA through major groove and thiazolidinone and 
phenyl moieties show intercalation between the nucleotide base pairs of DNA. The 
resulting relative binding energy of docked steroidal thiazolidinone-DNA complexes 
was found to be -262.2 kJ mol-1 (compound 40) and -269.1 kJ mol-1 (compound 41). 
These values are consistent with the high binding constant obtained from spectroscopic 
values. Thus, we can conclude that there is a mutual complement between spectroscopic 
techniques and molecular modeling, which can provide valuable information about the 
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mode of interaction of the compounds with DNA and the conformation constraints for 
adduct formation. 
 
Figure 3. Cartoon representation of DNA with bound compounds shows minimum 
energy poses of DNA-compounds (40, 41) (a and c) stick representation, (b and d) solid 
representation. 
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Anticancer activity 
The cytotoxicity of steroidal spirothiazolidinones (40, 41) and steroidal iminophenyls 
(38, 39) against Jurkat (human leukemia cancer cell) and PBMCs (blood peripheral 
mononuclear normal) cell lines were evaluated in vitro by MTT method, using 5-
fluorouracil (5-Fu) and Doxorubicin (Dox) as control. The synthesized compounds 
were screened for leukemia based on previous studies that nitrogen containing steroids 
are potential drug candidates for the treatment of blood cancers.60 We decided to 
evaluate their activity toward specific cell lines. We choose Jurkat as an example of 
cancer cells and PBMCs as an example of normal cells. Cancerous Jurkat cells are 
derived from T-cells, which, together with B-cells and monocytes, are present in 
PBMCs.61 Therefore, the Jurkat and PBMCs pair is a good model to study the cancer 
specificity of the synthesized compounds. Another reason for the selection of Jurkat 
was the fact that intracellular ROS concentrations in human leukemia were reported to 
be increased.62 Therefore, it was reasonable to suppose that our ROS-modulating 
steroidal spirothiazolidinones (40, 41) would be efficiently activated in Jurkat cells. The 
results (shown in Table 4) illustrated the IC50 values of the synthesized compounds 
against each cell lines. The synthesized compounds showed various levels of 
cytotoxicity and compound 41 showed the better cytotoxicity against Jurkat (IC50 = 
14.21 µmol L-1) cell lines. Cytotoxicity screening data also suggested that the 
appending of the thiazolidinones scaffold to the steroid nucleus may be one of the 
factors responsible for the cytotoxicity compounds. More significantly, the synthesized 
compounds were found to be non-toxic against PBMCs, all the compounds showed IC50 
> 60. This also suggests that steroidal spirothiazolidinones can be used specifically for 
the treatment of cancerous cells without showing any toxicity against normal cells. To 
explore the toxicity of the synthesized compounds toward the normal cells in more 
detail, we have studied the effects of compounds at a high concentration (10 µM) and 
at longer incubation times (48-72 h). We observed that IC50 survive 48 h of incubation 
in the presence of compounds (40, 41) having no effect, whereas 72 h incubation causes 
a reduction in the number of viable normal cells. These data indicate that high 
concentrations of compounds and prolonged incubation time can be cytotoxic to normal 
cells also.61 
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Table 4. Anticancer activity (IC50 ± SD values) of compounds (38-41) in human cancer 
and normal cell lines.  
 
Comp. 
IC50 ( µmol L
-1) 
Jurkat 
 
PBMC 
38 34.4 ± 2.3                             68.5 
39 32.2 ± 1.3                             66.2 
40 18.2 ± 4.1 65.2 
41             14.21 ± 2.1 64.7 
Doxa   4.3 ± 0.4 - 
5-Fub   9.1 ± 0.6 - 
Standard drugs used for reference. 
a Doxorubicin.  
b 5-Fluorouracil. 
 
Apoptosis detection 
As shown in Figure 4, agarose gel electrophoresis of soluble DNA of compound 41 
treated with Jurkat cells revealed DNA fragmentation characteristic of apoptotic cells 
(DNA ladder). The results indicated that the exposure of Jurkat cells to 0.1, 1 and 10 
µM of compound 41 lead to DNA fragmentation in 12 h and 24 h, suggesting that 
synthesized compounds induced cell death by apoptosis. 
 
Figure 4. Agarose gel electrophoresis of DNA fragments in Jurkat cells cultured for 12 
h and 24 h. Data shown are representative of three separate experiments. M stands for 
DNA marker. C stands for control. ST1, ST2 and ST3 stand for 0.1, 1 and 10 µM 
compound 41, respectively. 
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Nonenzymatic DNA damage 
The mechanisms governing the anticancer actions of steroid derivatives are not fully 
known. A number of pathways have been studied regarding the cytotoxic activity of 
steroids.63 Our experiments suggested that the cell death may be due to cleavage or 
fragmentation of DNA of cancer cells and the active species responsible for this are 
ROS (.OH) which is confirmed from the in vitro reaction of different concentrations of 
compound 41 with copper in presence of thiobarbituric acid (Figure 5). The results 
confirmed the relatively higher rate of formation of hydroxyl radicals and correlated 
with the rate of DNA degredation by the compound 41. The proposed reaction 
mechanism of DNA damage is believed to occur via redox cycling (Scheme 1). The 
DNA cleavage reactions mediated by various antioxidants in the presence of Cu (II), it 
has been well-known that Cu (II) is reduced to Cu (I) by the antioxidant which is an 
essential intermediate in the DNA cleavage reactions.64 It is also generally understood 
that DNA cleavage by various antioxidants and Cu (II) is the result of the generation of 
hydroxyl radicals. Cu (II) is reduced to Cu (I) and the re-oxidation of Cu (I) to Cu (II) 
by molecular oxygen gives rise to superoxide anion which in turn leads to the formation 
of H2O2.
65 Studies have also shown that Cu (II) has a high affinity to DNA, 
preferentially binding to guanine residues at the N7 position.66 This Cu (II)-DNA 
interaction has been shown to promote DNA oxidation and the resulting damage 
enhanced by packaging of DNA as a nucleosome.67 
 
Figure 5. Determination of hydroxyl radical production of compound 41 by assay 
thiobarbituric acid. 
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Scheme 1. Proposed reaction mechanism of oxidative DNA damage of compounds 40 
and 41. 
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teroidal thiazoles, oxazoles and imidazoles3 
Pharmacology 
Rule of Five and bioactivity score: 
The use of Lipinski’s rule as a filter to choose the reasonable scaffolds for biological 
activity is well known. The rule states that most molecules with good membrane 
permeability have log P ≤ 5, molecular weight ≤ 500, number of hydrogen bond 
acceptors ≤ 10, number of hydrogen bond donors ≤ 5 and polar surface area less than 
140 Å2. The synthesized compounds 3β-acetoxy-5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (51), 3β-chloro-5α-cholestan-
6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (52), 5α-cholestan-6-
(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-thiazole (53), 3β-acetoxy-5α-
cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (54), 3β-chloro-
5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (55), 5α-
cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-oxazole (56), 3β-acetoxy-
5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (57),  3β-
chloro-5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (58) 
and 5α-cholestan-6-(iminohydrazonomethylphenyl-2-yl)-benzo-[d]-imidazole (59) 
showed two violations of Lipinski rules due to a calculated Clog P value above the limit 
of 5 and the molecular weight above 500 (Table 5). 
 
Table 5. Calculated physicochemical properties of compounds 51-59. 
    Comp. Mw ClogP HBD HBA TPSA No 
violations 
51 680.01 9.59 0 5 63.92 2 
52 656.42 9.69 0 3 37.62 2 
53 621.97 9.72 0 3 37.62 2 
54 663.94 9.45 0 6 77.06 2 
55 640.35 9.57 0 4 50.76 2 
56 605.91 9.60 0 4 50.76 2 
57 662.96 9.42 1 6 79.71 2 
58 639.37 9.54 1 4 53.41 2 
59 604.92 9.57 1 4 53.41 2 
 
                                                          
3 Synthesis and characterization, in chapter 3. 
 
S 
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On the basis of above results, we can say the compounds obeyed the Lipinski’s “Rule 
of Five” analysis based on computational prediction of molecular and pharmacokinetic 
properties, it was found that the synthesized compounds have good oral absorption. The 
exceptions to the Lipinski’s rule are recognized and involve anticancer drugs such as 
Doxorubicin. The physicochemical properties of the synthesized compounds are 
reasonable starting points for a drug discovery effort. The bioactivity scores of the 
synthesized compounds were also calculated for six criteria, GPCR ligand activity, ion 
channel modulation, kinase inhibition activity, protease inhibitor, enzyme inhibitor and 
nuclear receptor ligand activity (Table 6). 
 
Table 6. Bioactivity score of compounds 51-59. 
Comp. GPCR 
ligand 
Ion 
channel 
Kinase 
inhibitor 
Protease 
inhibitor 
Nuclear 
Receptor 
ligand 
Enzyme 
inhibitor 
51 -0.65 -1.48 -1.34 -0.46 -0.90 -0.67 
52 -0.37 -1.14 -0.99 -0.38 -0.58 -0.40 
53 -0.33 -0.97 -0.84 -0.32 -0.43 -0.30 
54 -0.66 -1.48 -1.41 -0.55 -0.79 -0.69 
55 -0.39 -1.14 -1.06 -0.47 -0.46 -0.42 
56 -0.35 -0.97 -0.91 -0.42 -0.31 -0.32 
57 -0.48 -1.29 -1.20 -0.35 -0.81 -0.57 
58 -0.20 -0.93 -0.84 -0.27 -0.49 -0.29 
59 -0.16 -0.76 -0.68 -0.21 -0.34 -0.18 
 
As a general rule, larger is the bioactivity score, higher is the probability that 
investigated compound will be active. For organic molecules if the bioactivity score is 
(>0.00), then the compound is active, but if it is between -0.50 to 0.00 then the 
compound is moderately active and if the compound (<-0.50), then it is inactive 
compound. The results of the present study in Table 6, demonstrated that the some 
investigated compounds are biologically moderately active molecules and some are 
inactive molecules.  
 
Anticancer activity 
The in vitro anticancer screening of steroidal heterocyclic compounds (51-59) was done 
using human cancer cell lines Hep3 B, MCF 7, HeLa and non-cancer PBMCs cells. 
Doxorubicin (Dox) and 5-Fluorouracil (5-Fu) were used as cytotoxic drugs of 
reference. A period of 48 h of drug exposure was chosen to test cytotoxicity. The 
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cytotoxicity (IC50) is the concentration in ‘µM’ required for 50% inhibition of cell 
growth as compared to that of untreated control. The growth inhibitory effect of 
compounds (51-59) towards the cancer cells was measured by means of MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay in which the cell 
viability was measured with the purple formazan that was metabolized from MTT by 
mitochondrial dehydrogenase, which is active only in live cells. IC50 of the synthesized 
steroidal heterocyclic compounds 51-59 against cancer cell lines as well as normal cells 
are detailed in Table 7, whereas the bar graph of dose-dependent effects of the 
compounds (51-59) as displayed in Figure 6. 
 
Table 7. The cytotoxicity data of compounds (51-59) against human cancer and 
normal cell lines. 
 
Comp. 
 
Hep3 B 
IC50 ( µmol L
-
1) 
MCF 7 
 
HeLa 
 
PBMC 
51 16.94 ± 1.6   21.70 ± 1.5                    12.20 ± 1.3             51.31 ± 2.1             
52 09.03 ± 1.3                09.83 ± 2.1                    19.40 ± 1.5             53.32 ± 1.3      
53 12.70 ± 1.6                15.06 ± 2.2                    12.30 ± 1.4             52.22 ± 1.5      
54 21.20 ± 1.2                23.60 ± 2.4                    24.40 ± 2.1             54.12 ± 2.4 
55 21.18 ± 1.4                18.21 ± 1.7                   11.11 ± 1.5             50.17 ± 1.8 
56 19.12 ± 1.7                08.26 ± 1.6                    18.80 ± 1.3             51.11 ± 1.7 
57 19.05 ± 1.6                21.20 ± 2.5                    22.30 ± 3.1             56.38 ± 1.5 
58 29.19 ± 2.5                24.17 ± 2.4                    22.13 ± 1.7             52.24 ± 1.1 
59 11.80 ± 2.3                17.80 ± 1.6                    20.05 ± 2.3             54.21 ± 1.9 
Doxa 04.16 ± 1.6                06.18 ± 2.1                    06.80 ± 2.5                   - 
5-Fub                    01.95 ± 2.5                04.52 ± 1.3                    02.78 ± 1.1                   - 
Standard drugs used for reference. 
a Doxorubicin.  
b 5-Fluorouracil. 
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Figure 6. Dose-dependent effects of compounds (51-59) on cell viability of HeLa, 
Hep3 B, MCF 7 cancer cell lines and PBMCs cell. Data shown are mean ± standard 
error of at least three independent experiments. 
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A number of correlations can be made from the data given in the Table 7. It is evident 
from the IC50 values, that all the compounds showed moderate to good activity while 
compounds 52, 53, 55, 56 and 59 elicited a marked inhibitory activity (IC50 < 19 µM) 
against all three cell lines.  
       All the compounds were found to be nontoxic to normal cells (IC50 > 50 µM). It is 
noteworthy point that compound 53 was found to be active against all the three cancer 
cell lines. Compound 55 was specific to HeLa cells and compound 56 showed 
selectivity towards MCF 7 cells while compound 59 was found to be effective against 
Hep3 B cells. It might be concluded that substituents at 3β-position as well as 
heterocyclic moiety (S, O, NH) played a key role in determining activity. It is 
manifested from the data that chloro derivative (compound 52) with S in the 
heterocyclic ring showed marked inhibitory activity against Hep3 B and MCF 7 cell 
lines (IC50: 09.03 μM; Hep3 B, 09.83 μM; MCF 7) while delta-5 derivative containing 
oxygen was most active against MCF 7 (compound 56, IC50: 08.26 μM). This might be 
attributed to their differences in either polarity which changes their lipophilicity or the 
conformation which alters the target protein binding properties present within the cell 
or on the cell membrane. Although the exact reason of such kind of behaviour of 
compounds is unknown and there is no definite trend in structure activity relationship. 
Yet it gives useful information regarding SARS. 
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Antioxidant activity 
By DPPH assay: 
The in vitro antioxidant activity and scavenging effects of compounds 51-59 were 
evaluated by using different reactive species assay containing DPPH radical scavenging 
activity. The effect of antioxidants on DPPH radical scavenging was thought to be due 
to their hydrogen donating ability.68 DPPH is a stable free radical and accepts an 
electron or hydrogen radical to become a stable diamagnetic molecule.69 The reduction 
capability of DPPH radicals was determined by a decrease in their absorbance at 517 
nm induced by antioxidants. The decrease in absorbance of DPPH radical caused by 
antioxidants, because of reaction between antioxidant molecules and radical, 
progresses, which result in the scavenging of the radical by hydrogen donation. It is 
visually noticeable as a discoloration from purple to yellow. It has been documented 
that cysteine, glutathione, ascorbic acid, tocopherol, polyhydroxy aromatic compounds 
(e.g., hydroquinone, pyrogallol, gallic acid), reduce and decolorize 1,1-
diphenylpicrylhydrazyl (DPPH) by their hydrogen donating capabilities. The free 
radical scavenging activity of all the synthesized compounds 51-59 were evaluated 
through their ability to quench the DPPH. using ascorbic acid as a reference. The 
potencies for the antioxidant activity of compounds 51-59 to the reference compound 
are shown in Table 8 and Figure 7. 
 
Figure 7. Concentration dependent antioxidant activities of compounds 51-59. Data 
shown are mean ± standard error of at least three independent experiments. 
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In general, all the synthesized compounds were less potent than ascorbic acid as the 
reference. Among these compounds 57, 58 and 59 exhibited a slightly better antioxidant 
activity, with the strongest being observed in compound 57 and 59. 
 
Table 8. The DPPH antioxidant activity of compoundsa (51-59). 
 
Comp. 
 
25 µg/mL 
% inhibition 
50 µg/mL 
 
75 µg/mL 
 
100 µg/mL 
51 18.12 ± 1.20 23.41 ± 1.60 25.32 ± 1.10 29.14 ± 0.91 
52 16.23 ± 1.20 21.14 ± 1.40 26.31 ± 1.50 29.34 ± 1.30 
53 16.87 ± 0.81 22.34 ± 1.20 26.13 ± 1.70 31.42 ± 1.10 
54 17.23 ± 0.90 20.33 ± 1.20 25.31 ± 1.50 32.56 ± 1.10 
55 18.13 ± 1.40 23.52 ± 1.30 27.56 ± 1.70 32.54 ± 1.20 
56 14.74 ± 1.40 19.45 ± 1.10 25.12 ± 1.50 29.13 ± 0.91 
57 18.84 ± 1.30 26.34 ± 0.79 32.76 ± 1.10 36.13 ± 1.30 
58 18.92 ± 1.20 22.45 ± 1.50 27.24 ± 1.30 32.34 ± 1.20 
59 19.89 ± 1.30 27.67 ± 1.40 31.94 ± 1.10 39.34 ± 1.50 
Standard 38.23 ± 1.20 39.00 ± 1.10 47.23 ± 1.30 55.23 ± 1.50 
controlb - - - - 
aValues represent the mean ± standard error mean (SEM) of three experiments. 
bNo inhibition, standard: ascorbic acid. 
 
By Ferric reducing antioxidant power (FRAP) assay: 
The FRAP assay mainly depends on the reducing capacity of Fe3+ to Fe2+ conversion 
and serves as a significant indicator of its potential antioxidant activity. The antioxidant 
activities have been attributed to various reactions, binding of transition metal ion 
catalysts, decomposition of peroxides, prevention of continuous proton abstraction and 
radical scavenging activity.70 It has been also proved that the potential antioxidants 
through in vitro ferric reducing antioxidant power assay increased the total antioxidant 
capacity of blood plasma.71 In addition, the reducing capacity measures the ease of the 
compounds in donating electrons that terminates the oxidation chain reaction by 
reducing the oxidized intermediates into the stable form.72 The reducing power 
scavenging activity of all the synthesized compounds 51-59 were evaluated through 
their ability by radical quenching (H transfer) using trolox as a reference and the free 
radical scavenging power of compounds increased with an increasing concentration. 
The reducing power scavenging activity of the compounds 51-59 to the reference 
compound are shown in Table 9 and Figure 8. 
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Figure 8. Concentration dependant FRAP assay of compounds 51-59. Data shown are 
mean ± standard error of at least three independent experiments. 
 
 
 
Among the tested compounds, many compounds showed significant reducing power 
capacities. But compounds 57-59 showed good reducing power capacities while all 
other compounds exhibited moderate activity in comparison with the standard trolox. 
The good reducing power capacity of these compounds might be due to the presence of 
imidazole functionalities. 
 
Table 9. The reducing power scavenging antioxidant activity of compoundsa (51-59). 
 
Comp. 
 
25 µg/mL 
% inhibition 
50 µg/mL 
 
75 µg/mL 
 
100 µg/mL 
51 23.12 ± 3.20 35.41 ± 2.60 52.32 ± 3.10 62.14 ± 3.91 
52 24.23 ± 2.20 44.14 ± 3.40 58.91 ± 2.50 63.34 ± 3.30 
53 20.87 ± 2.81 33.54 ± 2.20 57.53 ± 3.70 65.56 ± 4.10 
54 21.23 ± 1.90 35.33 ± 2.20 52.31 ± 3.50 65.16 ± 4.10 
55 22.13 ± 2.40 43.32 ± 2.30 56.56 ± 2.70 62.24 ± 3.90 
56 18.74 ± 2.40 39.45 ± 2.10 52.12 ± 3.50 72.13 ± 3.91 
57 26.84 ± 1.30 51.34 ± 2.79 58.76 ± 3.10 74.13 ± 3.30 
58 22.92 ± 2.20 44.45 ± 3.50 55.24 ± 2.30 67.34 ± 3.20 
59 29.89 ± 2.30 49.45 ± 2.40 69.34 ± 3.10 79.34 ± 3.50 
Standard 39.23 ± 1.20 51.01 ± 1.10 77.23 ± 1.30 85.23 ± 1.50 
controlb - - - - 
aValues represent the mean ± standard error mean (SEM) of three experiments. 
bNo inhibition, standard: trolox. 
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By ABTS assay: 
The ABTS radical cation decolorization assay is an excellent tool for determining the 
antioxidant activity of hydrogen-donating antioxidants and chain-breaking 
antioxidants.73 ABTS is another widely used synthetic radical for both the polar and 
non-polar samples. The ABTS•+ scavenging abilities of the compounds 51-59 were also 
evaluated and reported in Table 10. 
 
Table 10. The radical scavenging antioxidant activity of compoundsa (51-59). 
 
Comp. 
 
25 µg/mL 
% inhibition 
50 µg/mL 
 
75 µg/mL 
 
100 µg/mL 
51 18.32 ± 1.2 29.51 ± 1.9 39.32 ± 2.8 54.14 ± 2.81 
52 19.23 ± 2.4 34.14 ± 2.7 48.91 ± 2.9 58.34 ± 3.80 
53 20.87 ± 2.7 31.54 ± 2.4 41.52 ± 3.3 55.56 ± 3.20 
54 20.23 ± 1.9 27.33 ± 2.6 42.33 ± 3.4 55.17 ± 3.90 
55 22.13 ± 2.4 29.32 ± 2.5 36.56 ± 2.4 53.24 ± 3.60 
56 19.84 ± 2.7 29.47 ± 2.5 39.42 ± 3.5 56.13 ± 3.30 
57 23.14 ± 3.3 41.24 ± 2.7 51.16 ± 3.3 64.43 ± 3.50 
58 21.94 ± 2.3 34.45 ± 3.1 45.54 ± 3.3 61.53 ± 3.40 
59 23.29 ± 2.5 49.67 ± 3.3 57.14 ± 2.9 68.24 ± 3.10 
Standard 37.25 ± 1.2 52.01 ± 1.1 61.24 ± 1.3 75.23 ± 1.50 
controlb - - - - 
aValues represent the mean ± standard error mean (SEM) of three experiments. 
bNo inhibition, standard: ascorbic acid. 
 
The radical has a relatively stable blue-green color, which equates to absorbance at 734 
nm. Antioxidant compounds reduce the intensity of this color to a degree that is 
proportionate to their antioxidant concentration or activity. Figure 9, depicts the 
scavenging activities of the compounds 51-59 against ABTS radicals.  
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Figure 9. Concentration dependant ABTS assay of compounds 51-59. Data shown are 
mean ± standard error of at least three independent experiments. 
 
 
 
These data demonstrate that scavenging activity increased as the concentration 
increased. The compounds 57-59 had a maximum scavenging activity among all in the 
order of 59 > 57 > 58. It was interesting to note that this order is in concordance with 
the DPPH and FRAP assay. 
 
Fluorescence Microscopy 
HeLa cells treated with compounds 51-59 were observed under Fluorescence 
Microscope and microscopic examination of gross morphology of the treated and 
untreated cancer cells are shown in Figure 10. These images clearly designated 
reduction in cancer cell count as well as cytotoxicity potential of above mentioned 
steroids, in the order of 55 > 51 > 53 > 56 > 52 > 59 > 58 > 57 > 54 and arrow indicates 
apoptosis of cells.  
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Figure 10. Micrographs showing effect of compounds 51-59 on HeLa Cells. 
Micrographs captured after 48 h of incubation in bright field under Fluorescence 
Microscope. A = Untreated control, B = Treated with compound 54, C = Treated with 
compound 57, D = Treated with compound 58, E = Treated with compound 59, F = 
Treated with compound 52, G = Treated with compound 56, H = Treated with 
compound 53, I = Treated with compound 51 and J = Treated with compound 55. 
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DNA condensation 
DNA condensation is an essential process to transport a therapeutic gene to its target. 
It includes the collapse of extended DNA chain into compact, orderly particles 
containing one or more molecule.74 Steroidal compounds are able to recognize and bind 
to single or double-stranded DNA with high affinity and selectivity due to structural 
hydrophobicity.75 In this study, DNA condensation to compound 53 was determined by 
employing various visualization techniques viz transmission electron microscopy 
(TEM) and atomic force microscopy (AFM). These techniques have been used here to 
analyze the morphology of the steroidal-DNA complex condensates. The TEM images 
of the compound 53 are given in Figure 11. 
 
Figure 11. The TEM images of the compound 53 before CT-DNA condensates (a) and 
after CT-DNA condensates (b-d). 
 
Chapter 5                                                            Biological evaluation of newly synthesized compounds 
 
198 
 
 
 
 
Chapter 5                                                            Biological evaluation of newly synthesized compounds 
 
199 
 
 
 
The shape of the particles is irregular and the particles are of variable diameter ranging 
from 15.2 to 697 nm. The particles size increases when CT-DNA condensed to it 
indicating that the compound 53 can condense fragments of CT-DNA to compact solid 
DNA drug condensate as shown in Figure 11. Several numbers of drugs are unable to 
be effective due to the lack of information of their structural and morphological details. 
To obtain the morphological and structural information of the compound and the 
condensates, tapping mode AFM experiments were performed using commercially 
etched silicon tips as AFM probes. Two and three dimensional AFM images of the 
compound and the condensate materials are shown in Figures 12. The change in the 
morphological structure of compound 53 and its condensates with CT-DNA clearly 
validate that the complex is facilitating the DNA condensation.  
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Figure 12. The AFM images of the compound 53 before CT-DNA condensates (a) 2D 
(Two dimensions) and (b) 3D (Three dimensions) and after CT-DNA condensates (c) 
2D (Two dimensions) and (d) 3D (Three dimensions). 
 
 
 
 
Nonenzymatic DNA damage 
The mechanisms governing the anticancer actions of steroid derivatives are not fully 
known. A number of pathways have been studied regarding the cytotoxic activity of 
steroids.63 Our experiments suggested that the cell death may be due to cleavage or 
fragmentation of DNA of cancer cells and the active species responsible for this are 
ROS (.OH) which is confirmed from the in vitro reaction of different concentrations of 
compound 53 with copper in presence of thiobarbituric acid (Figure 13). 
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Figure 13. Determination of hydroxyl radical production of compound 53 by assay 
thiobarbituric acid. 
 
 
 
The results confirmed the relatively higher rate of formation of hydroxyl radicals and 
correlated with the rate of DNA degredation by the compound 53. The proposed 
reaction mechanism of DNA damage is believed to occur via redox cycling (Scheme 
2). In the DNA cleavage reactions mediated by various antioxidants in the presence of 
Cu (II), it has been well known that Cu (II) is reduced to Cu (I) by the antioxidant which 
is an essential intermediate in the DNA cleavage reactions.64,74,75 It is also generally 
understood that DNA cleavage by various antioxidants and Cu (II) is the result of the 
generation of hydroxyl radicals. Cu (II) is reduced to Cu (I) and the re-oxidation of Cu 
(I) to Cu (II) by molecular oxygen gives rise to superoxide anion which in turn leads to 
the formation of H2O2.
65 Studies have also shown that Cu (II) has a high affinity to 
DNA, preferentially binding to guanine residues at the N7 position.66 This Cu (II)-DNA 
interaction has been shown to promote DNA oxidation and the resulting damage 
enhanced by packaging of DNA as a nucleosome.67 
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Scheme 2. Proposed reaction mechanism of oxidative DNA damage of compounds 51-
59. 
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In vitro acetylcholinesterase inhibition activity 
The anti-cholinesterase effects of the compounds (51-59) were determined by modified 
Ellman’s spectrophotometric method using AChE from Electrophorus electricus with 
Tacrine as reference compound. All the compounds were carefully measured and the 
results are shown in Table 11. The results were collected from at least three 
independent measurements. From the results obtained, compound 51, 54 and 57 (IC50 
= 0.31 ± 0.10, 0.37 ± 0.02 and 0.39 ± 0.03, respectively) exhibited significant inhibition 
on AChE among all the compounds. The improved activity of the acetoxy derivatives 
in comparison to all synthesized compounds can be explained on the basis of its 
skeleton and electronic properties at 3β-position of the cholestane ring. The presence 
of acetoxy group at C-3 of cholestane skeleton increases activity due to the formation 
of additional non-classical bonds with amino acid residues of the protein and easily 
performs as guest relation with receptor protein (host). The synthesized compounds 
were found to be fairly active with respect to the reference drug, Tacrine. 
 
Table 11. In vitro anti-AChE activities data of the synthesized compounds (51-59) 
and reference drug (Tacrine). 
Comp. AChE inhibitor IC50 (μM)a 
51 0.31 ± 0.10 
52 0.52 ± 0.30 
53 0.53 ± 0.01 
54 0.37 ± 0.02 
55 0.49 ± 0.02 
56 0.59 ± 0.10 
57 0.39 ± 0.03 
58 0.48 ± 0.02 
59 0.56 ± 0.20 
Tacrine 0.29 ± 0.06 
aThe values are mean of three independent experiments ± SD. 
 
Molecular docking 
Molecular docking is one of the important computational chemistry techniques that are 
routinely used for drug discovery processess. Molecular modelling studies of nucleic 
acids and their complexes can provide valuable information that is not available by 
other experimental techniques such as X-ray crystallography or NMR spectroscopic 
data. The conformational diversity of DNA allows for large deformations upon binding 
of ligands to it. Drug-DNA interactions are of high pharmaceutical interest since the 
Chapter 5                                                            Biological evaluation of newly synthesized compounds 
 
204 
 
mode of action of various drugs is directly associated with their binding to DNA. A 
reliable prediction of drug-DNA binding at the atomic level by molecular docking 
methods provides the basis for the design of new drug compounds.76 Targeting the 
minor groove of DNA by small molecules has long been considered as an important 
tool in molecular recognition of specific DNA sequence. Molecular modeling allows 
the flexibility within the ligand to be modeled that can utilize more detailed molecular 
mechanics to calculate the relative binding energy of the ligand-receptor complex in 
the context of the putative active site. In our experiment, structure of compounds (51-
59) was made flexible to attain different conformations in order to predict the best fit 
orientation of compounds with DNA duplex of sequence d(CGCGAATTCGCG)2 
dodecamer (PDB ID:1BNA) which provides an energetically favorable docked pose. 
Table 12 shows the minimized orientation of minor groove interaction of compounds 
51-59 with DNA and the resulting relative binding energy of the docked pose. The 
minimized conformation of only compound 57 sitting in the groove of the sequence 
d(CGCGAATTCGCG)2 show hydrogen bonding with the NH of the imidazole ring in 
the docked pose of the dodecamer. While all other compounds do not show any possible 
hydrogen bonding with the base pairs of the DNA dodecamer. Generally, the more 
negative the relative binding energy, the stronger is the interaction between molecule 
and DNA and more stable is the complex formed. Thus the complex formed between 
compound 54 and DNA with relative binding energy of -8.338 kcal/mol might be 
having highest stability.77-79 The relative binding energies of compound 57 and 51 with 
DNA are almost equal suggesting that both are forming equally stable complex with 
DNA and the presence of hydrogen bonds between compound 57 and DNA might not 
be affecting the stability of the complex. Irrespective of the absence of any net positive 
charge on compounds 51-59, negative values of the relative binding energies indicated 
a higher binding potential of these compounds with DNA. Hence, these docking results 
provide valuable information about the mode of interaction of our compounds with 
DNA and the conformation constraints for adduct formation. 
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Table 12. Molecular docked models of compounds 51-59. 
Product Docked pose Relative 
binding energy 
(kcal/mol) 
Stereoview of the docked 
pose 
showing possible H-bonding 
 
 
51 
 
 
 
 
-8.276 
 
 
 
52 
 
 
 
-7.953 
 
 
 
53 
 
 
 
-7.925 
 
 
 
54 
 
 
 
-8.338 
 
 
 
55 
 
 
 
-7.890 
 
 
 
56 
 
 
 
-7.930 
 
 
 
57 
 
 
 
-8.277 
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The S-, O- and N- termini of the compounds are shown as yellow, red and blue sticks, 
respectively. 
Docked pose showing the minor groove interaction of compounds 51-59 with DNA 
dodecamer duplex of sequence d(CGCGAATTCGCG)2 (PDB ID:1BNA) and the 
resulting relative binding energy of the docked DNA-compounds (51-59) complex.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product Docked pose Relative 
binding energy 
(kcal/mol) 
Stereoview of the docked 
pose 
Showing possible H-bonding 
 
 
58 
 
 
 
-8.026 
 
 
 
59 
 
 
 
-8.140 
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teroidal pyrimidines4 
HSA-binding 
Fluorescence Quenching Measurement of HSA: 
Qualitative analysis of binding of chemical compounds to HSA can be detected by 
examining fluorescence spectra. Generally, the fluorescence of protein is caused by 
three intrinsic fluorophores present in the protein, i.e. tryptophan, tyrosine, and phenyl 
alanine residues.80 Because of very low quantum yield of phenylalanine and tyrosine, 
normally fluorescence of tryptophan residue is investigated in researches. The 
tryptophan (Trp 214) of HSA possess fluorescence properties showing the maximum 
fluorescence intensity at 340 nm. Fluorescence quenching refers to a process that leads 
to reduction in fluorescence intensity of any fluorescent sample and it occurs due to a 
variety of molecular interactions. These include excited-state reactions, molecular 
rearrangements, energy transfer ground-state complex formation, and collisional 
quenching. Quenching can occur by different mechanisms, which usually classified as 
dynamic quenching and static quenching; dynamic quenching refers to a process that 
the fluorophore and the quencher come into contact during the transient existence of 
the excited state. Static quenching refers to fluorophore-quencher complex formation. 
In general, dynamic and static quenching can be distinguished by their differing 
dependence on temperature, viscosity and excited state lifetime.81 Dynamic quenching 
is caused by collision and higher temperature will result in larger diffusion coefficients, 
the dynamic quenching constants are expected to increase with increasing 
temperature.82 As, in both cases the fluorescence intensity is related to the concentration 
of the quencher. Therefore, the quenched fluorophore can serve as an indicator for 
quenching agent.83 According to experimental procedures, the fluorescence spectra of 
HSA-steroid systems were recorded (Figure 14). As shown in Figure 14, the 
fluorescence of HSA showing the maximum fluorescence intensity at 340 nm.  
 
 
 
 
                                                          
4 Synthesis and characterization, in chapter 4. 
 
S 
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Figure 14. Steroidal pyrimidine derivatives (39-41)-induced fluorescence quenching 
spectra of HSA. The concentration of HSA was 5 μM and the concentration of 
compounds (39-41) was varied from 0-16 μM. The intrinsic fluorescence of the protein 
was measured in 20 mM sodium phosphate buffer, pH 7.4 at 298 K upon excitation at 
295 nm.  
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The fluorescence intensity of HSA starts decreasing regularly upon increasing the 
concentration of compounds, indicating that compounds (39-41) interacted with HSA 
and acted as a fluorescence quencher. The fluorescence data were analysed according 
to the Stern-Volmer equation (1), which allows for calculating of quenching constants. 
𝐹0
𝐹
= 𝐾𝑠𝑣[𝑄] + 1 = 𝑘𝑞𝜏0[𝑄] + 1                                                                                          (1) 
Where F0 and F are the fluorescence intensities in the absence and presence of 
quencher, respectively, Ksv is the Stern-Volmer quenching constant and Q is the 
concentration of quencher, kq is the bimolecular quenching constant and τ₀ is the life 
time of tryptophan in the absence of quencher. Evidently, 
𝐾𝑠𝑣 = 𝑘𝑞𝜏0                                                                                                                                                  (2)  
Because the fluorescence lifetime of tryptophan for HSA (τ₀) is 5.6 ns,84 Ksv can be 
determined by linear regression of a plot of F0/F against [Q]. Stern-Volmer plots at 298 
K (Figure 15) and the calculation of Ksv from Stern-Volmer plots (Table 13) in all cases 
we got is in the order of 104 but maximum value was obtained in case of compound 40 
followed by compound 41 and 39, respectively, which indicated that the quenching 
mechanism between HSA and compounds 39-41 was not initiated by dynamic collision 
and the most probable mechanism should be static quenching. 
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Figure 15. A, B and C represents Stern-Volmer plot for HSA-in presence of compounds 
39-41, respectively.  
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Table 13. Stern-Volmer quenching constants and binding parameters for HSA with 
compounds (39-41) at 298 K. 
Condition Temp. 
(K) 
Ksv  
(M-1) 
kq  
(M-1s-1) 
Kb  
(M-1) 
n ΔG0  
(kJ mol-1) 
R2 
HSA-
Comp. 39 
298 2.38 × 104 4.25 × 1012 6.18 × 104 1.08 -27.34 0.99 
HSA-
Comp. 40 
298 7.03 × 104 1.25 × 1013 3.46 × 105 1.14 -31.54 0.99 
HSA-
Comp. 41 
298 5.18 × 104 9.25 × 1012 1.68 × 105 1.10 -29.82 0.99 
 
Since, the bimolecular quenching constant for steroid derivatives calculated to be is in 
the order of 1013 M-1s-1 which is greater than maximum collision quenching constant 2 
× 1010 M-1s-1 which suggest that the mode of quenching is static between HSA and 
compounds (39-41).  
 
Binding equilibrium:  
In the static quenching interaction, when small molecules bind independently to a set 
of equivalent sites on a macromolecule, the binding constant (Kb) and the number of 
binding sites (n) can be determined by the following equation:85  
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log (
𝐹0 − 𝐹
𝐹
) = log 𝐾𝑏 +  𝑛 log[𝑄]                                                                                      (3) 
Where F0, F, and [Q] are the same as in Eq. (1), Kb is the binding constant and n is the 
number of binding sites per HSA molecule. The value of log (F0-F/F) is linear with the 
value of log [Q], in which the slope is the number of binding sites (n) whereas the 
intercept (ordinate at the origin) is the logarithm value of Kb (logKb) (Table 13). The 
regression equations (Figure 16) shows the slopes are closed to 1, which indicates there 
is only one binding site with high affinity for compounds (39-41) in HSA molecule, 
under specified conditions. 
 
Figure 16. A, B and C represents Modified Stern-Volmer plot for HSA-in presence of 
compounds 39-41, respectively.  
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Circular Dichroism measurements: 
CD spectroscopy is very important technique in biophysics and structural biology to 
understand the conformational changes in proteins and nucleic acids.86 Consequently, 
we carried out CD measurements in order to monitor the conformational change of HSA 
Chapter 5                                                            Biological evaluation of newly synthesized compounds 
 
214 
 
induced by compounds 39-41. Binding of ligands to globular protein modulate the 
intermolecular forces liable for sustaining the secondary and tertiary structures resulting 
in conformational alteration of the protein. As it is clear from the Figure 17, the CD 
spectra of native HSA possess two negative bands one at 208 nm and other at 222 nm 
which is the characteristic feature of the α-helical class of the proteins.87 On increasing 
the concentration of compounds (39-41), the CD signals (both at 208 nm and 222 nm) 
increases regularly which indicated that there is increase in α-helical content in the HSA 
as depicted in Figure 17. This can be inferred from the Figure 17, maximum α-helical 
content induced by compound 40 followed by compound 41 and 39. These results are 
also in agreement with the previous reports that advocates that the binding of drugs and 
small molecules to HSA lead to increase in α-helical content in the protein.  
 
Figure 17. Far-UV CD spectra of HSA alone (a) and  in complex in the presence of 
1:1 (b) and 1:2 (c) molar ratio of HSA to compounds (39-41).  
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Differential light scattering measurements: 
DLS is very sensitive technique to determine the size of the proteins and drug-protein 
complexes. In order to determine the hydrodynamic radii of HSA alone and in the 
presence of compounds (39-41), DLS measurements were carried out. The 
hydrodynamic radii (Rh) and polydispersity (Pd) under different conditions are 
summarized in Table 14 and Figure 18. The lower value of polydispersity (5-15) 
indicate the presence of homogenous solution. The hydrodynamic radii of native HSA 
was found to be 3.4 nm.88 As it is clear inferred from the Table 14, in the presence of 
compounds (39-41) there is decrease in hydrodynamic radii of HSA. Maximum 
reduction in hydrodynamic radii was observed in case of compound 40 followed by 
compound 41 and 39. The reduction in hydrodynamic radii upon ligand binding may 
be due to the ‘‘collapsing’’ of the protein as compounds (39-41) binds with HSA. This 
response may result in shrinkage in the molecular volume due to a conformational 
alteration. The possible mechanism for the drop in protein hydrodynamic radius is that 
compounds (39-41) disrupts the solvent shell around the HSA. As CD data suggested, 
compounds 39-41 affects the secondary structure of HSA. This also might be a reason 
that conformationally altered secondary structural components tends to decrease 
hydrodynamic radius (Rh). 
 
Table 14. Hydrodynamic radii (Rh) and polydispersity (Pd) of HSA in the absence and 
presence of compounds (39-41). 
Condition Rh Pd (%) 
HSA 3.4 ± 0.03 13.5 
HSA + comp. 39 (1:2) 3.2 ± 0.02 12.2 
HSA + comp. 40 (1:2) 2.7 ± 0.03 5.1 
HSA + comp. 41 (1:2) 2.9 ± 0.02 7.5 
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Figure 18. Hydrodynamic radii of HSA alone (A), HSA + comp. 39 (B), HSA + comp. 
40 (C) and HSA + comp. 41 (D). 
 
 
Antioxidant activity 
Antioxidant compounds play an important role as a health protecting factor. Scientific 
evidence suggests that antioxidants reduce the risk for chronic diseases, including 
cancer and heart disease. An antioxidant is a molecule that inhibits the oxidation of 
other molecules. Oxidation is a chemical reaction that can produce free radicals, leading 
to chain reactions that may damage cells. Antioxidants such as thiols or ascorbic acid 
(vitamin C) terminate these chain reactions. Ascorbic acid is a water-soluble free radical 
scavenger. Ascorbic acid changes to the ascorbate radical (Scheme 3) by donating an 
electron to the lipid radical in order to terminate the lipid peroxidation chain reaction. 
The pairs of ascorbate radicals react rapidly to produce one molecule of ascorbate and 
one molecule of dehydroascorbate. The dehydroascorbate does not have any 
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antioxidant capacity. Hence, dehydroascorbate is converted back into the ascorbate by 
the addition of two electrons. The last stage of the addition of two electrons to the 
dehydroascorbate has been proposed to be carried out by oxidoreductase.89  
 
Scheme 3. Mechanism of radical scavenging activity of ascorbic acid. 
  
The main characteristic of an antioxidant is its ability to trap free radicals. Highly 
reactive free radicals and oxygen species are present in biological systems from a wide 
variety of sources. These free radicals may oxidize nucleic acids, proteins, lipids or 
DNA and can initiate degenerative disease. We carried out experiments to explore the 
free radical scavenging ability of the compounds 39-41, with the hope of developing 
potential antioxidants. The radical scavenging activities of our compounds along with 
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standards (L-ascorbic acid) have been examined with reference to DPPH radicals 
(DPPH.), hydroxyl radicals (OH.), nitric oxide radicals (NO.), and H2O2 scavenging 
assay and their corresponding IC50 values were shown in Table 15. 
 
 Table 15. Antioxidant activity: IC50 of compound (39-41)
a against various radicals. 
Comp. IC50 
         DPPH.                      OH.                         NO.                      
H2O2 
39 41.10 ± 1.10 36.32 ± 1.40 62.22 ± 1.20 54.24 ± 1.01 
40 61.13 ± 1.30 52.13 ± 1.60 79.39 ± 1.30 69.14 ± 1.20 
41 53.77 ± 1.21 40.29 ± 1.40 75.11 ± 1.80 62.32 ± 1.70 
Standard 39.45 ± 1.10 24.00 ± 1.10 56.13 ± 1.50 51.22 ± 1.30 
controlb - - - - 
aValues represent the mean ± standard error mean (SEM) of three experiments. 
bNo inhibition, standard: L-ascorbic acid. 
 
The principle for the reduction in DPPH. free radicals is that the antioxidant reacts with 
stable free radical DPPH and converts it to 1,1-diphenyl-2-picrylhydrazine. The ability 
to scavenge the stable free radical DPPH is measured by a decrease in the absorbance 
at 517 nm. The plausible mechanism of steroidal pyrimidine and DPPH. as shown in 
Scheme 4.90 Hydrogen peroxide itself is not very reactive, but sometimes it is toxic to 
cells because it may give rise to hydroxyl radicals in the cells.91 Nitric oxide or reactive 
nitrogen species, formed during their reaction with oxygen or with superoxide, such as 
NO2, N2O4, N3O4, NO
3- and NO2+ are very reactive. These species are responsible for 
altering the structural and functional behavior of many cellular components. Further, 
the scavenging activity may also help to arrest the chain of reactions initiated by the 
excess generation of NO that is detrimental to human health. Among all free radicals, 
the hydroxyl radical is a major product arising from the high-energy ionization of water, 
the most important biological sources, of which are the Haber-Weiss and Fenton 
reactions, involving the superoxide anion, hydrogen peroxide and transition metals.92 
This is the most aggressive oxidant known and therefore the most dangerous oxygen 
metabolite, which is capable of attacking any biological molecule and can be implicated 
in the tissue damage associated with inflammation, therefore elimination of this radical 
is one of the major aims of antioxidant administration.93 The IC50 values of all the 
synthesized compounds (39-41) (Table 15) obtained from different types of assay 
experiments were less potent than ascorbic acid as the reference. The OH. scavenging 
power of the tested compounds was greater than other radicals. Being a potent 
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scavenger of hydroxyl radicals, the compounds could capture superoxide anion radicals 
and hydrogen peroxide, as apparent from the IC50 values.
94 Substituents on the 3β 
position of the cholestane ring have shown a considerable effect on the antioxidant 
activity of the compounds (39-41). With respect to the 3β position, the antioxidant 
activity is in the order 39 > 41 > 40. The high antioxidant activity of compound 39 may 
be due to the presence of acetoxy group at 3β position of the cholestane ring. The IC50 
values (Table 15) indicated that the various radical scavenging activities of the 
compounds are in the order of NO. < H2O2 < DPPH. < OH.
 .  
 
Scheme 4. Proposed mechanism of compounds (39-41) and DPPH•. 
 
  
 
 
 
Chapter 5                                                            Biological evaluation of newly synthesized compounds 
 
221 
 
In vitro cytotoxicity and structure activity relationship 
To gain insight on how modifications on ring-B can affect cytotoxicity, steroidal 
pyrimidine derivatives (39-41) with a variety of functionalities attached to 3β position, 
were synthesized and assayed in vitro for cytotoxicity in human cancer and normal cell 
lines, using MTT assay. The cancer cells encompassed MDA-MB231 (breast 
carcinoma), HeLa (human cervical carcinoma), HepG2 (hepatic carcinoma) and one 
non-cancer normal cell lines, PBMCs (peripheral blood mononuclear cells). 
Doxorubicin (Dox) and 5-Fluorouracil (5-Fu) were used as cytotoxic drugs of 
reference. A period of 48 h of drug exposure was chosen to test cytotoxicity. The 
cytotoxicity (IC50) is the concentration in ‘µM’ required for 50% inhibition of cell 
growth as compared to that of untreated control. The growth inhibitory effect of 
compounds (39-41) towards the cancer cells was measured by means of MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay in which the cell 
viability was measured with the purple formazan that was metabolized from MTT by 
mitochondrial dehydrogenase, which is active only in live cells. The cytotoxicity (IC50) 
of the synthesized compounds (39-41) against cancer cell lines (MDA-
MB231/HeLa/HepG2) as well as normal cells are detailed in Table 16, whereas the 
curves of dose-dependent effects of the compounds (39-41) as displayed in Figure 19. 
A number of correlations can be made from the data given in the Table 16.  
 
Table 16. The cytotoxicity data of compounds (39-41) against human cancer and 
normal cell lines. 
 
Comp. 
 
MDA-MB231 
IC50 ( µmol L
-
1) 
HeLa 
 
HepG2 
 
PBMC 
39 18.34 ± 1.6   14.73 ± 1.5                    20.13 ± 1.3             >50             
40 13.08 ± 1.3                11.72 ± 2.1                    19.47 ± 1.5             >50      
41 09.17 ± 1.6                10.30 ± 2.2                    12.15 ± 1.4             >50      
Doxa 06.18 ± 1.6                07.68 ± 2.2                    09.29 ± 2.5                   - 
5-Fub                    04.25 ± 2.5                03.57 ± 1.2                    01.47 ± 1.1                   - 
Standard drugs used for reference. 
a Doxorubicin.  
b 5-Fluorouracil. 
It is evident from the IC50 values, that all the compounds showed moderate to good 
activity and found to be nontoxic to normal cells (IC50 > 50 µM). It is noteworthy point 
that compound 41 was found to be active against all the three cancer cell lines but more 
specific against MDA-MB231 cells (IC50: 09.17±1.6) while compound 39 and 40 was 
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found to be effective against HeLa cells (IC50: 14.73±1.5 and 11.72±2.1, respectively). 
Substituent at 3β-position as well as phenyl ring attached to pyrimidine ring played a 
crucial role in determining activity. It is manifested from the data that acetoxy group at 
3β-position impart lesser activity as compared to Δ5 and Cl (compound 40 is more 
potent than 39) due to presence of phenyl ring attached to pyrimidine ring nullified this 
effect and Δ5 derivatives were found to be more active (compound 41) among all. This 
could be attributed to their differences in either polarity which changes their 
lipophilicity or the conformation which alters the target protein binding properties 
present within the cell or on the cell membrane.  
 
Figure 19. Dose-dependent effects of compounds (39-41) on cell viability of MDA-
MB231, HepG2, HeLa cancer cell lines and PBMCs cell. Data shown are mean ± 
standard error of at least three independent experiments. 
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Molecular modelling 
In order to understand the mode of interaction and amino acid residues involved in 
binding of steroid derivatives to HSA molecular docking studies were employed. 
Autodock 4.2 program was used to examine the binding mode of compounds (39-41) 
to HSA. The docking results are summarises in Table 17 and Figure 20. These results 
reveal that compound 39 and 41, interact via hydrophobic interaction and hydrogen 
bonding to HSA but in case of compound 40, only hydrophobic interaction are 
involved. Further the negative sign of binding energy calculated by molecular docking 
depicts that interaction is feasible in all three cases.95  
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Figure 20. A1-C1 represents best conformation of compounds 39-41 docked to HSA, 
respectively, and A2-C2 cartoon representation of residues involved in binding of 
compounds 39-41 to HSA, respectively.  
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Table 17. Molecular docking parameters of HSA-steroid derivative complexes (39-
41). 
Complex Amino Acids Forces Involved ΔG (kJ mol-1) 
 
 
 
HSA-Comp. 39 
Phe395 
Glu396 
Gln397 
Leu398 
Lys399 
Glu400 
Lys402 
 
 
 
Hydrophobic 
and H- bonding 
 
 
-5.27 
 
 
 
 
HSA-Comp. 40 
Phe395 
Glu396 
Gly399 
Glu400 
Ser435 
Lys439 
 
 
 
Hydrophobic 
 
 
 
 
-5.42 
 
 
 
 
 
 
HSA-Comp. 41 
Arg218 
Asn295 
Val343 
Lys436 
Lys402 
His440 
Lys444 
Pro447 
Cys448 
Asp451 
Tyr452 
Val455 
 
 
 
 
 
H-bonding and 
hydrophobic 
 
 
 
 
 
-6.49 
 
           
 
 
 
 
 
 
 
 
 
 
Experimental 
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ancer cell lines of HL-60 (human leukemia), A549 (human lung carcinoma), 
Jurkat (human leukemia carcinoma), Hep3 B (human hepatocellular 
carcinoma), MCF 7 (human breast adeno carcinoma), HeLa (human cervical 
carcinoma), MDA-MB231 (breast carcinoma), HepG2 (hepatic carcinoma) and non-
cancer cell lines PBMCs (peripheral blood mononuclear cells) were taken for 
anticancer study. Fluorescence images were observed under Zeiss Imager M2, 
Gottingen (Germany) Fluorescence microscope. Transmission electron microscope 
(TEM) was obtained using JEOL JEM-2100 Electron Microscope at an accelerating 
voltage of 200 KV. Atomic force microscope (AFM) images were recorded with 
Agilent Model 5500 using tapping mode AFM, where cantilever and AFM tip oscillate 
and are scanned over the surface of the dry sample. 
 
In vitro anticancer activity of compounds 30-35, 38-41, 51-59 and 39-
41 (Chapter 1-4, respectively) 
The in vitro anticancer activity of steroidal compounds (30-35 against HL-60/A549), 
(38-41 against Jurkat), (51-59 against HeLa/Hep3 B/MCF 7) and (39-41 against 
MDA-MB231/HepG2/HeLa)  cancerous cell lines and blood peripheral mononuclear 
(PBMCs) normal cell lines was assessed by determining the number of viable cells 
surviving after their incubation with drug for stipulated time period using MTT (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)2H-
tetrazolium) method.96 The tumor cell lines and the normal cells were maintained in 
RPMI 1640 culture medium supplemented with 10% heat-inactivated foetal calf serum 
(FCS). The cells were plated at a density of 5×104 cells per well in a 96-well plate, and 
cultured for 24 h at 37 oC. Stock solutions of the synthesized compounds were prepared 
in 1:1 mixture of dimethyl sulfoxide (DMSO) and THF.97 The cells were subsequently 
exposed to drugs. The plates were incubated for 48 h, and cell proliferation was 
measured by adding 20 µL of MTT dye (5 mg/mL in phosphate-buffered saline) by 
wall. The plates were incubated for a further 4 h at 37 oC in a humidified chamber 
containing 5% CO2. Formazan crystals formed due to reduction of dye by viable cells 
in each well were dissolved in 150 µL DMSO, and absorbance was read at 570 nm. The 
absorption values were expressed as the cell viability (%), according to the control 
group as 100%. Assays were performed in triplicate on three independent experiments. 
C 
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The concentration required for 50% inhibition of cell viability (IC50) was calculated 
using the software ‘‘Prism 3.0’’. 
 
Blood peripheral mononuclear cell isolation 
The blood sample (20-15 mL) was diluted with the same volume of phosphate buffer 
saline (PBS). After that, the diluted blood sample was layered on Ficoll-Histopaque. 
The mixture was centrifuged at 400 g for 30 min at 20-22 oC. The undisturbed 
lymphocyte layer was transferred out. The lymphocyte was washed and pelleted down 
with three volumes of PBS twice and resuspended RPMI-1640 media with antibiotic 
and antimycotic solution 10%, v/v FCS. Cell counting was performed to determine the 
PBMCs cell number with equal volume of trypan blue.98,99 
 
Apoptosis detection (Chapter 2) 
To examine apoptosis by electrophoresis of nucleosomal fragments, a standard 
procedure for precipitating cytosolic nucleic acid was used.100 0.1, 1 and 10 µM of 
compound 41 treated Jurkat cells were pelleted (200×, 5 min) and lysed at 4 oC for 15 
min (250 µL, 0.4% Triton-X, 20 mM Tris, and 0.4 mM EDTA). Nuclei were then 
pelleted (13,000×, 5 min, 4 oC) and the supernatant were transferred to a clean 
microfuge tube. Nucleosomal fragments were precipitated overnight with an equal 
volume of isopropanol after adjustment to 0.5 M NaCl. The pellet was washed twice in 
70% ethanol, dried briefly, and resuspended in 40 µL TE (10 mM Tris-HCl, 0.1 mM 
EDTA, pH 8.8). The extracted DNA was separated 
 
Pharmacology 
Rule of Five and bioactivity score of compounds 38-41 and 51-59 (Chapter 2 and 3, 
respectively) 
The physicochemical parameters including octanol partition coefficients (Clog P), Mw, 
HBD, HBA and TPSA were calculated using ChemBioOffice 2012. The Bioactivity 
score Calculated using molinspiration server (http://www.molinspiration.com/cgi-bin/ 
properties). 
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Binding Experiments 
DNA-binding of compounds 40 and 41 (Chapter 2) 
The UV-measurements of CT-DNA were recorded on a Beckman DU 40 
Spectrophotometer (USA) by using a cuvette of 1 cm path length. The absorbance 
values of the synthesized compounds in the absence and presence of DNA were 
recorded in the range of 260-400 nm. Appropriate blanks corresponding to the DNA 
solutions and buffer were subtracted to correct the base line. Fluorescence 
measurements were recorded on a Shimadzu Spectrofluorometer-5000 (Japan). The 
fluorescence quenching with increasing concentration of DNA was recorded after 
exciting the drug solution at 270 nm, using 10/10 nm as slit widths. 
 
HSA-binding of compounds 39-41 (Chapter 4) 
Fluorescence Quenching Measurement of HSA 
The fluorescence spectra were recorded on a Shimadzu spectrofluorimeter RF-5301 
equipped with PC. All fluorescence spectra were measured at 25 ± 0.1 °C using 1 cm 
path length cell with both excitation and emission band-width set at 5 nm. The intrinsic 
fluorescence of the HSA was measured at an excitation wavelength of 295 nm and 
emission spectra was recorded in the range of 300-400 nm. A fixed concentration of 
HSA (5 µM) and concentration of compounds (39-41) were varied form 0-16 µM. The 
intensity at 340 nm (tryptophan) was used to calculate the binding Stern-Volmer 
constant (Ksv). 
 
Circular dichroism spectra 
Circular dichroism (CD) spectra of HSA alone and HSA-steroid complexes (39-41) was 
carried out on JASCO-J 813 spectropolarimeter equipped with a Peltier-type 
temperature controller at 25 oC using a quartz cell with a path length of 0.1 cm.  Two 
scans were accumulated at a scan speed of 100 nm min-1, with data being collected from 
Far UV-CD (190-250 nm) range. The concentration of HSA was 5 µM Far UV-CD 
measurements.  The protein-drug molar ratio 1:0, 1:1 and 1:2 were taken. In addition 
respective blanks were subtracted. The CD results have been analyzed in terms of mean 
residue ellipticity (MRE) in deg cm2 dmol-1 according to the following equation: 
  𝑀𝑅𝐸  =
𝜃𝑜𝑏𝑠(𝑚 𝑑𝑒𝑔)
10𝑛𝑙𝐶𝑝
                                                                                                                  
Chapter 5                                                            Biological evaluation of newly synthesized compounds 
 
230 
 
Where θobs is the CD in millidegree, n is the number of amino acid residues (212), l is 
the pathlength of the cell in cm and Cp is the molar concentration of protein.  
 
Dynamic light scattering (DLS) measurements 
DLS measurements were carried out at 830 nm using DynaPro-TC-04 dynamic light 
scattering equipment (Protein Solutions, Wyatt Technology, Santa Barbara, CA) 
equipped with a temperature-controlled micro sampler. HSA (2 mg/mL) was incubated 
with compounds (39-41) for 12 h. The samples were spun at 10,000 rpm for 10 min and 
were filtered serially through 0.22 and 0.02 µM Whatman syringe filters directly into a 
12 µL quartz cuvette. For each experiment, 20 measurements were carried out. Mean 
hydrodynamic radius (Rh) and polydispersity were analyzed using Dynamics 6.10.0.10 
software at optimized resolution. The Rh was estimated on the basis of an 
autocorrelation analysis of scattered light intensity data based on translational diffusion 
coefficient by Stokes-Einstein relationship: 
𝑅ℎ =
𝑘𝑇
6𝜋𝜂𝐷
                                                                                                                                        
Where Rh is the hydrodynamic radius, k is Boltzmann constant, T is temperature, η is 
the viscosity of water and D is diffusion coefficient.101  
 
Molecular docking  
Molecular docking of compounds (40, 41) and (51-59) with DNA (Chapter 2 and 3, 
respectively) 
The rigid molecular docking studies were performed using HEX 8.0.0 software. HEX 
is an interactive molecular graphics program for calculating and displaying feasible 
docking modes of DNA.102 The initial structures of the steroidal compounds (40, 41 
and 51-59) were generated by Avagadro 1.01 using MMFF94 force field and 
ChemBioDraw Ultra 12.0 software. The structures of compounds were optimized for 
use in the following docking study. The parameters that were used for docking include: 
correlation type-shape only, FFT mode-3D, grid dimension-0.6, receptor range-180, 
ligand range-180, twist range-360, distance range-40. The crystal structure of the B-
DNA dodecamer d(CGCAAATTTCGC)2 (PDB ID: 1BNA) were downloaded from the 
protein data bank (http://www.rcsb.org./pdb). All calculations were carried out on an 
Intel CORE i5, 2.6 GHz based machine running MS Windows 8 as the operating 
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system. Visualization of the docked pose have been done using PyMol molecular 
graphics program.103 
 
Molecular docking of compounds 39-41 with HSA (Chapter 4) 
To determine the amino acid residues involved in the binding site of compounds 39-41 
on HSA, the docking studies were performed using Autodock 4.2.0 and Autodock tools 
(ADT).104 Lamarckian genetic algorithm (LGA) implemented with an adaptive local 
method search was applied to determine the possible conformation of the drug that 
binds to the protein.105 The crystal structure of HSA (PDB id: 1AO6) was obtained from 
Brookhaven Protein Data Bank. The PDB file of compounds (39-41) were created using 
Discovery studio 4.0 client. Chain A of the protein was selected, water molecules and 
ions were removed and all hydrogen atoms were added. Then partial Kollman charges 
were assigned to HSA. The protein was held rigid and all torsional bonds are taken as 
being free during docking calculations. Moreover, the protein was set to be rigid and 
there is no consideration of solvent molecules on docking. To determine the binding 
site on HSA, blind docking was carried out and the grid size was set to be 120, 120 and 
120 along X, Y and Z axes with 0.524 Å grid spacing. Autodock parameters used were 
GA population size: 150 and maximum number of energy evolutions: 2 500 000. The 
10 best solutions based on docking score was retained for further analysis. Discovery 
studio 4.0 client were used for visualization and for the identification of residues 
involved in binding.  
 
Antioxidant activity  
Antioxidant activity of the compounds 51-59 (Chapter 3) 
By DPPH assay 
Steroidal heterocyclic compounds (51-59) were tested for their antioxidant property by 
1,1-diphenylpicrylhydrazyl (DPPH) method.106 Drug stock solution (1 mg/mL) was 
diluted to final concentration of 2, 4, 6, 8, 10 and 12 mg/mL in methanol. Methanolic 
DPPH solution (1 mL, 0.3 mmol) was added to 3.0 mL of drug solution of different 
concentrations. The mixture was shaken vigorously and incubated in dark at an ambient 
temperature for 30 min and the absorbance was measured as the decrease in the 
absorbance of DPPH at 517 nm resulting from the color change from purple to yellow. 
The decrease in absorbance is because of formation of stable molecule of DPPH on 
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reaction with an antioxidant through donation of hydrogen or electron by an 
antioxidant. The free electron on DPPH radical is responsible for giving absorbance 
peak at 517 nm and appears purple in color. The antioxidant agent pair up through 
donation of electron or release of hydrogen with the free electron on DPPH radical and 
form stable molecule of DPPH-H. The change of color from purple to yellow is 
attributed to decrease of molar absorptivity of DPPH radical when odd electron of 
DPPH pair up with the antioxidant agent. The resulting decrease in color is also 
stiochiometric with number of electrons captured. The DPPH radical-scavenging 
activity (%) was calculated by the following formula: 
[% inhibition = [(AControl 
_ ASample/AControl) × 100] 
Where AControl is the absorbance of the L-ascorbic acid (Standard) and ASample is the 
absorbance of different compounds. The methanolic DPPH solution (1 mL, 0.3 mM) 
was used as a negative control whereas L-ascorbic acid was used as a positive control. 
 
By FRAP assay 
FRAP assay measures the antioxidant capacity by the reduction of ferric 2,4,6-
tripyridyl-s-triazine complex [FeIII(TPTZ)2]
3+ to the intensely blue colored ferrous 
complex [FeII(TPTZ)2]
2+.107 The reagent composed of 10 mM TPTZ (2,4,6-Tripyridyl-
s-Triazine) (10 mL), 20 mM FeCl3.6H2O (10 mL), and 300 mM acetate buffer (100 
mL) in ratio of 1:1:10 were freshly prepared. 300 mM acetate buffer (pH 3.6) was 
prepared by dissolving sodium acetate trihydrate (3.1 g) in distilled water (500 mL) 
then glacial acetic acid (16 mL) was added and made up to the mark of 1 L with distilled 
water and checked for its pH. 10 mM TPTZ solution was prepared in 40 mM HCl and 
20 mM FeCl3.6H2O was prepared in distilled water. Different concentrations of 
compounds (25, 50, 75 and 100 µg/mL) were taken and an increase in the absorbance 
by [FeIII(TPTZ)2]
3+ complex was measured at 593 nm after 5 min of incubation at 37 
oC. Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) was used as the 
standard solution and the concentration of FRAP content in the compounds were 
expressed in terms of mg trolox-equivalent (TE)/g deduced from the standard curve of 
trolox.108,109 
 
By ABTS assay 
The total antioxidant activity of compounds 51-59 were measured by ABTS (2′,2′-
azinobis(3-ethylbenzothiazoline-6-sulfonic acid) radical cation decolorization assay 
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with some modification.110 A stock solution of ABTS (2 mM) was prepared by 
dissolving the ABTS in phosphate-buffered saline (PBS, 50 mL) to produce a solution 
with a pH of 7.4. The ABTS•+ was generated by reacting 50 mL of the stock solution 
with 200 mL of a 70 mM aqueous K2S2O8 solution. The resulting ABTS
•+ solution was 
diluted with PBS to obtain a reasonable absorbance at 734 nm. A 100 µL of drug 
solution at different concentration (25, 50, 75 and 100 mg/mL) was mixed with ABTS•+ 
solution (1.9 mL), and the absorbance of the mixed solution was read at ambient 
temperature after 3 min. The PBS solution was used as a blank sample.111 The 
experiment was done in triplicates and the radical scavenging activity of the sample 
was calculated with the following formula:  
𝑆𝐶% =
𝐵𝑂 − 𝐵𝑆
𝐵𝑂
× 100                                                                                                                  
Where, BO and BS are the absorbance values of the blank and of the tested samples, 
respectively. The assay was carried out on ascorbic acid, which served as a standard.  
 
Antioxidant activity of the compounds 39-41 (Chapter 4) 
The in vitro antioxidant activity of compounds (39-41) was explored by conducting a 
series of antioxidant assays involving DPPH, OH. radical, NO. radical, hydrogen 
peroxide radical and comparing the outcomes with standard antioxidants (L-ascorbic 
acid).112  
 
DPPH. scavenging assay 
The DPPH radical scavenging activity of the compounds (39-41) was measured 
according to the reported method.113 Drug stock solution (1 mg/mL) were taken and the 
volume was diluted to 100 mL with different concentration in methanol. About 5 mL 
of a 0.1 mM methanolic solution of DPPH was added to the aliquots of samples and 
standard (L-ascorbic acid) and shaken vigorously. A negative control was made by 
adding 100 mL of methanol in 5 mL of 0.1 mM methanolic solution of DPPH. The 
tubes were allowed to stand for 30 min at 27 oC. The absorbance of the sample was 
quantified at 517 nm against the blank (methanol). The DPPH radical is a stable free 
radical.114 Because of the odd electron, DPPH shows a strong absorption band at 517 
nm in the visible spectrum. As this electron becomes paired off in the presence of a free 
radical scavenger, the absorption vanishes and the resulting decolorization is 
stoichiometric with respect to the number of electrons taken up. 
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Antioxidant-H + DPPH. → Antioxidant. + DPPH-H 
Antioxidant-H → Antioxidant- + H+ 
Antioxidant- + DPPH. → Antioxidant. + DPPH- 
DPPH. + H+ → DPPH-H 
The change of colour from purple to yellow is attributed to decrease of molar 
absorptivity of DPPH radical when odd electron of DPPH pair up with the antioxidant 
agent. 
 
OH. scavenging assay 
The hydroxyl radical scavenging activity of the compounds (39-41) were tested in 
accordance with a reported method.115 In vitro hydroxyl radicals were generated by a 
Fe3+/ascorbic acid system. The detection of hydroxyl radicals was carried out by 
measuring the amount of formaldehyde formed from the oxidation reaction with 
DMSO. The formaldehyde produced was detected spectrophotometrically at 412 nm. 
A mixture of 1.0 mL of iron-EDTA solution (0.13% ferrous ammonium sulfate and 
0.26% EDTA), 0.5 mL of EDTA solution (0.018%) and 1.0 mL of DMSO (0.85% 
DMSO (v/v) in 0.1 M phosphate buffer, pH 7.4) were sequentially added in the test 
tubes. The reaction was initiated by adding 0.5 mL of ascorbic acid (0.22%) and was 
incubated at 80-90 oC for 20 min in a water bath. After incubation, the reaction was 
terminated by the addition of 1.0 mL of ice-cold trichloroacetic acid (17.5% w/v). 
Subsequently, 3.0 mL of Nash reagent was added to each tube and left at room 
temperature for 15 min. The intensity of the color formed was measured 
spectrophotometrically at 412 nm against the reagent blank. 
 
NO. scavenging assay 
The nitric oxide scavenging activity is based on a method in which sodium nitroprusside 
in aqueous solution at physiological pH spontaneously generates nitric oxide, which 
interacts with oxygen to produce nitrite ions.116 These can be estimated using the Griess 
reagent. Scavengers of nitric oxide compete with oxygen leading to reduced production 
of nitrite ions. For the experiment, sodium nitroprusside (10 mM) in phosphate buffered 
saline was mixed with a fixed concentration of the compounds (39-41) and standards, 
incubated at room temperature for 170 min. After the incubation period, 0.5 mL of 
Griess reagent containing 1% sulfanilamide, 2% H3PO4 and 0.1% N-(1-naphthyl) 
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ethylenediamine dihydrochloride was added. The absorbance of the chromophore 
formed was measured at 546 nm. 
 
H2O2 scavenging assay 
The ability of the compounds (39-41) to scavenge hydrogen peroxide was determined 
using the reported procedure.117 A solution of hydrogen peroxide (2.0 mM) was 
prepared in phosphate buffer (0.2 M, pH 7.4) and its concentration was determined 
spectrophotometrically from absorption at 230 nm with molar absorptivity 81 M-1 cm-
1. The compounds (39-41) (100 µg/mL), L-ascorbic acid (100 µg/mL) were added to 
3.4 mL of phosphate buffer together with hydrogen peroxide solution (0.6 mL). An 
identical reaction mixture without the sample was considered as negative control. 
Absorbance of hydrogen peroxide at 230 nm was determined after 15 min against the 
blank (phosphate buffer). 
For the four assays described above, all the tests were run in triplicate and the 
percentage of scavenging activity was calculated using the following formula: 
% 𝑜𝑓 𝑠𝑐𝑎𝑣𝑒𝑛𝑔𝑖𝑛𝑔 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = [
𝐴0 − 𝐴𝑐
𝐴0
] × 100 
Where, A0 and Ac are the absorbance in the absence and presence of the compounds 
tested. The assay was carried out on L-ascorbic acid, which served as a standard. The 
concentration required for 50% scavenging the corresponding radical (IC50 value) was 
obtained by linear regression analysis of the curve plotting between % inhibition and 
concentrations. 
 
Fluorescence microscopy (Chapter 3) 
The HeLa cell line was maintained in RPMI-1640 culture medium supplemented with 
10% heat-inactivated FCS. The cells were plated at a density of 5×103 cells on glass 
cover slips, and cultured for 24 h at 37 oC. These were subsequently exposed with 
compounds for 48 h. Cells were fixed by 2% paraformaldehyde for 2 h followed by 
washing with Hank's Balanced Salt Solution (HBSS). The HeLa cells treated with 
compounds 51-59 were observed under Fluorescence Microscope.  
 
Preparation for TEM and AFM (Chapter 3) 
The sample for TEM analysis was prepared by placing a drop of colloidal solution on 
a copper grid coated with a carbon film and allowed to equilibrate for 3-5 min. The 
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solution was wiped off with filter paper and allowed to air dry. Images were taken using 
TEM, JEOL JEM-2100 Electron Microscope set at an accelerating voltage of 200 kV 
to determine the size and morphology of the condensate material. The samples for AFM 
analysis of the compound 53 and its condensate with CT-DNA were prepared from the 
solution of the compound 53 (prepared in DMSO) and equimolar mixture of compound 
53 and CT-DNA (dissolved in 0.01 M Tris-HCl buffer pH 7.2). The samples were 
placed drop wise on a mica wafer, then air dried at room temperature for 12 h and the 
images were recorded with Agilent Model 5500 using tapping mode AFM, where 
cantilever and AFM tip oscillate and are scanned over the surface of the dry sample. 
 
Nonenzymatic DNA damage of compound 41 and 53 (Chapter 2 and 
3, respectively) 
In order to identify and determine the possible role of ROS, the reaction mixture (0.5 
mL) containing Tris-HCl (10 mM, pH 7.5), CT-DNA (200 mg), Cu (II) (100 mM) and 
increasing concentration of compound 41 (Figure 5) and 53 (Figure 13) (12.5 mM, 25 
mM, 50 mM, 75 mM, 100 mM, 200 mM, 400 mM, 600 mM). The volume was made 
up to 1 mL by buffer solutions and incubated at 37 oC for 60 min. Reaction was stopped 
using 0.5 mL of trichloroacetic acid solution (TCA) (28%) and 0.5 mL of 1% 
thiobarbituric acid (TBA) was added, boiled for 15 min and cooled to room 
temperature. The intensity was read at 532 nm.117 
 
In vitro acetylcholinesterase inhibition activity of compounds 51-59 
(Chapter 3) 
The ability of synthesized compounds (51-59) to inhibit AChE activity was assessed by 
Ellman's method.118 AChE stock solution was prepared by dissolving human 
recombinant AChE (EC:3.1.1.7) lyophilized powder in 0.1 M phosphate buffer (pH 8.0) 
containing Triton X-100 (0.1%). Five increasing concentrations of test compounds 
were assayed to obtain percent inhibition of the enzymatic activity in the range of 20-
80. The assay solution consisted of a 0.1 M phosphate buffer pH 8.0, with the addition 
of 340 mM 5,5ʹ-dithio-bis(2-nitrobenzoic acid), 0.02 unit per mL of human 
recombinant AChE from human serum and 550 µM of substrate (acetylthiocholine 
iodide, ATCh). Increasing concentration of tested inhibitor were added to the assay 
solution and pre-incubated for 5 min at 37 oC with the enzyme followed by the addition 
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of substrate. Initial rate assays were performed at 37 oC with a Jasco V-530 double 
beam spectrophotometer. Absorbance value at 412 nm was recorded for 5 min and 
enzyme activity was calculated from the slope of the obtained linear trend. Assays were 
carried out with a blank containing all components except AChE to account for the non-
enzymatic reaction. The reaction rates were compared and the percent inhibition due to 
the presence of tested inhibitors was calculated. Each concentration was analyzed in 
triplicate and IC50 values were determined graphically from log concentration-
inhibition curves (GraphPad Prism 4.03 software, Graph-Pad Software Inc.). Tacrine 
was used as a standard inhibitor. 
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